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Abstract 
The passage of fluid, ions and macromolecules across the epithelium 
is controlled primarily by epithelial tight junctions.  Altered epithelial 
permeability is associated with lung disease, and barrier function is impaired 
by the Th2 cytokine IL-13.  This thesis investigates the signalling pathways 
involved in the modulation of the epithelial barrier by IL-13 stimulation. 
Initial experiments demonstrated that the human sub-bronchial 
epithelial cell line Calu-3 could be easily manipulated when grown using an 
air-liquid culture system. Expression of various key tight junction proteins 
was demonstrated, as well as a high trans-epithelial resistance (TER) for up 
to 7 days.  Stimulation with IL-13 resulted in a decrease in TER compared 
with controls and this decrease was shown to be prevented with the PI3K 
inhibitor ZSTK474. IL-13 did not increase paracellular permeability of the 
epithelial monolayer to FITC-dextran from the apical to the basolateral 
chamber and ZSTK474 did not influence FITC-dextran flux. 
Immunocytochemistry showed that the expression of the tight junction 
protein claudin 2 was increased by IL-13 stimulation and this change in 
expression was shown to be PI3K dependent with the PI3K inhibitor 
ZSKT474 preventing the increase.   
Further studies were carried out in an attempt to uncover the PI3K 
isoform responsible for the effects seen on both the TER and the TJ 
expression.  It was shown that inhibition of the p110α isoform with PIK75 
mimicked the result observed with the pan-PI3K inhibitor ZSTK474 and 
prevented the IL-13-induced claudin 2 upregulation.  However none of the 
PI3K isoform inhibitiors showed the prevention of TER, as shown by the pan 
PI3K inhibitor ZSTK474.  The role of STAT6 in TJ modulation was shown to 
be similar to that of PI3K, in that inhibition of STAT6 had a positive effect on 
the epithelial barrier by preventing the IL-13-induced TER decrease and the 
increase in the expression of claudin 2. In addition, both PI3K inhibition and 
STAT6 inhibition demonstrated effects on basal TER and claudin 2 
expression, indicating that both pathways are involved in maintenance of 
epithelial barrier integrity.  
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1.1 Inflammatory lung diseases 
 
Lung diseases are the cause of around 14.5% of all deaths worldwide 
every year according to the world health organisation [1].  The term lung 
disease refers to disorders that prevent optimal function of the lungs, such as 
asthma, Chronic Obstructive Pulmonary Disease (COPD), cystic fibrosis, 
pneumonia, influenza and lung cancer.  Chronic respiratory diseases are 
chronic diseases of the airways and other structures in the lung, some of the 
most common are asthma, COPD and pulmonary hypertension.   COPD is 
an umbrella term for the disorders chronic bronchitis and emphysema and is 
thought to be the third leading cause of death by 2020.   
A defining characteristic of all respiratory diseases is an increase in 
inflammatory leukocytes.  These white blood cells are recruited to the site of 
inflammation and their presence results in the activation of multiple cell 
signalling pathways to prolong and increase the inflammatory response.   
 
1.2  Innate and Adaptive immune system 
 
In order for multicellular organisms to survive they must have a line of 
defence in place against pathogens and be able to efficiently repair and 
regenerate after damage caused by injury and infection.  In humans our 
defence is known as the immune system, which can be separated into two 
branches, innate and adaptive immunity.  Innate immunity is the first line of 
defence for the body, it involves a number of leukocytes including 
eosinophils, basophils, natural killer (NK) cells, mast cells along with the 
phagocytic cells macrophages, neutrophils and dentritic cells.  Innate 
immune cells recognise the pathogen-associated molecular patterns which 
are broadly shared by pathogens with their own pattern recognition 
receptors. Innate immune cells either engulf pathogens (phagocytes) or 
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release inflammatory mediators such as histamine and leukotrienes (mast 
cells).  
The adaptive immune response involves dentritic cells which are known 
as professional antigen presenting cells. Dentritic cells present selected 
peptides on MHC class II molecules to naive T-cells [2]. Naive T cells then 
differentiate into a range of cell types including T helper type 2 cells (TH2) 
which produce many cytokines such as IL-13, IL-4, IL-5 and IL-9.  These 
cytokines have been shown to be responsible for IgE production leading to 
mast cell activation and eosinophil recruitment both of which play an 
important role in sustaining inflammation [3]. 
 
1.3 Asthma 
 
Asthma is a common respiratory disease with some 5.4 million people 
currently receiving treatment for this condition in the UK alone and 3 asthma 
related deaths per day [4].  The number of patients suffering with asthma 
increased dramatically between 2001 and 2010 in the USA and it is now 
thought to affect between 7-10% of the world’s population  [5, 6].  Over half 
of asthma is allergic, also known as atopic, which is triggered by inhaled 
allergens such as house dust mite allergen, pet dander and pollen.  Non-
allergic asthma was originally thought not to involve the immune system, a 
claim which has been widely challenged of late [7], nonetheless the 
symptoms are the same.  Asthma is characterised by chronic inflammation of 
the airways, smooth muscle hypersensitivity and mucus overproduction 
causing narrowing of the airways resulting in the common symptoms of 
coughing and shortness of breath.  In chronic cases of asthma these 
features cause increased smooth muscle mass and subepithelial fibrosis 
through a process known as airway remodelling.  Unlike features apparent in 
mild asthma, airway remodelling is an irreversible process.    Mild asthma 
can be adequately treated in most patients by existing medication which 
consists of beta-adrenergic agonists and glucocorticoid steroids.  β2 agonists 
are fast acting and exert their effects by relaxing the underlying airway 
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smooth muscle which leads to airway widening, making breathing much 
easier. Inhaled glucocorticoids are given as an ongoing daily treatment to 
reduce overall inflammation but they need to be taken for prolonged periods 
of time to ensure efficacy.  As the results are not immediate, patient 
compliance plays a role as sufferers are less likely to religiously administer 
this treatment when the effects are not obvious.  GCs are considered the 
most effective treatment for asthma as they improve overall lung function and 
quality of life by reducing airway hyperresponsiveness, disease 
exacerbations and hospitalisations.  Withdrawal from GCs however will result 
in  airways reverting back to their ‘natural’ inflamed state [8].  Over recent 
years asthma has been shown to have a number of sub-phenotypes, which 
include displaying a high or low Th2 response [9, 10].  Results from the 
severe asthma research program in 2010 identified five separate sub-
phenotypes of asthma using cluster analysis; asthma subjects were placed in 
groups according to parameters such as pulmonary lung function, age, sex 
and response to current treatment  [11].  This heterogeneity can explain why 
a varied response to current treatments has been observed.  The subset of 
patients who do not display any bronchodilator reversibility are somewhat 
ignored when it comes to research with many studies and clinical trials only 
using patients who respond to beta-agonists [12].  These patients often 
undergo an accelerated loss of pulmonary function, hence there is clearly an 
urgent need for greater understanding and new potential drug targets in this 
field.   
 
1.4 Chronic Inflammation in the lung 
 
Upon allergic activation T-lymphocytes and mast cells become activated 
and release cytokines which can signal to endothelial and epithelial cells to 
express cellular adhesion molecules (CAMs).  Infiltrating cells such as 
lymphocytes, basophils and eosinophils adhere to these CAMs and can 
travel through the junctional complexes of both the endothelium and 
epithelium.  This is an important feature of allergic inflammation as the 
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intrusion by leukocytes sustains inflammation and causes disruption to the 
epithelial layer.  Asthmatic patients have been shown to have a disrupted 
epithelium [13] and in chronic asthma the main histological changes are 
infiltration of macrophages and lymphocytes along with an increase in 
fibroblast proliferation, angiogenesis, fibrosis and tissue damage [14, 15].    
As well as producing cytokines and chemokines activated mast cells also 
release histamine and lipid compounds such as leukotrienes and 
prostaglandins, which cause smooth muscle contraction leading to 
bronchoconstriction.  Airway hyperresponsiveness (AH) has been shown to 
be a result of airway remodelling rather than sustained inflammation [16].  
AH is characterized by exaggerated narrowing of the airways in response to 
non-specific stimuli such as histamine, methacholine, cold and exercise.    
As mentioned previously in cases of chronic asthma airway remodelling 
occurs, a process describing the irreversible changes that take place in the 
lung after a period of sustained inflammation.  It is characterised by an 
increase in fibrotic cells, smooth muscle hypertrophy and basement 
membrane thickening [17]. Two key features that contribute to airway 
remodelling in asthma are epithelial to mesenchymal transitions and goblet 
cell metaplasia [18]. 
1.4.1 Epithelial to mesenchymal transitions 
  
An epithelial-mesenchymal-transition (EMT) is one where an adherent 
epithelial cell is converted to an individual migratory cell which then travels 
into the extracellular matrix to promote the activation of the process again 
(Figure 1.1).  The term ‘transition’ is now widely used for this event as it is 
known to be a reversible process [19].  Cells can also undergo 
mesenchymal-epithelial transitions (MET) and this transition is seen in 
embryonic development as the mesoderm and ectoderm are generated and 
begin to contribute to many adult tissues by undergoing EMT and MET 
transitions [20].  In a healthy adult the EMT-MET transition is seen in wound 
repair and tissue regeneration, but it is also observed in cancer progression 
and metastasis [21, 22]. 
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Figure 1.1 An epithelial-to-mesenchymal (EMT) transition.     
The epithelial-to-mesenchymal transition consists of a normal intact epithelial cell (A) 
that begins to lose its connection to adjacent cells through adherens junctional 
proteins and actin filament breakdown, followed by internalisation (B+C).  The cell 
then loses its tight junctions and its structure begins to change to that of a mobile 
myofibroblast which then passes through the basement membrane and into the 
submucosal epithelium (D).  
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1.4.2 Goblet cell metaplasia 
 
Goblet cell metaplasia is a process where epithelial cells differentiate 
into goblet cells. Goblet cells have the primary role of producing mucus and 
can act as a protective cell or a pathogenic cell depending on the amount 
present.  In a normal intact epithelium there are few goblet cells and little 
mucus produced which has the protective role of moving debris from the 
surface of the cell by movement of the cilia.  However in patients with severe 
asthma the number of goblet cells is greatly increased, which leads to mucus 
hypersecretion, a feature which plays a significant role in airway obstruction 
and contributes greatly to morbidity and mortality [18, 23].  
A mucin is a very large glycosylated protein which is usually >1000 
kDa.  There are around 20 different mucins present in the human body but 
the main mucin genes present in the lung are MUC5AC and MUC5B [24].  
The term ‘mucus’ is often used and it refers to a mixture of mucins along with 
cell debris, ions, water, antimicrobial proteins and proteoglycans.   In a 
healthy airway, the mucus layer is usually between 5-50μm thick [25, 26] 
which increases substantially in thickness in severe asthmatics during 
inflammation and it is reported that this obstruction by mucus plugs is the 
cause of 98% of all deaths in severe asthma [27-30]. 
The regulation of goblet cell metaplasia (GCM), mucus production and 
secretion in respiratory and inflammatory bowel diseases have been popular 
research areas over the last 15 years where findings have shown that the 
cytokine IL-13 plays a crucial role in its pathogenesis [31, 32].  Other known 
mediators are ligands that activate the epidermal growth factor receptor 
(EGFR) and upregulate the calcium activated chloride channel CLCA-1 [33, 
34].  
1.5 IL-13 structure and its role in asthma 
 
Interleukin-13 (IL-13) was discovered in 1989 in mice when it was 
named P600, it was later cloned and discovered that the human cDNA 
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sequence was 66% homologous to that of the murine sequence [35-37].  IL-
13 is part of a group of messenger proteins called cytokines and is produced 
principally by T-helper type 2 cells but also by mast cells, natural killer (NK) 
cells, eosinophils and basophils.  It has similar roles to IL-4 which is 
understandable given their binding regions have high sequence homology 
and that both are found on the cytokine gene cluster on chromosome 5q31 
along with GMSF, IL-3, IL-5 and IL-9 [38].   
IL-13 is a key cytokine released during allergic inflammation and has 
been linked to asthma in many murine models; recently the link between IL-
13 and asthma has been proven in human asthma [39].  Treatment with the 
monoclonal IL-13-antibody, lebrikizumab was shown to reduce the late 
asthmatic response to an inhaled allergen by 50% along with improving the 
prebronchodilator forced expiratory volume (FEV1) by 5.5%.  This 
improvement in lung function was seen in patients with high pretreatment 
levels of the matricellular protein periostin.  Recent studies have linked 
periostin to the induction of chemokines in pulmonary fibrosis and it has been 
shown to be a biomarker of airway eosinophilia in asthma [40, 41]. 
 IL-13 has been shown to have many roles in asthma (Figure 1.2), it is 
involved in B cell maturation and differentiation as well as inducing B-cell IgE 
switching [42].  IL-13 activates epithelial cells to produce the chemokine 
eotaxin which attracts eosinophils to the lung [43], it has recently been 
shown that eotaxin 2 and 3 (but not 1) is produced as a result of cooperation 
of IL-13 with leukotriene D4 [44].  IL-13 is also known to play an important 
role in the pathogenesis of severe asthma features, such as fibrosis and 
mucus hypersecretion [45].   
IL-13 has been shown to both upregulate and downregulate nitric 
oxide (NO) production, where upregulation of NO can have a protective role 
on the epithelium as it acts as a bronchodilator [46].  This increase of NO is 
shown to be a result of upregulation of the enzyme nitric oxide synthase 
(NOS) which  catalyses the oxidation of L-arginine to L-citrulline where NO is 
produced as a by-product [47].   IL-13 however has also been demonstrated 
to increase the expression of the enzyme arginase, which converts the L-
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arginine to L-ornithine.  Upregulation of arginase has been shown to undergo 
competition with NOS for the substrate L-arginine and increased levels of 
arginase have been reported to diminish the L-arginine pool resulting in a 
decrease in the production of NO.  Upregulated arginase has also been 
shown to increase the downstream products of polyamines and L-proline 
which are known to produce extra-cellular matrix components and lead to 
increased collagen deposition and eventually fibrosis.  Upregulation of 
arginase has also been shown to increase the formation of the procontractile 
peroxynitrite species which has been linked to airway hyperresponsiveness 
[48].  This signalling loop has therefore been labelled as a key mechanism 
behind the increased bronchoconstriction in asthma caused by upregulation 
of IL-13 and arginase inhibition has been extensively researched in the 
treatment of asthma [49-53].   
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Figure 1.2 The role of IL-13 in asthma.  
Upon allergic stimulation Th2 cells produce the cytokine IL-13 which has been shown to play a role in many pathological features of asthma.  IL-13 
stimulates B cells to produce IgE which binds to FcεRI receptors of mast cells leading to degranulation and the release of the pro-contractile 
compounds histamine, prostaglandins and leukotrienes which initiate smooth muscle contraction.  Mast cells along with eosinophils also produce IL-13 
during inflammation and upregulation of IL-13 in the airway submucosa has been shown to play a role in driving epithelial differentiation into 
mesenchymal cells (EMT). EMT leads to an increase of pro-fibrotic components such as collagen and fibronectin being irreversibly deposited in the 
sub-epithelium, if not adequately treated.  Long term IL-13 stimulation causes epithelial cells to differentiate into goblet cells leading to an increase in 
mucus secretion and airway obstruction in severe asthma.  More recently IL-13 upregulation has been linked with the regulation of the apical junction 
complex consisting of tight junction and adherens junction proteins; which are responsible for maintaining a strong paracellular seal between epithelial 
cells.  
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1.6.1 IL-13 receptors and signalling 
  
IL-13 has two known receptors, IL-13Rα1 and IL-13Rα2. Human IL-
13Rα1 was first cloned in 1996 shortly after the murine analogue and the 
cloned cDNA encodes a 270 amino acid protein. It has 76% homology to the 
murine IL-13Rα1 protein and has typical haematopoietic receptor patterns 
including a short cytoplasmic tail which contains a proline rich motif 
(PXXPXP) close to the transmembrane region [54, 55].  IL-13 has very little 
affinity for the IL-13Rα1 alone (Kd = 4.5 ± 0.5nM), however when it forms a 
heterodimer with the IL-4Rα receptor its affinity dramatically increases (Kd = 
32 ± 8pM).  The order in which the association occurs is IL-13 binds to IL-
13Rα1 then it recruits the IL-4Rα complex to form the high binding affinity 
receptor [56].   
The second IL-13 receptor IL-13Rα2 was initially thought of as a 
decoy receptor, however in recent years it has been found to have signalling 
properties [57].  IL-13Rα1 is 27% identical to the IL-13Rα2 protein which 
comprises of 380 amino acids and binds IL-13 but not IL-4 [54, 58].  Studies 
have been carried out to assess the binding properties of IL-13 with IL-
13Rα2 however, the values reported in the literature are inconsistent varying 
from 20pM to 2.5nM [59].  IL-13Rα2 has been shown to bind with a higher 
affinity than IL-13 with the IL-13Rα1 complex and does not need a second 
receptor chain to do so [58].  However binding to IL-13Rα2 has been 
reported to dampen the IL-13 response as overexpression of the IL-13Rα2 
complex in histiocytic lymphoma cells resulted in inhibition of IL-13 signalling 
[60].   
IL-13 carries out its signalling principally via phosphoinositide 3-kinase 
(PI3K) and the signal transducer and activator of transcription 6 (STAT6) 
activation.  IL-13 binds to the receptor IL-13Rα1 which then causes the IL-
4Rα to bind to form a high affinity binding complex for IL-13. This recruitment 
of the receptors along with the binding of IL-13 causes activation of PI3K 
along with Janus kinases (JAK) and tyrosine kinase 2 (Tyk2) recruitment to 
the cell membrane leading to STAT6 activation. 
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1.7 The PI3K pathway 
  
Phosphatidylinositols are lipids that are present in mammalian cell 
membranes, where the hydroxyl groups present on the inositol ring can be 
phosphorylated by PI3K to give many products with different functions within 
the cell.  PI3K is activated by the dimerisation of cell surface receptors such 
as receptor tyrosine kinases (RTKs) caused by ligand binding, e.g. IL-13 
binding to the IL-13Rα1 receptor which initiates dimerisation with IL-4Rα.  
PI3K becomes activated and phosphorylates the hydroxyl group on the D-3 
position on the inositol ring of phosphatidylinositol 4,5-bisphosphate 
[PI(4,5)P2] which is present in the cell membrane to produce  
phosphatidylinositol (3,4,5)-trisphosphate [PI(3,4,5)P3] [61].  [PI(4,5)P3] acts 
as a docking domain to plekstrin homology (PH) domain proteins such as Akt 
(protein kinase B) and 3-phosphoinositide dependent protein kinase-1 
(PDK1) [62].  Akt is phosphorylated by PDK1 on Threonine 308 and by 
mTORC2 on Serine 473 which leads to a number of downstream signalling 
effects such as inhibiting the pro-apoptotic protein BAD, leading to increased 
cell survival.  Akt is an important target in many cancers as it promotes tumor 
growth and survival [63]. This cell survival pathway is negatively regulated by 
phosphatase and tensin homologue deleted on chromosome ten (PTEN) 
[64].  PTEN de-phosphorylates [PI(3,4,5)P3]  at the hydroxyl group on 
position 3 of the inositol ring which reforms the starter [PI(4,5)P2]  complex.  
Mutations in PTEN are commonly seen in human cancers [65]. 
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Figure 1.3 The Class I PI3K signalling pathway 
The class IA PI3Ks consist of PI3Kα, β and δ; they all contain the p110 catalytic subunit and the p85 regulatory subunit.  Upon ligand stimulation (IL-13 binding to IL-
13Rα1) the receptor tyrosine kinase phosphorylates class IA PI3K indirectly through an interaction with the adaptor proteins insulin receptor substrate 1 or 2 
(IRS1/2) via phosphorylation at the SRC-homology domains (SH2) in p85.  This interaction between IRS1/2 and p85 positions PI3K at the plasma membrane in 
close proximity to its substrate PIP2 and also stops p85 from having an inhibitory effect on p110, which allows PIP2 to be converted to PIP3.  PIP3 then recruits the 
serine/threonine kinases PDK1 and Akt to the cell membrane via their plekstrin homology domains (PH). PDK1 activates Akt at threonine 308 and the 
serine/threonine kinase mammalian target of rapamycin 2 (mTORC2) phosphorylates Akt at serine 473.  Akt activation leads to a plethora of downstream events 
such as cell proliferation, differentiation and glucose metabolism.  The class IB PI3K pathway can signal independently of Akt, p110γ consists of the p110 catalytic 
subunit and the p101 regulatory subunit and can be activated through the binding of chemokines to the G-protein coupled receptor (GPCR).  Activation of the GPCR 
recruits the G-protein subunit Gβγ which directly activates p110γ resulting in PIP2 conversion into PIP3. BD; binding domain, C2; C2 domain, CD; catalytic domain. 
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1.7.1 The PI3K family 
 
In the last decade research into the PI3K family has been very 
prominent and it is now widely known that four classes of PI3Ks exist. The 
standard ‘PI3K core’ consists of a catalytic subunit, a helical and a C2 
binding domain [66].  Class I PI3Ks are between 110-130kDa and there are 
two subtypes, Class IA and Class IB, which along with the PI3K core contain 
a Ras binding site and a lipid binding domain.  In Class IA PI3Ks there are 
three catalytic subunits p110α, p110β and p110δ which binds to one of five 
regulatory subunits: p85α, p85β, p55γ, p55α and p50α [64].  Class IB PI3Ks 
consist solely of the catalytic subunit p110γ which can bind to one of the 
three regulatory subunits p101, p87 or p84.  In Class I PI3Ks the catalytic 
subunit binds directly to the GTPase –Ras which switches on PI3K activity 
via a conformation change from GTP bound-Ras converting to GDP resulting 
in Ras inactivation and PI3K activation.  Class IA isoforms of PI3K are 
expressed ubiquitously whereas the Class IB isoform is mainly expressed in 
leukocytes.   
           Class II PI3Ks are larger proteins with a molecular weight of ~170kDa 
and lack the regulatory binding domain that Class I PI3Ks express.  They 
have a C-terminus extension consisting of an extra C2 binding and a PX 
domain [67].  There are three class II PI3Ks, PI3K-C2α, PI3K-C2β and PI3K-
C2γ and they phosphorylate phosphatidylinositol [PI] and 
phosphatidylinositol 4-phosphate [PI(4)P] to phosphatidylinositol 3-
phosphate [PI(3)P] and phosphatidylinositol 3,4-bisphosphate [PI(3,4)P2] 
respectively.  PI3K-C2α and PI3K-C2β are widely expressed whereas PI3K-
C2γ is more localised to liver, prostate, breast and salivary glands.  PI3K-
C2α is predominately localized in clathrin-coated vesicles and in the trans-
Golgi network, it is suggested that PI3K-C2α binds to clathrin via its N-
terminus for activation and is important in clathrin-mediated membrane 
trafficking. 
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 The class III PI3K Vps34 was originally identified in yeast and 
phosphorylates phosphatidylinositol [PI] to phosphatidylinositol 3-phosphate 
[PI(3)P] [68].  Vps34 binds to the protein kinase Vps15 for activation and it is 
known to play an essential role in autophagy and is crucial in normal heart 
and liver function [69]. 
 
1.7.2 PI3K signalling and biological functions  
 
Class I PI3Ks phosphorylate the hydroxyl group on the D-3 position on 
the inositol ring of phosphatidylinositol 4,5-bisphosphate [PI(3,4)P2]  to 
produce  phosphatidylinositol (3,4,5)-trisphosphate [PI(3,4,5)P3].  PI3K 
isoforms, p110α and p110β have been shown to be essential in cell survival 
and de-novo DNA synthesis [70, 71].  
Class II PI3Ks phosphorylate PI and PI(4)P to form PIP and PI(3,4)P2. 
The PI3K-C2α isoform has been researched more extensively than PI3K-
C2β and PI3K-C2γ and clathrin is found to play a role in its signalling by 
binding to the N-terminal domain which alters the substrate preference 
resulting in an increase in its binding affinity for PI and PI(4)P [72].  Previous 
work in the group has showed that silencing PI3KC2β in A549 cells results in 
a decrease in the rate of wound healing [73].  The role of class II PI3K in 
biological functions is still largely unknown, which is also the case for the 
Class III PI3K Vps34.  The involvement of Vps34 has been indicated in 
innate immune responses, superoxide formation and the gene PIK3C3 that 
encodes the protein has been associated with schizophrenia [74].  
 The PI3K pathway is negatively regulated by both the 
phosphoinositide 3-phosphate PTEN and also by the phosphoinositide 4-
phosphate SHIP.  PTEN de-phosphorylates the product of the class I PI3K 
PI(3,4,5)P3 back to PI(4,5)P2.  It has been shown to have important roles in 
apoptosis, cell migration, adhesion and angiogenesis [64, 75, 76] and is 
frequently mutated, deleted or silenced in human cancers, especially in 
prostate and endometrial cancer.  PTEN inactivation results in an increase in  
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Table 1.1 Mammalian phosphatidylinositide kinases  
 
 
 
 
Class Protein Regulatory subunits Activated by Gene 
Chromosome 
locus Expression 
Class 1A PI3K p110α p85α, p85β, p55γ, p55α, p50α RTKs PIK3CA 3q26 ubiquitously  
  p110β p85α, p85β, p55γ, p55α, p50α RTKs/GPCRs PIK3CB 3q22 ubiquitously  
  p110δ p85α, p85β, p55γ, p55α, p50α RTKs PIK3CD 1q36 ubiquitously  
Class 1B PI3K p110γ p101,p87,p84 GPCRs PIK3CG 7q22 mainly leukocytes 
Class II PI3K PI3K-C2α Clathrin ?? PIK3C2A 11p15 ubiquitously  
  PI3K-C2β Clathrin ?? PIK3C2B 1q32 ubiquitously  
  PI3K-C2γ Clathrin ?? PIK3C2G 12p12 liver, prostate, breast and salivary glands  
Class III PI3K Vps34 p150, VPS15 ?? PIK3C3 18q12 
ubiquitous but highest in heart  
and skeletal muscle 
Chapter 1 – Introduction 
17 
 
Akt activity followed by uncontrolled cell proliferation [77].  SHIP de- 
phosphorylates the D-5 position of PI(3,4,5)P3 to produce PI(3,4)P2.  SHIP 
mutations are often observed in cancers such as acute myeloid leukaemia 
(AML) where a dominant negative mutation of SHIP is reported to be 
involved [78]. 
 
1.6.3. Pharmacological inhibitors of PI3K  
 
 In 1988 the first PI3K inhibitor wortmanin was discovered which is a 
metabolite of the fungi Penicillium funiculosum and was found to inhibit PI3K 
potently with an IC50 of 5 nM [79].  The structure of wortmannin is shown in 
Figure 1.4. The primary amine on Lysine-833 in the catalytic site covalently 
bonds to wortmannin by its furan ring which results in irreversible inhibition of 
PI3K [80].  The discovery of wortmannin was shortly followed by the 
production of LY294002, a compound synthesised by Lilly research 
laboratories in 1994, which also acts as a PI3K inhibitor but, unlike 
wortmannin, binds reversibly to the ATP binding pocket [81].  LY294002 is a 
morpholine derivative from the flavanoid quertcetin and has a lower IC50 (1.4 
μM) than wortmannin but researchers often use LY294002 due to greater 
stability in solution.  It has been shown that both wortmanin and LY294002 
inhibit mammalian target of rapamycin (mTOR), mitogen activated protein 
kinase (MAPK), myosin light chain kinase (MLCK) and phosphatidylinositol 
4-kinases (PI4P) at high concentrations which is why these inhibitors are 
referred to as the ‘dirty’ inhibitors due to their numerous off target effects [82-
86].  The ATP binding pocket of PI3Kγ and its interaction with wortmannin 
and LY294002 was obtained by X-ray crystallography in 2000 [87] and this 
provided a greater understanding of how inhibitors bind to PI3K and helped 
in the production of isoform specific inhibitors.  
 The first isoform selective inhibitor synthesised by the ICOS 
corporation  (now Eli Lilly) was IC87114 which inhibits p110δ with an IC50 of 
60 nM but does not target the other PI3K isoforms until >1000 nM (Table 
1.2).  p110δ has been shown to have a key role in the immune system and 
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IC87114 has been used in a vast array of in-vitro and in-vivo studies such as 
investigating airway inflammation in asthma, neutrophil accumulation in 
inflamed tissue and its role in chronic lymphocytic leukaemia [88-90]. The 
selective p110β inhibitor TGX-221 is also an ATP competitive inhibitor which 
is highly selective for p110β with an IC50 of 9 nM and does not target other 
isoforms until its concentration is raised to 211 nM at which point it begins to 
inhibit p110δ [91]. TGX-221 has been used to successfully inhibit p110β and 
has been shown to play a role in insulin signalling, thrombosis and cancer 
[92-95].  The p110β isoform was activated by the gut hormone gastric 
inhibitory peptide (GIP) which led to a potentiation in insulin sensitivity in 
adipocytes [95].  The alpha isoform of PI3K, p110α is important in many 
diseases, deletion of the binding domain present in p110α results in 
embryonic death between E9.5 and 10.5 [96].  The roles for p110α and 
p110β are quite similar since p110α has also been shown to play a key role 
in insulin activity and tumorgenesis [97].  Of the selective p110α inhibitors 
commercially available, PIK75 is the most selective with an IC50 of 8 nM (43x 
less than other isoforms) [98]. 
             In recent years ‘cleaner’ pan-PI3K inhibitors have been generated to 
replace the first generation PI3K inhibitors such as wortmannin and 
LY294002.  One such inhibitor, the triazine derivative known as ZSTK474, 
was produced by Zenyaku Kogyo Co (Tokyo, Japan) in 2000.  Its structure 
differed from previous inhibitors and it proved not only to be more potent than 
LY294002 with an IC50 of 35 nM, but also more selective as it was shown not 
to target mTOR at low concentration [99].   ZSTK474 has been studied in 
human cancer xenographs and has shown strong antitumor activity without 
critical toxic effects [100]. The selection of highly selective PI3K isoform 
inhibitors available makes investigating possible roles for PI3K and its 
individual isoforms much easier.  Other methods such as knockouts and 
siRNA interference can be used but as the essential roles of both p110α and 
p110β have been shown it is not surprising that many researchers favour the 
use of small molecule inhibitors through experimental ease and cost 
effectiveness. 
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Table 1.2 IC50 values for PI3K inhibitors (nM) 
IC50 values were obtained from a cell-free lipid kinase assay, which involved 
recombinant expression and purification of p85α and either p110α, β or δ.  
Enzymatic analysis was performed with 100 μM ATP (with exception of 
ZSTK474 which used 10 μM ATP), the substrate PIP2 and various 
concentrations of each PI3K inhibitor [91]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Inhibitor p110α p110β p110δ 
PIK75 8 343 907 
TGX-221 >1000 9 21 
IC87114 >1000 >1000 60 
Wortmannin 0.6 2.3 0.4 
LY294002 500 970 570 
ZSTK474 0.016 0.044 0.0046 
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LY294002 
TGX-221 
IC87114 
Wortmannin 
ZSTK474 
PIK75 
Figure 1.4 Chemical structures and IC50s of PI3K inhibitors. 
The pan PI3K inhibitors consist of Wortmannin, LY294002 and ZSTK474.  
The isoform selective inhibitors are IC87114 (p110δ), TGX-221 (p110β) and 
PIK75 (p110α).   
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1.6.4 Role of PI3K in airway disease 
 
 The PI3K pathway has been reported to be involved in many 
respiratory diseases such as COPD, idiopathic pulmonary fibrosis (IPF) and 
chronic asthma. In one of the first PI3K related reports, in-vitro human 
eosinophils sensitised with ovalbumin resulted in an increase in superoxide 
(O2
-) anion release and degranulation of eosinophils which was shown to be 
PI3K dependent as treatment with the PI3K inhibitor wortmannin reduced 
both superoxide formation and de-granulation [101].  The same group also 
investigated the role of PI3K in-vivo using a guinea pig model of asthma, in 
which wortmannin was administered intra-nasally in an attempt to localise 
the effect of the inhibitor to the lungs.  It was shown that AH to histamine was 
prevented through treatment with wortmannin which was shown to be 
through the prevention of eosinophil degranulation rather than accumulation 
in the lung [101].  Similarly, pan class I inhibition using LY294002 attenuated 
the allergic response in mice by reducing cytokine production, eosinophil 
filtration and AH in an OVA sensitised model of asthma [102].  The isoforms 
responsible for causing this prevention of AH were studied by  Lee et al who 
investigated the role of p110δ in the same murine OVA sensitization model 
which showed that the p110δ was responsible for the prevention in AH as 
inhibition with IC87114 reduced influx of neutrophils, eosinophils and 
leukocytes [103].   Class IA PI3K isoforms were also shown to be involved in 
the degranulation of mast cells in which p110β and p110δ inhibition was 
shown to block the upregulation of FcεR1 expression [104].  PI3K γ-deficient 
mice do not develop AH or bronchoconstriction in response to ovalbumin 
allergen challenges [105, 106] and PI3K δ-kinase dead mice resulted in 
impaired signalling in B-cells [107, 108] , which indicates the role of p110δ 
and p110γ in allergic inflammation.   
 
  
PIK75 
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1.7 STAT6 pathway 
 
 Aside from PI3K, IL-13 signalling has been linked to the signal 
transducer and activator of transcription 6 (STAT6).  IL-13 binds to IL-13Rα1 
which phosphorylates Janus kinase 2 (JAK2) which in turn activates STAT6 
resulting in its dimerisation and translocation into the nucleus [109]. STAT6 
plays a role in asthma and it has been shown to induce the expression of 15-
lipoxgenase 1, RhoA, eotaxin, VCAM and MUC5AC, all of which are linked to 
airway dysregulation [109-113].  This makes it an interesting transcription 
factor to study, however no inhibitors exist that target STAT6 selectively.  
A novel class of antineoplastic agents which mimick histone 
deacetylases (HDAC) have been shown to inhibit STAT proteins [114, 115].  
In the nucleus of eukaryotic cells, DNA is packed into a tightly conserved 
structure called chromatin which consists of nucleosomes that at pH 7, carry 
a negative charge along with histones that carry a positive charge. Gene 
expression is controlled by the modification of chromatin, including histone 
acetylation which regulates the template accessibility to RNA polymerase II 
and DNA binding factors.  Transcription can also be initiated through histone 
phosphorylation, methylation and in non-histone proteins through DNA 
acetylation itself [116]. This balance between acetylation and deacetylation 
states of histones are controlled by two groups of enzymes; histone 
deacetylases (HDAC) and histone acetyltransferases (HAT).  HAT enzymes 
preferentially acetylate specific lysine residues whereas HDACs deacetylate 
these residues, restoring the positive charge of histones which enables them 
to strongly bind to the negatively charged phosphate backbone preventing 
transcription (Figure 1.5).   Histone hyperacetylation results in an open 
chromatin structure which modifies gene expression and promotes a variety 
of features such as cell proliferation, survival, apoptosis and differentiation 
[117-120].   
A hallmark feature of cancer is silencing of the cell cycle inhibitor p21 
through hypoacetylation; gene expression can be restored through HDAC 
inhibition which enables acetylation. HDAC is therefore a popular drug target 
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tin cancer and other diseases in which there is an epigenetic imbalance 
[121].  The HDAC inhibitor trichostatin A (TSA) has been studied in human 
carcinomic cells where it was shown to be a potent inhibitor of tumour growth 
indicating its potential as a skin anti-cancer drug [122, 123].  In accordance 
with this, TSA has also been shown to possess antitumor activity against 
breast cancer in-vitro and in-vivo [123]. 
There are 11 known HDAC isoforms, which can be split into different 
classes through their sequence homology, location within the cell and 
enzymatic properties. Class I HDACs consist of 1, 2, 3 and 8, which are 
mostly expressed in the nuclei of all healthy cell types (excluding HDAC8), 
however overexpression has been reported in aggressive malignancies 
[124].  There are two subclasses of Class II HDACs, Class IIb (6, 10) are 
expressed  primarily in the cytoplasm whereas class IIa (4, 5, 7 and 9) are 
found in both the nucleus and cytoplasm [121, 125]. Class III are the only 
class of HDACs that are NAD+ dependent with other classes being zinc 
dependent. Suberoylanilide hydroxamic acid (SAHA) also known as 
Vorinostat [126], was produced by Richon et al in 1996 and was reported to 
inhibit HDAC1-3 by binding to the enzymes active site in the presence of zinc 
[115].  SAHA was later shown to inhibit all HDACs [127].  Similar to other 
HDAC inhibitors such as TSA, SAHA showed promising potential as an 
anticancer drug and was tested in clinical trials in 2004 [116, 128].  More 
recently SAHA has been shown to have anti-inflammatory effects, by 
reducing the expression of pro-inflammatory cytokines produced in murine 
macrophages after LPS stimulation [129].  SAHA was also found to have a 
dual effect in a model of Hodgkin Lymphoma (HL) where it had direct anti-
proliferative effects and an indirect immunoregulatory effect by reducing the 
cytokine and chemokine release from TH2 cells through inhibition of STAT6 
[130].  This association between SAHA and STAT6 activity was first shown in 
2003 by Rascle et al [84] and as knowledge of HDAC inhibitors increased it 
become evident that SAHA decreased the phosphorylation of STAT6 without 
inhibiting other STAT proteins [114].   
HDAC inhibitors have also been shown to target non-histone proteins 
such as α-tubulin, one of the main proteins in microtubules.  Microtubules 
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make up part of the cytoskeleton and are essential in aiding the migration of 
fibroblasts. Inhibition of HDAC6 deacetylation of α-tubulin resulted in 
inhibition of fibroblast invasive motility and decreased focal adhesion 
dynamics and turnover [131].  Recently, STAT5 transcription has been 
shown to be inhibited by the HDAC inhibitor trichostatin A (TSA) by blocking 
basal transcription machinery following STAT5 DNA binding [132]. Both 
STAT1 and STAT3 can be direct acetylated resulting in the recruitment of 
tyrosine phosphatases [133, 134], which render the protein resistant to 
further phosphorylation. It is yet to be shown if this is true for STAT6.  In 
asthma an abnormal HDAC/HAT ratio is observed [135] along with 
prevalence for increased STAT6 expression; little is known about how 
STAT6 is regulated by HDAC.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 – Introduction 
25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Regulation of gene expression via histone acetylation and 
deacetylation. 
Histone actyltransferase (HAT) enzymes preferentially acetylate specific lysine 
residues whereas histone deacetylases (HDAC) restore the positive charge of 
histones through deacetylation.  HDAC inhibitors such as Trichostatin A and SAHA 
result in hyperacetylation of histones, in which the chromatin structure is relaxed 
inducing gene expression.  HDAC inhibitors increase the expression of 1-2% of 
genes such as the inhibitor of cell cycle kinase p21 resulting in cell growth arrest 
along with other tumour suppressing genes which account for the anti-tumour 
effects displayed.  HDAC inhibitors also upregulate the expression of anti-
inflammatory genes and can regulate the expression of transcription factors such as 
STATs through direct acetylation.   
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1.8 Glycogen synthase kinase-3- beta (GSK3β) 
 
 GSK3β is a multifunctional serine/threonine kinase that is present in 
all eukaryotes and plays a much more complicated role than merely 
catalysing the conversion of glucose to glycogen.  It acts as a crucial 
downstream regulatory switch and responds to signals from Wnt, PI3K, 
RTKs as well as G-protein coupled receptors giving a variety of different 
signalling outcomes [136].  GSK3β has been linked to numerous diseases 
including Alzheimer’s [137, 138], bipolar disease [139-141] and cancer [142].  
It is an unusual kinase in the respect that phosphorylation renders it inactive 
therefore it is regulated through this inactivation. 
    Crystal structures of GSK3β were released in 2001 and they 
provided new insights into this peculiar signalling molecule [143, 144].  
Phosphorylation of GSK3β at serine 9 by Akt results in formation of a 
pseudosubstrate which occupies the active site causing inactivation.  This 
inhibition is described as competitive however at high concentrations of 
primed substrates can overcome this inhibition.  Another strange feature of 
GSK3 is its affinity for pre-phosphorylated (primed) substrates, 
phosphorylation of the substrate beta-catenin reduced the Km 30 fold 
resulting in a much higher affinity for the enzyme [145]. 
The role of GSK3 in insulin regulation has been extensively studied, 
insulin has been shown to inhibit GSK activity which leads to the activation of 
glycogen synthase and increased deposition of glycogen.  GSKβ activity is 
upregulated in diabetes and inhibition of GSK has been shown to increase 
insulin sensitivity and improve glucose tolerance [146, 147].  Early studies 
which overexpressed GSK3 in human skeletal muscle cells showed a 
reduction of IRS1 phosphorylation and a decrease in the binding affinity of 
GS for glucose-6-phosphate, both of which impaired insulin signalling [148].   
Many small molecule inhibitors have been synthesised to target 
GSK3, where the ATP competitive 6-bromoindirubin-3′-oxime (BIO) was the 
first GSK3α/β inhibitor to show the importance of GSK in self renewal of 
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human and mouse stem cells [149].  Since then more selective inhibitors 
have been synthesised, such as 1m, which was shown to be more potent 
than BIO and more selective for GSK3β alone [149]. 
 
1.9 MAPK signalling 
 
 The MAPK pathway is one of the most studied signalling pathways in 
the body.  It is involved in a plethora of cellular processes such as 
proliferation, differentiation, apoptosis and cell cycle to name but a few and 
can be activated by a range of ligands such as cytokines, growth factors and 
viruses.   MAPK signalling initiates through activation of RTKs, such as the 
epidermal growth factor receptor (EGFR), which are present at the cell 
surface.  EGFR is activated by the ligand EGF and this ‘switches’ on the 
signalling cascade.  The pathway begins with the activation of the small 
GTPase protein Ras; after GDP is removed Ras can bind to GTP and 
become active.  Ras then proceeds to activate the protein kinase Raf which 
in turn phosphorylates and activates MEK.  Once activated, MEK 
phosphorylates extracellular signal-related kinases 1/2 (ERK 1/2) (aka 
MAPK) at Thr 202 and Tyr 204 of Erk 1 and Thr 185 and Tyr 187 of Erk 2.  
The phosphorylated form of ERK activates many transcription factors such 
as E twenty-six (ETS)-like transcription factor 1 (ELK1) and early growth 
response protein 1 (EGR1) which regulate transcription, differentiation and 
mitogenesis.   
 ERK has been a popular drug target in cancer since its roles are 
mainly focused on cell survival and proliferation.  Increased expression of 
ELK1 through ERK activation induces the expression of the anti-apoptotic 
protein myeloid cell leukaemia (Mcl-1) along with the plasminogen activator 
inhibitor-1 (PAI-1) whose levels are elevated in many tumours including 
breast cancer [150, 151].  
 In recent years, many compounds have been produced that inhibit the 
MAPK pathway. The most successful target to inhibit in the MAPK signalling 
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cascade was MEK 1/2.  MEK is activated by Raf on residues Ser 218 and 
Ser 222 and requires both sites to be phosphorylated to become fully active 
[152]. The first inhibitor generated was PD98059 [153] shortly followed by 
U0126 [154], these first generation MEK inhibitors were unique as they were 
not competitive ATP binding inhibitors.  Both were potent in preventing MEK 
phosphorylation and stopping ERK activation in vitro but both were 
unsuccessful at doing so in vivo.  There was substantial controversy over the 
potency and mechanism of action of these inhibitors which led to a second 
generation of MEK inhibitors being produced.  The first MEK inhibitor to 
reach clinical studies for treatment of cancer was CI-1040, phase I results 
proved promising with it being well tolerated and showing antitumor activity, 
however investigations were stopped at phase 2 due to insufficient antitumor 
activity in patients with solid tumours [155, 156]. The MEK 1/2 inhibitor 
PD0325901 produced by Pfizer was shown to inhibit MEK 1 and 2 more 
potently than CI-1040 with an IC50 of 0.33nM (compared to 17nM for CI-
1040) [156-158]. 
TGFβ is a known ligand of EGFR and along with IL-13 has been 
shown to play roles in the epithelial-to-mesenchymal transition in many 
studies [159-161].  A synergistic role for IL-13 and TGF-β was hypothesised 
when IL-13+TGFβ but not IL-13 alone increased the production of the 
eosinophil chemokine eotaxin 1(CCL11) by airway fibroblasts [161].  It was 
later found that inhibition with the MEK/ERK inhibitor PD98059 after 
stimulation with IL-13+TGFβ resulted in an increase in IL-13Rα2 expression 
[162].  As eotaxin expression causes the accumulation of eosinophils in the 
lung, the finding linking these pathways was an interesting and a relevant 
one for asthma research.  Zhou et al hypothesised that TGFβ increases 
eotaxin expression by dampening the IL-13 autoregulatory mechanism by 
reducing the amount of binding to IL-13Rα2. 
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Figure 1.6 Chemical structures of the STAT6, GSK3β and MEK 
inhibitors SAHA, 1m and PD0325901 
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1.10 The lung epithelium 
 
 The lung epithelium has many roles, the most obvious being gas 
exchange in the alveoli, however another major role is in the protection of the 
underlying cells from inhaled pathogens from the external environment.  It is 
made up of a heterogeneous layer of cells and is defined as a ciliated 
pseudostratified columnar epithelium. This description is due to the 
heterogeneous nature of the cells that line the trachea, bronchi and larger 
bronchioles (upper airways) which consist of ciliated stratified cells tightly 
packed together with goblet and basal cells attached to the basal lamina.  
The smaller bronchioles and the connecting alveoli are lined with simple 
squamous epithelial cells to enable quick exchange of oxygen and carbon 
dioxide across the membrane. 
The epithelial cells in the upper airway have a much more complicated 
role than those at the gas exchange level, they are involved in the transport 
of a plethora of substances a such as cells, pathogens and tissue fluids 
across the membrane via paracellular permeability.  Paracellular permeability 
is controlled by the proteins that hold adjacent epithelial cells together, which 
are collectively known as junctional proteins. 
 
1.10.1 Junctional proteins 
 
Junctional proteins that bind adjacent epithelial cells were discovered in the 
early 1960s but have been more extensively researched over the last 20 
years [163-165].  There are 4 main groups of junctional proteins that can 
have roles in anchoring, communication and regulation, these groups are: 
adherens junctions, desmosomes, gap junctions and tight junctions.  
Adherens junctions and desmosomes have anchoring roles, whereas gap 
junctions are responsible for communication and tight junctions have roles in 
regulation.  The tight junction complex is located at the most apical part of 
the adjoining membrane, it is made up of proteins such as occludin and the 
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complex family of claudins.  These tight junction proteins are essential in 
regulating paracellular permeability and bind to important scaffold proteins 
known as zonula occludens.  The adherens junction (AJ) is situated below 
the TJ complex and consists of catenins and cadherins proteins.  The most 
studied adherens junction protein is E-cadherin which requires calcium ions 
for localisation at the junction [166].  Desmosomes and hemidesmosomes 
are intracellular adhesive junction proteins which anchor the intermediate 
filaments to the plasma membrane [167].  Desmosomes lie beneath 
cadherins, wheras hemidesmosomes link the epithelial cell to the basement 
membrane.   Gap junctions are clusters of intracellular channels between 
adjacent epithelial cells; they link the cytoplasm of two cells and act as a 
form of communication [168, 169].  The main family of gap junction proteins 
are connexins, in which there are around 21 members.   
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Figure 1.7 An overview of the junctional protein arrangement between adjacent 
epithelial cells.   
Adjacent epithelial cells are connected via junctional proteins that are responsible for 
controlling paracellular permeability and maintaining cell polarity.  The 
transmembrane tight junction proteins occludin and claudin bind to the scaffold 
proteins ZO-1 and ZO-2 anchoring them to the actin cytoskeleton.  The adherens 
junction protein E-cadherin is positioned below the tight junction and requires Ca2+ 
ions for junctional assembly.  Desmosomes and gap junctions associate below the 
apical junctional complex and hemidesmosomes link the epithelial cell to the 
basement membrane. Hemidesmosomes are connected to desmosomes via 
intermediate filaments; they associate with integrins and play a role in wound 
healing. (NB. Diagram not drawn to scale)  
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1.10.2 The discovery of tight junction proteins 
 
 The first transmembrane tight junction protein occludin was 
discovered in 1993 by Furuse et al, who examined chick liver and found a 
65kDa protein which was observed directly over the points of contact 
between epithelial and endothelial cells (the tight junction) under both light 
and electron microscopy [170].  The structure of occludin is now well known, 
it is a transmembrane protein with four transmembrane domains, two 
extracellular loops, a short N-terminus and a long C-terminus.  The 
importance of occludin was shown in many studies; overexpression in MDCK 
cells resulted in an 30-40% increase in the trans-epithelial resistance (TER) 
(i.e. a measure of TJ strength) as well as a 15% increase in tight junction 
strand density [171] and truncation of the C-terminus resulted in a decrease 
in TER [172]. The essential role of occludin at the TJ was questioned by two 
contrasting studies which altered the C-terminus of the protein and still 
observed an intact TJ, which posed a question as to the degree of 
involvement other integral transmembrane proteins have [172, 173].   During 
further investigation of chick liver an un-identified 22kDa protein was 
discovered and after sequencing was found to encode two proteins, 211 and 
230 amino acids long.  The structure of these proteins had four 
transmembrane domains similar to occludin but had no sequence homology.  
These proteins were named Claudin 1 and Claudin 2 and were the start of 
the ‘claudin family’[174].  It soon became evident that Claudin 1 and 2 
showed a stronger ability to form TJ strands than occludin [175]  and over 
the years more members of the claudin family have been discovered with 24 
individual claudin proteins presently known [176]. 
The first tight junction protein discovered was not occludin but the 
important tight junction associative protein zonula occluden which was 
discovered around 1966 [177] and was found to be present in three forms, 
zonula occluden 1, 2 and 3 (ZO-1, 2, 3) [178, 179].  These proteins were 
classed as belonging to the membrane associated guanylate kinase protein 
family termed MAGUK.  ZO-1 was reported to associate with the 
transmembrane protein occludin [116] and later studies showed to also binds 
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members of the claudin family [180-182] this complex made up of occludin, 
claudin and ZO-1 and ZO-2 become known as the core tight junction 
complex.  Today ZO-1, 2 and 3 are often referred to as scaffold proteins as 
their role is to anchor occludin and claudin in place by binding to the actin 
cytoskeleton [182]. 
 
1.10.3 Zonula occludens 
 
Zonula occludens possess the common MAGUK modules PDZ, SH3 
and GUK (the term PDZ is derived from the first letter of the proteins in which 
the binding domain were first witnessed, PSD-95, Drosophila lethal (1) discs 
large-1 and ZO-1).   The PDZ domains are protein binding domains which 
are important in the anchoring of transmembrane proteins by recognition of 
certain sequences in other protein e.g. S /TXV [183].  SH3 domains contain 
the binding domain PXXP and are known to regulate enzymatic activity by 
coupling substrates.  The guanylate kinase domain is thought to be 
enzymatically inactive as it doesn’t catalyse the reaction of GMP to GDP 
[183]. 
ZO-1 is a 220-225kDa protein, which is mainly expressed in epithelial 
and endothelial cells although it has been reported in fibroblasts, astrocytes 
and Schwann cells [184].  The C-terminal domain in ZO-1 is 3 and 10 times 
longer than that of ZO-2 and ZO-3 respectively.  The C-terminus is important 
in anchoring transmembrane proteins such as occludin to the actin 
cytoskeleton.   
ZO-1 has many binding partners, the most well known being the TJ 
proteins occludin along with many members of the claudin family (Figure 
1.7).  ZO-1 has been shown to interact with the peripheral membrane 
protein, junction-enriched and –associated protein, JEAP [185], along with 
the second member of the connexin family, connexin 45 which also 
associates with ZO-3 via its PDZ domain but not with ZO-2 [186].  The 
junctional adhesion molecule (JAM) interacts with the PDZ domain in the N-
Chapter 1 – Introduction 
35 
 
terminal region of ZO-1 along with cingulin, both interactions are thought to 
stabilise the association between ZO-1 and occludin [187].    Cingulin is a 
component of the multiprotein TJ complex and has been shown to interact 
with ZO-1 via activation of Rho A; unlike ZO-1 its expression is restricted to 
epithelial tissues [188].   ZO-2 is similar to ZO-1 with 51% amino acid 
identity, however its C-terminal tail is quite different only displaying 25% 
sequence homology which indicates that ZO-2 will function differently to ZO-
1 as the C-terminus is responsible for the regulation of the protein [189]. 
ZO-3 was identified in 1998 by Haskins et al and was shown to be 
homologous to ZO-1 and ZO-2 with 3 PDZ domains, an SH3 domain and an 
acidic C-terminal tail.  It differed from ZO-1 and ZO-2 by containing a proline 
rich region between the second and third PDZ domains [178].  The exact 
roles of these three MAGUK proteins are still not fully characterised.  ZO-2 
was shown to be essential for embryonic development as ZO-2 deficient 
embryos died shortly after implantation, whereas ZO-3 was shown to be 
dispensable and cells even remained polarized [190].   
 
1.10.4 Occludin 
 
 Occludin is a four transmembrane protein, with 2 extracellular loops, a 
long C-terminus and a shorter N-terminus shown in Figure 1.8.  The C-
terminus has been shown to be vital in TJ assembly, it spans 254 amino 
acids and the COOH-terminal domain contains a 27-amino acid stretch 
which binds ZO-1, this region contains hydrophobic clusters and is termed 
the coiled-coil domain [191].  This coiled-coil region was found to be redox 
sensitive and occludin was shown to undergo dimerisation by forming a 
disulphide bridge at cysteine 408 [192, 193].   
 The N-terminus domain consists of 149 amino acids and has also 
shown to be essential in the function of occludin at the TJ, as an occludin 
construct which lacked the N-terminus was found to inhibit the production of 
a high TER and increased paracellular mannitol flux [194]. 
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 A crucial role for the second extracellular loop of occludin was 
reported by Medina et al who found that deletion of the second but not the 
first extracellular loop proved detrimental to its function and location at the 
TJ.  These data were consistent with other studies which showed that the 
extracellular loops can impair adhesion, tight junction re-sealing and 
localization [173, 195-197]. 
 Occludin has many binding partners, the first shown to interact with 
the TJ protein were ZO-1 and ZO-2 [198].  In recent years occludin has been 
shown to bind VAP33, caveolin and PKCη to name but a few [199-201].  
Occludin phosphorylation at the coiled-coil domain of the C-terminus is 
reportedly involved in the regulation of the TJ protein.  Highly phosphorylated 
occludin was found localised at the tight junction whereas non-
phosphorylated occludin was distributed on the basement membrane [202].  
The effect that phosphorylation has on occludin was shown when 
phosphorylation on serine and threonine residues led to the assembly of 
occludin at the tight junction [203], whereas tyrosine phosphorylation was 
shown to disrupt occludin function.  Phosphorylation of tyrosine on residues 
398 and 402 prevents it interaction with ZO-1 and prevents TJ assembly 
[204].  Protein kinase C η (PKCη), a novel isoform found only in epithelial 
cells, was shown to phosphorylate threonine 403 and 404 at the coiled-coiled 
domain which was shown to be essential for assembly and maintenance of 
occludin at the TJ [199].  Although tyrosine phosphorylation has been shown 
to be damaging to the integrity of the TJ, it plays a role in the re-formation of 
occludin, ZO-2 and ZO-3 and hence the recovery of the paracellular barrier 
after injury [205]. 
 
1.10.5 The Claudin family  
 
 Since the discovery of claudin 1 and 2 in 1998, a further 22 
members of the claudin family have been discovered.  Claudins are named 
after the latin word ‘claudere’ which means to close, as they were understood 
to have an important role in the tight junction.  They are comprised of four 
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transmembrane domains, two extracellular loops, a longer cytosolic C-
terminus and a shorter cytosolic N-terminus (Figure 1.8).  Compared to other 
TJ proteins claudins are quite small ranging from 22-27kDa, the first 
extracellular loop (EL) is larger than the second at around 50 amino acids 
long and is thought to regulate paracellular tightness and control selective 
ion paracellular permeability [206].  It contains charged amino acids and 
reactive cysteine residues that are thought to form di-sulphide bridges to 
stabilize the protein as many claudins are insensitive to thio-reactive agents 
[207]. The second extracellular loop (EL2) comprises of around 16-33 
residues and contains the receptor for Clostridium perfringens enterotoxin 
(CPE), an interesting finding from a drug delivery perspective [208].  The EL2 
is also thought to contribute to various interactions between claudin 
members.  Interactions between the same claudin members are termed 
homotypic or homomeric depending on whether the proteins interact head to 
head or side to side respectively.  If these interactions occur with differing 
claudin members they are termed hetrotypic and heterometric [180].  
Claudins are thought to restrict the paracellular space through these 
interactions and different claudins have varying selectivity to size and 
charge.  Claudin 1 and 5 have been reported to be involved in homotypic and 
hetrotypic interactions and their dimerisation is thought to be aided by the 
aromatic amino acids present in the EL2 [209].  It is likely that this variety of 
possible claudin associations can shed some light on why paracellular 
permeability is such a dynamic process.   
 
 The C-terminal region of claudins ranges greatly between different 
isoforms suggesting that it is responsible for the differing roles observed.  It 
contains a PDZ domain which binds the MAGUK proteins ZO-1, 2 and 3, 
[182] as in occludin. It has also been shown to bind junctional adhesion 
molecule (JAM-1) through binding of ZO-1 which triggers the binding of 
protease activated receptor 3 (PAR-3) to the tight junction [210].  ZO-1 and 
ZO-2 are responsible for the organization of the spatial arrangement of 
claudin strands in epithelial cells but are not required for claudin strand 
formation shown by claudin transfection into non-polar fibroblasts  [175, 211].  
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The N-terminus of claudin is very short only spanning around 7 amino acids 
and has no known functionality.  There are two classes of claudins, each of 
which have opposing functions, class I are made up of proteins that seal the 
tight junction and class II are made up of pore forming  tight junctions.  The 
pore forming tight junctions are claudin 2, 10, 15 and 20.  Claudin 2 and 10 
are expressed in the lung whereas 15 and 20 have not been shown to be 
present [212].  The most studied pore forming tight junction is claudin 2, 
which forms pores that have been shown to be oligomeric and dependent on 
cysteine 66, as manipulation of this residue lead to blockage of the pore 
[213].  Claudin 1 and 8 are known to interact with the multi PDZ-domain 
protein 1  (MUPP1) which is found localised in the tight junction [214]. 
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Figure 1.8 The structure of occludin and claudin at the apical junctional complex. The tight junction transmembrane proteins occludin 
and the family of claudins consist of 2 extracellular loops, 4 transmembrane domains, an N-terminal and a C-terminal intracellular domain. The first 
extracellular loop (EL1) of claudins is responsible for their assembly at the TJ and for charge selective pore formation.  All claudins contain 2 reactive cysteine 
residues in their EL1, which form a disulphide bridge and are crucial to the structure and function of claudins. Site directed mutagenesis at either cysteine 
residue results in a decrease in TER and disruption of TJ assembly [207, 213, 215].  The second extracellular loop (EL2) has been linked with claudin 
oligomerisation across adjacent epithelial cells and is known to contain the binding domain for Clostridium perfringens enterotoxin (CPE) [208].  The C-
terminal tail of occludin contains the redox sensitive coiled-coil (CC) domain.  Phosphorylation at threonine 403 and 404 present in the CC domain is critical 
for assembly and maintenance at the TJ, whereas phosphorylation of tyrosine 398 and 402 prevents the interaction with ZO-1 and disrupts TJ formation 
[204].  In contrast to claudins, the EL2 of occludin is required for its localization at the TJ [216]. GD; guanylate kinase domain, CC; colied-coil domain, JAM; 
junctional adhesion molecule, PDZ; PSD95/dlg/ZO-1. 
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1.10.6 The cadherin family – E-cadherin 
 
 The 135 kDa intracellular adherens junctional protein E-cadherin was 
discovered in 1984 and is part of the cadherin family of junctional proteins 
[217]. Other original members of the cadherin family are N-cadherin and P-
cadherin, where the letter denotes the location of protein expression in the 
body, E-cadherin is expressed in epithelial tissue. N-cadherin is mainly 
expressed in neural tissue and P-cadherin expression was first identified in 
the placenta [217-220].  This family of proteins got their name from their 
“calcium dependent adhesion” properties; hence they depend on calcium 
ions to function adequately.   
 E-cadherin  has around 723-748 amino acids, its structure consists of 
a single transmembrane domain, an extracellular N-terminus and a 
cytoplasmic C-terminus domain [217]. The amino acid sequence is highly 
conserved (between 69-89%) in the cytoplasmic tail and this was the region 
found to regulate cell-cell binding [221]. 
 
1.10.7 Regulation of the TJ in the intestine and the kidney 
 
The regulation of the epithelial barrier through modulation of tight 
junction proteins in the intestine and kidney has been researched in relation 
to Ulcerative colitis (UC) and Crohn’s Disease (CD), which are both 
conditions involving the breakdown of the epithelial barrier of the intestine 
leading to uncontrolled flux of solutes resulting in a common symptom of 
severe diarrhoea.  Epithelial breakdown is characterised in UC by a 
disruption of tight junction proteins and a decrease in the number of tight 
junction strands at the apical membrane [222]. Tight junction strand breaks 
can also be seen in CD [223, 224], along with cell apoptosis and epithelial 
cell lesions [225].  Although TJ strand numbers are reduced, an increase in 
the expression of the TJ protein claudin 2 has been reported in UC and 
decreases in claudin 5 and claudin 8 have also been observed [226, 227].   
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Extracellular calcium levels were one of the first known regulators of 
the apical junction complex (AJC).  Depletion of calcium levels resulted in 
diffuse TJ staining in the cell and upon returning to normal calcium levels, TJ 
proteins becomes localised to the AJC (an experiment known as a ‘calcium 
switch’) [166, 228-231].  The tight junction protein ZO-1 was the first protein 
shown to be modulated by calcium in this way [228].  
AMP-activated protein kinase (AMPK) has a prominent role in 
regulating cell metabolism and was also shown to be involved in the 
regulation of  the TJ.  AMPK was phosphorylated at threronine 172 and this 
phosphorylation decreased during calcium depletion leading to re-distribution 
of ZO-1 from the TJ to the cytoplasm [232, 233].  To ensure the TJ regulation 
was due to AMPK not just calcium changes, AMPK was activated through 
addition of the AMP precursor 5-aminoimidizole-4carboxamide riboside 
(AICAR) and the result remained the same, indicating an important role for 
AMPK in TJ regulation.  AMPK is activated by the serine-threonine kinase 
LKB1 which has been shown to inhibit GSK3β, an association which lead 
Zhang et al to investigate the role of GSK3β in TJ modulation.  Inhibition of 
GSK3β by LiCl or SB216763 resulted in the deposition of TJ components 
ZO-1 and occludin even before the restoration of normal calcium levels 
indiating that GSK3β modulation of the TJ is independent of calcium [234].  
GSK3β inhibiton further increased the deopsition of TJ components even 
after maximum AMPK activation was reached. GSK3β inhibtion by 
SB415286 in intestine (SKCO-15) and kidney cells (MDCK) resulted in an 
increase in paracellular permeability coupled with a decrease in claudin 1, 
occludin and E-cadherin expression [235].   
The MAPK pathway has been shown to be involved in the protection 
of epithelial integrity from hydrogen peroxide through EGF activation.  EGF 
has been reported to achieve this through prevention of tyrosine 
phosphorylation on ZO-1 and occludin [236].  Protein kinase C (PKC) has 
been pinpointed as a player in the regulation of the TJ with a specific role in 
the assembly of the tight junction proteins ZO-1, claudin1, claudin 4 and 
occludin [199, 237-239]. Claudin 1 and claudin 4 are specifically regulated by 
phosphorylation through the novel isoform PKCθ, which doesn’t require 
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calcium for activation.  On the other hand occludin assembly has been 
reported to involve PKCη [238] and PKCβ has been shown in an opposite 
role in endothelial cells, by controlling the paracellular permeability of VEGF 
by phosphorylating occludin which leads to its ubiquitination [240-242]. There 
has also been a correlation to the amount of PKCα at the membrane and the 
level of paracellular permeability [199]. The spatial organization of the TJ 
was shown to be associated with the small GTPase proteins RhoA and 
Rac1, the epithelial barrier was disrupted resulting in a leaky system when 
RhoA and Rac1 were constitutively active or dominant negative, although 
ZO-1 and occludin expression remained constant [243].  This notion of 
controlling the spatial  arrangement of the TJ was followed up by Terry et al 
who discovered that RhoA is driven by a junction-associated Rho signalling 
molecule called p114RhoGEF that spatially restricts the activation of Rho 
which results in TJ formation [244]. 
The pore forming tight junction protein claudin 2 was reported to be 
upregulated by IL-13 [245] a discovery which pin-pointed the Th2 cytokine as 
a key effector in UC.  IL-13 was shown to induce apoptosis, increase claudin 
2 expression and mucus secretion.  The signalling mechanisms by which IL-
13 elicits its responses has come under some scrutiny with Rosen et al 
proposing an involvement for STAT6 in epithelial barrier dysfunction in UC 
which is consistent with results from Maddon et al [246, 247].  However, 
these data have been opposed by Ceponis et al who believe IL-13 signals 
via PI3K and is independent of STAT6 activation [248].  Although the 
argument has not been settled there seems to be a role played by both PI3K 
and STAT6 which raises the question of whether a complementary effect or 
cross-over in their signalling pathways exists.  Claudin 2 up-regulation has 
also been shown to be attributable to the pro-inflammatory cytokine tumour 
necrosis factor-α (TNFα).  TNFα up-regulates claudin 2 in colonic HT29/B6 
cells after 24 hours stimulation and is shown to be mediated by the PI3K 
pathway as the up-regulation was prevented by inhibition with the pan-PI3K 
inhibitor LY294002 [249]. 
Combination of the pro-inflammatory cytokines TNFα and IFN-γ 
altered expression of claudin 1, claudin 2, claudin 3 and occludin  in MDCK 
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cells and inhibition of ERK 1/2 enhanced the expression of occludin and 
claudin 1 at the TJ interface [250].  This indicated a role for the MAPK 
pathway in TJ regulation which has been examined in a number of studies 
which found that activation of ERK1/2 has been shown to both up-regulate 
claudin 2 in intestine cells [249] and down-regulate claudin 2 in kidney cells, 
[250] this discrepancy may be a result of TJ proteins having different 
regulation patterns in respect to their location in the body. 
 
1.10.8 Regulation of the TJ in the airway 
 
 There is significantly less research on the regulation of the AJC in the 
lung epithelial layer although it has been found that cytokines, bacteria and 
oxidative stress can play a significant role in both assembly and dysfunction 
of the highly dynamic TJ complex.  Combined treatment with TH1 cytokines 
TNFα and IFNγ in primary human airway epithelial cells has been reported to 
alter the localisation of ZO-1 and junctional adhesion molecule (JAM) and 
decrease their expression after 24 hours treatment [251].  IL-13 and IL-4 
were shown to disrupt the epithelial TJ complex as is seen in the intestine, 
treatment with both cytokines for 72 hours increased mannitol permeability 
2.5 fold compared with controls [252].  In human epithelial Calu-3 cells IFNγ 
has been shown to reduce the levels of occludin and ZO-1 but it also plays 
an unusual role as it enhances the barrier by increasing the transepithelial 
resistance and prevents disruption of the TJ by IL-4 and IL-13.  This 
observation is interesting as it is not observed in the intestine, T84 cells show 
a decrease in TER and paracellular permeability after IFNγ stimulation [253].   
The role of inhaled allergens in the regulation of the TJ has been 
researched.  The alkaline serine protease from P.chrysogenum (Pen ch 13) 
was reported to upregulate the expression of prostaglandin 2 (PGE2), IL-8 
and TGFβ in A549, and 16-HBE lung epithelial cell lines.  PGE2 has been 
shown to dampen the TH1 response and enhance the TH2 inflammation 
leading to TJ disruption [254, 255].  The non-proteolytic group 2 allergen Der 
p 2 is derived from house dust mite and has been linked to triggering asthma 
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attacks, the mechanism by which Der p 2 exerts its effects was recently 
researched where it was shown that Der p 2 increases the cell surface 
expression of claudin 2 in A549 cells via ERK 1/2 and GSK3β 
phosphorylation [256].  A Der p2 DNA mutant vaccine was shown to prevent 
AH and allergenic airway inflammation in mice by upregulating Toll-like 
receptor 9 (TLR9) and inhibiting STAT6 [257, 258].  Der p 2 and Der p 1 
have also been shown to disrupt the TJ by cleavage of occludin [256, 259].    
Oxidative stress has been linked to epithelial barrier disruption with an 
inflamed epithelium producing increased amounts of nitric oxide via 
upregulation of the enzyme nitric oxide synthase NOS in the airways [260].  
Nitric oxide synthase has many isoforms, inducible nitric oxide synthase 
(iNOS) has been shown to promote epithelial wound healing in the lung 
epithelial cell line 16-HBE [46].  Research carried out on NO in the lung has 
mainly focused on Cystic Fibrosis (CF) as a key characteristic in patients is 
their deficiency of nitric oxide production due to an alteration in the signalling 
pathways that produce NO and the expression of NOS [261, 262].  CF has a 
mutated cystic fibrosis transmembrane conductance regulator gene (CFTR) 
which affects the chloride ion transport. Cells with a CFTR mutation 
(CFBE41o and AF508) were reported not to increase their expression of 
iNOS after IFNγ, IL-1β and TNFα stimulation whereas normal HBE cells 
showed a dramatic increase [263].  This finding may explain why patients 
with CF are much more susceptible to infection.  In 16-HBE airway epithelial 
cells nitric oxide was shown not to impair the TJ integrity but has a role in the 
assembly of the TJ [46]. 
Rho A and Rac are involved in TJ maintenance through regulation of 
the actin cytoskeleton (see review [264]).  Rho and Rac mutants cause a 
decrease in TER but do not alter the TJ protein expression, however cause 
apical clumping and actin strand loss at the basolateral side [243]. 
Cytoskeletal modulation via activation of Rho kinase (ROCK) and myosin 
light chain kinase (MLCK) has been linked to cigarette smoke.  Treatment 
with cigarette smoke resulted in a decreased association between ZO-1 and 
occludin via destabilisation of occludin through tyrosine phosphorylation 
[265].  ROCK has been shown to increase F-actin expression at the 
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periphery of the cell [266] through phosphorylation of the myosin binding 
subunit (MBS) [267], which results in increased permeability [268] and TJ 
redistribution resulting in disruption of the epithelial barrier.  TGFβ is also 
shown to play a role in upregulating RhoA in the mobilization of the actin 
cytoskeleton at the TJ [269]. 
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Figure 1.9 Overview of important signalling pathways in TJ regulation.  
The complexity of the multiple interconnecting signalling pathways behind the highly dynamic regulation of the tight junction complex has given rise to many conflicting results. 
The MAPK pathway is activated through receptor tyrosine kinase (RTK) activation and has been shown to both disrupt the TJ complex in corneal epithelial cells [270] as well 
as stabilise it in intestinal cells [271].  RhoA kinase is activated through G-protein coupled receptors (GPCR) via the guanine nucleotide exchange factor (GEF) which activates 
GTPases leading to ROCK activation. ROCK phosphorylates myosin light chain (MLC) at serine 19 and also inhibits MLC phosphatase activity, which dephosphorylates MLC.  
The ROCK/Rho signalling pathway has been linked with regulation of the actin cytoskeleton [266]. PI3K is activated via RTKs such as the cytokine receptor IL-13Rα1 through 
IL-13 binding and can inhibit GSK3β through phosphorylation at Serine 9.  GSK3β inhibition has been shown to be beneficial to barrier integrity by increasing occludin and ZO-
1 expression and deposition at the TJ [234].  STAT6 is activated by RTK activation leading to the recruitment of janus kinases (JAK) and tyrosine kinase 2 (Tyk2) which 
phosphorylate STAT6. There is limited research on the role of PI3K and STAT6 in TJ regulation in the lung, however both have been shown to play a role in altering the barrier 
integrity in IBD [247, 248].  
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1.11 Aims of the project 
 
 The junctional complex is responsible for the maintenance of epithelial 
polarity along with the control of paracellular permeability.  As shown in this 
introductory chapter, asthmatic patients have a disrupted epithelial layer 
during allergic inflammation, resulting in loss of barrier integrity which 
becomes a vicious circle sustaining inflammation.  The regulation of the tight 
junction is highly dynamic and not well established in lung epithelial cells.  IL-
13 has been shown to play a key role in the modulation of the TJ in IBD, 
however research into regulation of the TJ in the lung is lacking.  The overall 
aim of this thesis was to characterise the role of IL-13 in the regulation of the 
TJ.  This can be subdivided into the following aims: 
1. To establish a physiologically relevant airway epithelial model which 
could be easily manipulated 
2. To investigate the role of IL-13 in the regulation of the TJ, in particular 
the main objectives were: 
 To investigate the effect of IL-13 on the integrity of the epithelial 
barrier, by monitoring resistance and paracellular permeability 
 To assess the effects of IL-13 on junctional protein expression 
and distribution within Calu-3 cells 
 To interpret the signalling pathways that are involved in the 
effects of IL-13 in the modulation of the epithelial barrier. 
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2.1 Cell culture 
 
2.1.1 Calu-3 cells 
 Human sub-mucosal Calu-3 cells from a pleural effusion [272] (HTB-
55) were obtained from the American Type Culture Collection (ATCC).  Calu-
3 cells were cultured in Minimal essential media (MEM) supplemented with 
10% fetal bovine serum (FBS), 2 mM glutamine, 5% non essential amino 
acids (NEAA) 100 U/ml pencillin, 100 μg/ml streptomycin, 1% fungizone and 
5 μg/ml plasmocin (referred to as complete MEM media) at 37°C in a 5% 
CO2 humidified atmosphere.  Calu-3 cells were cultured in flasks or multi-well 
plates which were pre-treated with a coating solution (1 mg/ml bovine serum 
albumin, 3 mg/ml collagen I and 1 mg/ml human fibronectin in LHC basal 
media) overnight to ensure cell adherence. 
Calu-3 cells were grown using an air-liquid-interface (ALI) culture 
system with 12-well transwell plates which comprised of 12 mm polyester 
filters with a 0.4 μm pore size (Figure 2.1).  300 μl of cells were plated onto 
the apical side of the filter and 1 ml of complete media was placed in the 
basolateral chamber, cells were placed in incubation at 37°C for 48 hours.  
After this time the cells have attached to the filter, the media was removed 
from the apical chamber and the cell monolayer was exposed to air at the 
apical side and media at the basolateral side so ALI was established.  In 
either ALI or normal immersion culture, media was changed every other day 
until confluency.  Calu-3 cells  were used between passages 20-40 which is 
similar to other research groups who study them between passages 24-40  
[273]. 
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2.1.2 A549 cells 
 Human alveolar epithelial cells A549s were obtained from the 
European Collection of Animal Cell Culture and cultured in a 1:1 mix of 
Dulbecco’s Modified Eagle Media (DMEM) and Ham’s F-12 nutrient mixture 
(DMEM/F-12) supplemented with 10% FBS, 2 mM glutamine, 100 U/ml 
pencillin, 100 μg/ml streptomycin and 1% fungizone at 37°C in a 5% CO2 
humidified atmosphere. Culture media was changed every other day until 
confluency. 
2.1.3 Subculture 
When cells reached 80-90% confluency, the medium in the 75 cm2 
flask was removed and cells were washed with pre-warmed PBS to wash 
away any traces of serum.  They were then placed in 7ml of 0.25% 
Trypsin/EDTA for 15-20 minutes at 37°C.  Once cells had detached from the 
flask, 15 ml of complete media was added to stop the reaction. Cells were 
centrifuged at 25000 g for 5 minutes at 25°C, the media was removed and 
the cell pellet was dissolved in 2ml of complete media for cell counting using 
a dye exclusion method with trypan blue.  Cells were mixed with trypan blue 
 
Figure 2.1 Schematic diagram of an air-liquid interface culture system.  
Cells are seeded onto the apical chamber, a polycarbonate filter with 0.4 μm 
pores.  Cells were left with complete media in the apical chamber (immersion 
culture) for 2 days after which time the media was removed to establish the air-
liquid-interface.  Basolateral media was changed every other day 
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in a 1:1 ratio and 10 μl of the mixture was placed in a haemocytometer and a 
cell count was performed. Dye exclusion works as intact cells will not allow 
trypan blue in whereas cells which are dying will have a compromised cell 
membrane and will let the dye enter, therefore, all cells that are stained blue 
are excluded from the count.  Cells were then plated either into flasks or into 
multiwall plates at a seeding density of 2x105 cells/ml for subsequent 
experiments.  A549 subculture is as detailed for Calu-3 cells except cells 
were placed in 3ml of 0.05% Tryspin/EDTA for 3 minutes and plated in larger 
175 cm2 flasks due to an increased rate of growth. 
2.1.4. Thawing and freezing cell lines 
Vials were removed from liquid nitrogen and quickly thawed in a 37°C 
water bath, cells were added to 9ml of complete media and centrifuged for 
10mins at 250 g at 25°C.  The media was aspirated off and the pellet was re-
dissolved in 1 ml of complete media followed by the addition of another 9ml 
and centrifuged as before, cells were then placed into a small 25 cm2 flask 
(coated for Calu-3 cells) and incubated for 24 hours.   After 24 h the media 
was changed and then cells were cultured normally with a media change 
every 2 days. 
 Cells were frozen down at 60-80% confluency, they were detached 
using trypsin/EDTA, checked for viability and counted using trypan blue.  
Freezing media consisted of 50% FBS, 40% complete media and 10% 
DMSO.  Cells were resuspended at 1x106 cells/ml into cryotubes and placed 
at -80°C for 24 hours after which time they were transferred to liquid 
nitrogen. 
 
2.1.5 Routine testing for mycoplasma 
Every three months cell lines were screened for the presence of a 
mycoplasma infection.  Mycoplasma are a group of bacteria which lack a cell 
wall, this feature makes them resistant to many antibiotics such as penicillin. 
Cells were cultured in 75 cm2 flasks and when they reached 50% confluence, 
2 ml of media was removed after it had been in contact with the cells for at 
least 24 hours.  The sample was tested using a mycoplasma kit (Lonza), 600 
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μl of assay buffer was added to both substrate and reagent vials.  The media 
was centrifuged at 11000 g for 5 minutes at room temperature and reading A 
was obtained by adding 100 μl of media to 100 μl of reagent in a 96 well 
white plate.  The luminescence was read on a Fluostar optima plate reader, 
after which 100 μl of the substrate was added to the well and left for 5 
minutes before reading B was taken.  The result of the test was dependant 
on the ratio of reading B/reading A, if the answer was less than one then 
cells were mycoplasma free however if it was greater than one then cells 
were infected.  If cells were infected they could be treated with Plasmocin to 
eliminate the infection in 2 weeks and to prevent further infection Plasmocin 
was routinely added to the media. 
   
2.2  Transepithelial resistance 
Calu-3 cells grown via ALI were monitored using transepithelial 
resistance measurements to check on their confluency this was necessary 
as the standard method using light microscopy proved inefficient due to poor 
lighting on the surface of the filter.  Resistance was measured using STX-2 
chopstick electrodes which have one long and one short arm, the short arm 
rests in the apical chamber media and the longer arm in the basolateral 
chamber media, the resistance between the electrodes is measured using an 
EVOM voltohmmeter to give the raw value in ohms.   The higher the 
resistance between the electrodes the more confluent the cells are as less 
ions can flow between them.  The TER was measured everyday once ALI 
culture had begun and the value obtained was converted into ohms.cm2.   
Pre-warmed serum-free media (300 μl) was placed in the apical chamber 
and incubated at 37°C for 30 minutes to equilibrate.  During this time, the 
STX-2 electrodes were sterilized using 100% ethanol for 30 minutes, they 
were then placed in serum free media to wash off all traces of ethanol. As a 
background reading a well without cells (just media) was used before every 
experimental plate.  The chopsticks were placed in undiluted bleach for 3 
minutes followed by rinsing with water for 20 minutes to ensure a deep clean, 
this was done every 3-4 months and their performance was also routinely 
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checked using a CALICELL12 (WPI instruments) to check for any variations 
in TER measurements.  TER is a useful technique as it is seen as an indirect 
measure of epithelial integrity and presence of tight junction proteins [274]. 
 
2.2.1 Cytokine stimulation  
Once the raw resistance value had reached over 400 Ωcm2 the cells 
were considered confluent and if none of the basolateral media was seeping 
into the apical chamber i.e non ‘leaky’ then they were ready for cytokine 
stimulation.   For long term experiments cytokines were added to the 
basolateral chamber in serum media and the TER was monitored every 24 
hours, cytokines were refreshed every 72 hours.  For shorter stimulations, 
cells were starved overnight prior to experimental use.  
2.3. FITC Dextran permeability  
 
To investigate the integrity of the epithelial barrier a FITC dextran 
permeability study was used.  Dextran is a high molecular weight polymer of 
glucose and when tagged with fluorescein isothiocyanate (FITC) it can be 
used to look at paracellular barrier properties.  FITC dextran (4 kDa) was 
dissolved in HBSS buffer to a concentration of 500 μg/ml.  
 Cells were grown via ALI culture and after 7 days confluent cells were 
stimulated with IL-13 or treated with various inhibitors.  Cells were washed 
with pre-warmed HBSS to remove all the phenol red in the media and 600 μl 
of HBSS was added to the basolateral chamber.  FITC-dextran (200 μl) at 
500 μg/ml was added to the apical chamber and incubated for 30 minutes,   
triplicate samples (100μl each) were taken from the basolateral chamber of 
each well and placed into a black 96 well plate to measure fluorescence 
intensity on a Fluostar optima plate reader at excitation and emission 
wavelength of 485 nm and 530 nm respectively.  
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2.4 Immunocytochemistry 
Immunocytochemistry is an extremely useful technique and in this 
thesis it is used to assess the distribution of junctional proteins within the cell 
after stimulation with cytokines or inhibitors. 
2.4.1 Sample preparation and antibody staining 
  It was necessary to use two methods in order to achieve the optimal 
staining outcome, some antibodies can be very sensitive to the fixing 
method.  Method 1 was used for all junctional antibodies except for E-
cadherin which used method 2.   
Fixing method one  
Cells were grown via ALI (see section 2.1.1) and once confluent, various 
cytokines and/or inhibitors were administered to the basolateral chamber for 
24-72 hours. Cells were washed twice with PBS and fixed in 4% 
paraformaldehyde for 20 minutes at room temperature. Cells were 
permeabilized using 0.1% Triton-X-100 in PBS for 30 minutes and blocked 
for 30 minutes in a 10% blocking buffer (Roche).  Cells were covered with 
the primary antibody (1 in 100 dilution) in 2% blocking buffer in PBS and left 
on the rocker at 4°C overnight.  After which they were washed three times 
with PBS for 15 minutes per wash and then covered with either an anti-
mouse or anti-rabbit Alexa Fluor secondary antibody which was conjugated 
with a 488 (green) or 546 dye (red) in 2% blocking buffer in PBS for 1 hour in 
the dark.  Cells were washed three times with PBS for 15 minutes and on the 
final wash the fluorescent stain 4',6-diamidino-2-phenylindole (DAPI) was 
added to the wash to stain the nuclei by strongly binding A-T rich regions in 
DNA.  Cells were placed in water to rinse off any remaining PBS and the 
filters were cut out using a scalpel and fixed onto glass slides using a 
mounting media solution containing Mowiol 4-88, which has the same 
refractive index as immersion oil.  The slides were kept in the dark at 4°C 
overnight and then viewed on a LSM510META confocal laser scanning 
microscope.  Images were digitally recorded and manipulated using LSM 
image examiner software (Carl Zeiss Microscopy). 
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Fixing method two 
Cells were grown via ALI and once confluent, various cytokines and/or 
inhibitors were administered to the basolateral chamber for 24-72 hours. 
Cells were quickly washed twice with PBS and fixed in ethanol at 4°C for 30 
minutes. Cells were permeabilized using acetone cooled to -20°C for 3 
minutes at room temperature and then washed twice with PBS and blocked 
in 10% FBS in PBS for 30 minutes (or overnight at 4°C is desired).  Cells 
were washed twice with 2% FBS in PBS and once with PBS and then 
covered with the primary antibody (1 in 100 dilution) in 2% FBS in PBS and 
left on the rocker at 4°C overnight.  The cells were washed three-to-five 
times with 2% FBS in PBS and three times with PBS for a mixture of very 
quick or 5 minute washes. Cells were then covered with either an anti-mouse 
or anti-rabbit Alexa Fluor secondary antibody which was conjugated with a 
488 (green) or 546 dye (red)  in 2% FBS in PBS for 1 hour in the dark.  Cells 
were washed as before and then placed in DAPI in PBS (1 in 20,000 dilution) 
for 10 minutes. Cells were placed in water to rinse off any remaining PBS 
and the filters were cut out using a scalpel and mounted onto glass slides 
using Mowiol.  
 
2.5 Flow cytometry 
 
 The surface expression of the IL-13 receptor IL-13Rα2 was analysed 
to determine its possible role in IL-13 treated cells with and without PI3K 
inhibition.  Calu-3 cells were cultured by ALI and stimulated with a variety of 
PI3K inhibitors along with varying concentrations of IL-13.  Cells were 
washed with pre-warmed PBS and placed in 300 μl of 0.25% trypsin/EDTA in 
the incubator for 15 minutes. Once cells had detached the reaction was 
stopped with the addition of 700 μl of complete media, and each well was 
pipetted several times and placed in a 1.5 ml plastic tubes (Eppendorf), 
which were incubated for 30 minutes to allow cells to recover.  Cells were 
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washed once with ice-cold PBS and then re-suspended in the anti-IL-13Rα2 
antibody and incubated at 4°C for 1 hour, cells were washed with ice-cold 
2% FBS in PBS three times.  Cells were placed in an anti-mouse secondary 
antibody labelled with Alexa Fluor 488 dye for 1 hour at 4°C in the dark.  
They were washed twice with ice-cold 1% FBS in PBS and re-suspended in 
500 μl PBS and analysed on a FACSCanto flow cytometer (Becton 
Dickinson). 
 
2.6 Quantitative real-time PCR 
 
 To evaluate the mRNA expression of the junctional proteins after IL-
13 and PI3K inhibition quantitative PCR was carried out.  In this process a 
single RNA strand is first reversed transcribed to its DNA complement, this 
double strand of DNA is then denatured which allows specifically made 
primers to anneal to the single stranded DNA template.  This DNA strand is 
then elongated using polymerase enzymes and the whole process is 
repeated causing amplification of the DNA. 
 RNA was extracted from Calu-3 cells using an RNeasy mini kit 
(Qiagen) according to the manufacturer’s instructions.  Cells were washed 
twice with PBS then 250 μl of lysis buffer (with added 2-mercaptoethanol 10 
μl/ml) was added to the well and the sample was pipetted up and down a few 
times to ensure homogeneity.  The lysate was pipetted into QIAshredder spin 
column and centrifuged at 5000 g for 2 minutes, 70% ethanol was added to 
the lysate and mixed well.  The sample was then transferred to an RNeasy 
spin column in a 2ml collection tube and centrifuged at 5000 g for 15 
seconds. The sample was subjected to DNase digestion, was cleaned using 
RPE washes and then eluted using RNase free water. 
 The RNA was quantified using a Qubit 2.0 fluorimeter and was then 
reverse transcribed using a high capacity cDNA reverse transcription kit (see 
section 8.3 for more details). Reactions were performed on a StepOnePlus 
Real-time PCR system (Applied Biosystems) using a SYBR Green system, 
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for each well 10 μl of SYBR green was added to 0.4 μl of forward and 0.4 μl 
of reverse primers, 9.2 μl of cDNA was added to this mixture. The PCR 
reaction consisted of 2 steps, firstly heating to 95°C for 10 minutes for the 
initial hold, then 40 cycles of 95°C for 15 seconds followed by 1 minute at 
60°C.   
 
2.7 Immunoblotting  
 
Immunoblotting (also known as western blotting) is a technique 
whereby visualisation of specific proteins in a cell is achieved using gel 
electrophoresis.  Gel electrophoresis is a method by which proteins are 
separated by charge and size.  Protein samples are run through a 
polyacrylamide gel and then transferred onto a nitrocellulose membrane by 
using an electric current.  The membrane is then blocked and probed using 
primary antibodies that are specific to the protein of interest followed by 
further washing and secondary antibodies which recognise the primary 
antibodies that are used via the species in which they were raised in (e.g 
mouse or rabbit).  The secondary antibodies are tagged with a horseradish 
peroxidise (HRP) enzyme and detection is achieved in the presence of 
chemiluminescence agents which catalyse the HRP which causes emission 
of light (luminescence) which is picked up on a photosensitive film. 
 
2.7.1 Cell lysis 
 After incubation with cytokines and various inhibitors, cells were 
washed three times in ice cold PBS and were then placed in lysis buffer (see 
section 8.1) for 5 minutes on ice.  Cells were detached from the plate/well 
using a cell scraper and the sample was pipetted multiple times before being 
place in a pre-cooled 1.5ml plastic tube (Eppendorf).  The samples were then 
centrifuged at 4°C at 7000 g for 3 minutes to pellet the cell debris and the 
supernatant was carefully removed and placed in another pre-cooled 1.5ml 
plastic tube. 
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2.7.2 Quantification of protein 
To ensure each sample contained the same amount of protein a 
Bradford assay was carried out.  This assay works by colorimetric analysis, 
when the coomassie dye present binds to the hydrophobic amino acids 
residues found in protein it undergoes an absorbance shift.   Samples were 
prepared with varying concentrations of bovine serum albumin (BSA) 0, 2, 4, 
6, 8 and 10 μg/ml from which a standard curve was constructed. The 
Bradford dye reagent was diluted in water (1:5) and 198 μl was placed in 
each 1.5 ml plastic tube, 2 μl of sample was added to the dye and the tube 
was mixed well.  100 μl was pipetted out of each sample in triplicate into a 
clear 96 well plate and the concentration of protein was measured at 595nm 
using a VersaMax plate reader (Molecular Devices).  The protein 
concentration in each sample was calculated using the standard curve. 
 
2.7.3 Sample preparation 
 After the amount of protein was calculated, each sample was made up 
to 25 μg (or as close to it as possible) of protein in 20 μl with the addition of 
water to dilute if necessary.   5 μl of 5X sample buffer (see section 8.1) was 
added to each sample and the tubes were heated to 90°C for 7 minutes, 
after which they were quickly centrifuged at 200 g and placed back on ice.  
 
2.7.4 Gel electrophoresis 
 One dimensional gel electrophoresis was used, in which proteins are 
separated by size using an electrical current by moving through pores in a 
gel matrix, the size of the pore depends on the percentage of acrylamide 
used, the higher the percentage the smaller the pores so the slower the 
proteins will migrate.  As the size of the protein determines how quickly it 
migrates through the gel it is necessary to pick the correct acrylamide 
percentage gel to use, for larger proteins lower percentage gels are required 
and vice versa.  
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 Different percentage gels 7.5, 10 or 12% were prepared  to make up 
the resolving gel, this was pipetted between the assembled glass plates to 
around 75% total volume, the remaining 25% was filled with water to ensure 
the resolving gel set flat. After around 20-30 minutes the gel would 
polymerise and the water could be tipped out.   A gel comb containing either 
10 or 15 wells was placed on top of the resolving gel and a stacking gel 
consisting of 5% acrylamide was pipetted around the comb carefully 
ensuring no bubbles were present.  After 15 minutes the stacking gel set and 
the comb was carefully removed leaving intact wells in its place.  The wells 
were washed well with MQ water and the gel was placed in a Bio-Rad Mini 
Protean II system with running buffer (see section 8.1).  The first well was 
reserved for a standard protein ladder (5-10 μl) which is a molecular weight 
marker.  All subsequent wells were filled with the specific protein samples.  
Gels were run for 15 minutes at 80V to ensure the proteins moved though 
the stacking gel and lined up at the edge of the resolving gel, then the 
voltage was turned up to 150-180V for 1 hour. 
2.7.5 Semi-dry transfer of proteins 
 The proteins were transferred onto nitrocellulose membrane in order 
to be accessible to antibody detection.  The graphite plates of the Flowgen 
E702 (Consort) transfer machine were dampened with semi-dry transfer 
buffer (section 8.1)   The gel was placed in a ‘sandwich’ containing 4 pieces 
of Whatman filter paper, followed by a piece of nitrocellulose paper, the gel 
itself and then another 4 pieces of Whatman filter paper, all cut to the size of 
the gel and soaked in buffer before placing onto the plate. The sandwich was 
gently rolled after the first set of Whatman paper and at the end to gently 
expel any bubbles. The apparatus was assembled and run for 1 hour at 40 
mA per gel. The proteins move according to an electric current as in the last 
stage.  After the transfer was complete, the membranes were quickly washed 
in phosphate buffered saline (PBS) and a ponceau stain was added which 
enabled visualisation of all bound protein on the membrane and helped in 
verifying the success of the transfer. 
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2.7.6 Antibody probing and Immunoblot developing 
 After the transfer was complete, the ponceau stain was washed off 
with phosphate buffered saline with 0.1% Tween 20 (PBST) for 10 minutes 
and then the membrane was blocked for 1 hour at room temperature on a 
rocking platform in either 5% (w/v) powdered milk or 5% BSA (w/v), 1% 
ovalbumin (w/v) both in PBS with the addition of 0.05% azide.  The block 
was rinsed off with a phosphate-buffered-saline solution with 0.1% Tween-20  
(PBST) and the primary antibody was diluted (see section 8.2 for specific 
antibody dilutions) 1:5 with blocking buffer in PBST and incubated overnight 
at 4°C on a rocking platform.   The next day the primary antibody was 
removed and the membrane was washed 3 times with PBST for 10 minutes 
per wash and then once with PBS for 10 minutes.  After washing the 
secondary antibody was diluted (1:10000) in PBST and placed onto the 
membrane for 2-3 hours at room temperature on the rocker.   The membrane 
was then washed again with PBST and PBS as after the primary antibody 
step and the membrane was prepared for the detection step.  An enhanced 
chemiluminescent lumigen (ECL, Pierce) reagent was added to membrane 
for 1 minute after which time the membrane was placed on absorbent paper 
to remove the excess reagent.  The membrane was then placed between 
two layers of cling film in a photosensitive cassette and in a dark room 
photosensitive film was placed upon the membrane for varying length 
exposures depending on the antibody used.  The film was developed and 
computer scanned to be analysed using ImageJ software (Wayne Rasband, 
National Institutes of Health, USA) 
 
2.7.7 Membrane stripping 
 With many immunoblotting experiments protein phosphorylation is 
examined, both the phosphorylated and non-phosphorylated proteins will 
appear at the same size therefore it is necessary to probe for one and then 
strip the membrane and re-probe for the other.  The membrane was placed 
in 20 ml of 1X stripping buffer supplemented with 2-mercaptoethanol (see 
section 8.1) in a sealed container for 30 minutes at 60°C on a rocking 
platform in a water bath.  After which the stripping buffer was disposed of into 
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a solvent bottle in the hood and membrane was transferred to a clean 
container.  The membrane was washed three times with PBS for 15 minutes 
per wash and then once with PBS, after the final wash, the membrane was 
blocked again as described in section 2.7. 
 
2.7.8 Poly-acrylamide gel recipes 
 Before pouring add 50μl of 10% AMPS and 20μl of TEMED 
 
 
Sufficient for 2 x 1mm thick gels 
 
Final % gel 
 
5 
30% Acrylamide-Bis solution (ml) 0.84 
MQ water (ml) 3 
1M Tris pH 6.8 (ml) 0.63 
10% SDS (ml) 0.075 
   
 Before pouring add 20μl of 10% AMPS and 13μl of TEMED 
Table 2.1  Resolving and stacking gel recipes.   
The size of the protein of interest depends on the percentage of resolving gel 
used, with larger proteins a lower percentage gel is used (6 or 7.5%) as the 
pores are much larger to allow the protein to pass through.  The reverse is 
true when blotting for smaller proteins. 
 
 
   
 
Sufficient for 2x 1mm thick gels 
 
Final % gel 
 
6 7.5 10 12 
30% Acrylamide-Bis solution (ml) 3 2.5 5 4 
MQ water (ml) 6.35 5 4.35 3.5 
1M Tris pH 8.8 (ml) 5.6 2.5 5.6 2.5 
10% SDS (ml) 0.25 0.16 0.25 0.16 
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2.8 Scanning electron microscopy (SEM) 
 
 To assess the surface of the cells, electron microscopy was used.  
Calu-3 cells were grown via air-liquid interface culture for 7 days, then 
washed with serum free media and placed in the fixative solution, 2.5% GDA 
and 0.5 g potassium ferrocyanide were dissolved in 50 ml normal strength 
culture media. Cells were washed again with serum free media and then the 
fixative solution was added for 2 hours at 37°C. Cells were then washed with 
serum-free media and postfixed with 1% osmium tetroxide + 1% potassium 
ferrocyanide for 1 hour at room temperature.  Cells are washed twice with 
water over 10 minutes,the filters are cut out and placed in small glass vials 
and stained with 2% uranyl acetate for 1 hour in the dark. The filters are 
further washed with acetone 50, 70 and 90% each one over 10 minutes and 
then twice with 100% acetone, followed by one 15 minute wash with an 
equal mix of acetone and HMDS and then two final 15 minute washes with 
HMDS.  The cells are then coated with an ultrathin layer of gold and viewed 
on a JEOL SEM6480LV scanning electron microscope.  
 
2.9 Wound healing 
 
               A common method of examining the ability of cells to repair wounds 
is the scratch assay.  Cells were grown on 12-well plates and when confluent 
were scratched with a small plastic pipette tip (10-200 μl) to make a 
horizontal scratch and a needle tip to make a vertical scratch (as shown in 
Figure 2.2).  The method of crossing over the scratches allowed for the area 
photographed each time to remain constant.  Cells were washed twice with 
serum-free media to remove any cell debris and were viewed on an Olympus 
CKX41 microscope with an attached C-3030 camera and photographs were 
taken in the area directly left of the vertical needle scratch. Cells were placed 
in media containing IL-13 and/or inhibitors and incubated for 24 hours, after 
which time the media was removed and cells were washed with serum free 
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media twice to remove any cell debris and photographed again.  The photos 
were then analysed using Tscratch software (CSElab) and the amount of 
wound that had closed was given as a percentage of the initial wound area. 
                              
  
                     
2.10 Calcium switch Assay 
 
                  Another method useful in investigating the mechanisms behind 
cell repair and regrowth is a calcium switch assay [230] in which cells are 
subjected to low calcium followed by normal levels of calcium and monitored 
by TER measurements.  Confluent cells grown via ALI were measured by 
TER to get an initial value, they were then placed in 4 mM EGTA for 30 
minutes to destroy tight junctions and adherens junctions and their TER was 
measured again to check that this was the case (depicted by a large 
decrease in TER).  Cells were then placed back in normal calcium containing 
media with the addition of IL-13 and/or inhibitors for 24 hours in the 
incubator.  After which time the TER was measured and compared with the 
initial value to see the effect the various cytokines/inhibitors had on tight 
junction re-formation. 
 
 
Pipette scratch 
Needle scratch 
Figure 2.2 Wound healing assay  
Area to be 
photographed  
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2.11 Lactate dehydrogenase (LDH) assay 
 To assess the membrane integrity of the cells as a measure of cell 
necrosis after treatment of the various inhibitors the TOX7 Lactate 
dehydrogenase (LDH) kit was used.  The assay measures the amount of 
NADP reduced to NADPH by LDH through the stoichiometric conversion of a 
tetrazolium dye by the reduced NADPH.  The red coloured result can then be 
measured spectroscopically by monitoring the absorbance at 490 nm.  Cells 
were grown to confluency in 12-well plates and treated with inhibitors for 24 
hours after which the media from each sample was sampled to assess the 
amount of LDH released.  In each experiment media was placed in a cell 
containing no cells (negative control) and triplicate wells were lysed and 
averaged to give the total LDH present in each sample. 
 
2.12 Statistical analysis 
 
 To test the statistical significance the following tests were used:  either 
a 1-way or 2-way ANOVA followed by Dunnett’s or Tukeys post-hoc test.  A 
paired t-test was also used when only comparing 2 groups.   A P value of 
less than 0.05 was considered to be statistically significant. 
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2.13 Materials 
Material  Catalogue No Source 
10ml plastic pipettes CC114 Appleton Woods, Birmingham UK. 
12-well plates 665180 Greiner Bio-One, Gloucestershire UK 
13mm cover slips  MNJ-500-010G Fisher Scientific, Loughborough UK. 
25ml plastic pipettes CC116 Appleton Woods, Birmingham UK. 
2-mercaptoethanol M3148 Sigma-Aldrich, Dorset UK 
30% Acrylamide/Bis 161-0154 Bio-rad, Hertfordshire UK 
35mm tissue culture dishes BC150 Appleton Woods, Birmingham UK. 
4-well plates TKT190130 Fisher Scientific, Loughborough UK. 
6-well plates 657160 Greiner Bio-One, Gloucestershire UK 
Ammonium persulphate (AMPS) A/P470/46 Fisher Scientific, Loughborough UK. 
Anti beta-actin antibody 4967S New England Biolabs, Hertfordshire UK 
Anti- phospho STAT6 antibody 9361S New England Biolabs, Hertfordshire UK 
Anti- STAT6 antibody 9362S New England Biolabs, Hertfordshire UK 
Anti-Akt (1/2/3) antibody sc-8312 Santa Cruz,  Heidelberg, Germany 
Anti-claudin 2 antibody 32-5600 Invitrogen,Paisley UK 
Anti-Ecadherin antibody 3195S New England Biolabs, Hertfordshire UK 
Anti-GSK3β antibody 9315S New England Biolabs, Hertfordshire UK 
Anti-IL-13Rα2 ab55275 Abcam, Cambridge UK 
Anti-mouse alexa fluor 488 antibody A11001 Fisher Scientific, Loughborough UK. 
Anti-mouse PE conjugated IL-13Rα1 12-2130-80 ebioscience, Hatfield UK 
Anti-MUC5AC antibody ab24070 Abcam, Cambridge UK 
anti-occludin antibody 55065 New England Biolabs, Hertfordshire UK 
Anti-phospho Akt (ser473) 9271S New England Biolabs, Hertfordshire UK 
Anti-phospho GSK3β antibody 9331S New England Biolabs, Hertfordshire UK 
Anti-phospho-p44/42 MAPK antibody 4377 New England Biolabs, Hertfordshire UK 
Anti-rabbit alexa fluor 546 antibody A11010 Fisher Scientific, Loughborough UK. 
Anti-rabbit Claudin 1 antibody 4933S New England Biolabs, Hertfordshire UK 
Anti-rabbit Claudin 8  40-2600 Invitrogen,Paisley UK 
Anti-rabbit phosphoβ-catenin antibody 9561P New England Biolabs, Hertfordshire UK 
Anti-rabbit ZO-1 antibody VX339100 Fisher Scientific, Loughborough UK. 
Anti-rabbit β-catenin antibody 95625 New England Biolabs, Hertfordshire UK 
Aprotinin A1152 Sigma-Aldrich, Dorset UK 
Aspirating needles FB50253 Fisher Scientific, Loughborough UK. 
Autoclave tape AUY-170-030P Fisher Scientific, Loughborough UK. 
Black 96-well plates 655086 Greiner Bio-One, Gloucestershire UK 
Blocking buffer 11096176001 Roche, West Sussex UK 
Bovine Collagen 354231 BD Biosciences, Oxford UK 
Bovine serum albumin A6003 Sigma-Aldrich, Dorset UK 
Bradford protein assay dye 500-0006 Bio-rad, Hertfordshire UK 
Bromophenol blue B/P620/44 Fisher Scientific, Loughborough UK. 
Calibration kit for TER experiments CALICELL12 World Precision Instruments 
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Cell scrapers 541070 Greiner Bio-One, Gloucestershire UK 
Clear 96-well plates 655180 Greiner Bio-One, Gloucestershire UK 
Dimethyl sulphoxide D8418 Sigma-Aldrich, Dorset UK 
DMEM/F12 media 21331-046 Invitrogen, Paisley UK 
ECL kit  32109 Pierce, Northumberland UK 
ECL prime blocking agent RPN2232 GE Healthcare, Amersham UK 
ECL prime kit RPN418 GE Healthcare, Amersham UK 
EDTA pH8 0.5M BPE2482-500 Fisher Scientific, Loughborough UK. 
EGTA E0396 Sigma-Aldrich, Dorset UK 
Fetal bovine serum (FBS) 10082147 Invitrogen, Paisley UK 
FITC-dextran (Mwt 3000-5000) FDR Sigma-Aldrich, Dorset UK 
FUJI X-ray film  2731261 Fisher Scientific, Loughborough UK. 
Fungizone 15290-026 Invitrogen, Paisley UK 
Gel loading pipette tips PMP-130-100A Fisher Scientific, Loughborough UK. 
Glass plates for western blotting 1653308 Bio-rad, Hertfordshire UK 
Glucose G7021 Sigma-Aldrich, Dorset UK 
Glutamine 25030024 Invitrogen, Paisley UK 
Glycerol G5516 Sigma-Aldrich, Dorset UK 
Glycine G/P460/53 Fisher Scientific, Loughborough UK. 
HBSS (1X) 14025-050  Invitrogen, Paisley UK  
Hepes H3784 Sigma-Aldrich, Dorset UK 
High capacity cDNA RT kit  VY4368814 Fisher Scientific, Loughborough UK. 
Hi-res Agarose A4-0700-S Geneflow, Staffordshire UK 
HotstarTaq DNA polymerase 203203 Qiagen, Crawley UK 
Human EGF AF-100-15 Peprotech, London UK 
Human fibronectin 354008 BD Biosciences, Oxford UK 
Human IL-13 200-13 Peprotech, London UK 
Human TGFα 100-16B Peprotech, London UK 
Human TGFβ 100-21 Peprotech, London UK 
IC87114 inhibitor S1268 Selleck chemicals, Suffolk UK 
LDH assay kit TOX7 Sigma-Aldrich, Dorset UK 
Leupeptin BPE2662-5 Fisher Scientific, Loughborough UK. 
LHC basal medium 12677-027 Invitrogen, Paisley UK 
LY294002 inhibitor L9908 Sigma-Aldrich, Dorset UK 
MicroAmp 96-well plates VY4346906 Fisher Scientific, Loughborough UK. 
MicroAmp optical adhesive film VY4360954 Fisher Scientific, Loughborough UK. 
Microscope slides MNJ-700-010N Fisher Scientific, Loughborough UK. 
Millipore filters FDR-050-071N Fisher Scientific, Loughborough UK. 
Minimum essential media (MEM) 21430-079 Invitrogen, Paisley UK 
Mowiol  10852 Sigma-Aldrich, Dorset UK 
MUC5AC antibody ab3649 Abcam, Cambridge UK 
Mycoalert mycoplasma detection kit LT07-218 Lonza, Blackley UK 
NEAA 100X 11140035 Invitrogen, Paisley UK 
Nitrocellulose membrane  162-0115 Bio-rad, Hertfordshire UK 
Nonidet P-40 56009 Sigma-Aldrich, Dorset UK 
Chapter 2 – Materials and Methods 
67 
 
Oligo (dT)15 primer C1101 Promega, Southampton UK 
Omniscript RT kit 205111 Qiagen, Crawley UK 
p10 pipette tips FB34511 Fisher Scientific, Loughborough UK. 
p1000 pipette tips FB34611 Fisher Scientific, Loughborough UK. 
p200 pipette tips FB34541 Fisher Scientific, Loughborough UK. 
PBS (without Ca2+ and Mg2+) 14190-169 Invitrogen, Paisley UK 
PBS tablets P4417 Sigma-Aldrich, Dorset UK 
PCR mixed colour tubes FB68729 Fisher Scientific, Loughborough UK. 
PD0325901 inhibitor 4192 Tocris Bioscience, Bristol UK 
Pencillin/Streptomycin 15140122 Invitrogen, Paisley UK 
Pepstatin A BPE2671-250 Fisher Scientific, Loughborough UK. 
pH electrode PHL-650-520T Fisher Scientific, Loughborough UK. 
Phenol Red P0290 Sigma-Aldrich, Dorset UK 
PIK75 inhibitor S1205 Selleck chemicals, Suffolk UK 
Plasmocin ant-mpt Source Bioscience, Nottingham UK 
Presept tablets  HYG-210-010P Fisher Scientific, Loughborough UK. 
Primers N/A Sigma-Aldrich, Dorset UK 
Protein standard marker 161-0375 Bio-rad, Hertfordshire UK 
QIA shredders 79654 Qiagen, Crawley UK 
Qubit RNA BR Buffer Q10210 Invitrogen, Paisley UK 
Recombinant Dnase I AM2235 Ambion, Paisley UK 
Rnase free water BPE561-1 Fisher Scientific, Loughborough UK. 
Rnase-free Dnase set 79254 Qiagen, Crawley UK 
Rnasin Plus Rnase inhibitor N2611 Promega, Southampton UK 
Rneasy mini kit  74104 Qiagen, Crawley UK 
SAHA inhibitor 1604-1 Cambridge Bioscience, UK 
Set of dNTPs U1330 Promega, Southampton UK 
Sodium  S/P530/53 Fisher Scientific, Loughborough UK. 
Sodium azide S2360 Sigma-Aldrich, Dorset UK 
Sodium fluoride S1504 Sigma-Aldrich, Dorset UK 
Sodium molybdate S6646 Sigma-Aldrich, Dorset UK 
Sodium orthovanadate S6508 Sigma-Aldrich, Dorset UK 
STX2 Tweezer electrode for TER STX2 World Precision Instruments, Florida  
SYBR Green PCR master mix VY4364344 Fisher Scientific, Loughborough UK. 
TEMED T/P190104 Fisher Scientific, Loughborough UK. 
Tissue culture flasks 175 cm2 660175 Greiner Bio-One, Gloucestershire UK 
Tissue culture flasks 25 cm2 690175 Greiner Bio-One, Gloucestershire UK 
Tissue culture flasks 75 cm2 658175 Greiner Bio-One, Gloucestershire UK 
Transwell plates 12mm CLS3460 Sigma-Aldrich, Dorset UK 
Trizol 15596-018 Invitrogen, Paisley UK 
Trypan blue dye T8154 Sigma-Aldrich, Dorset UK 
Trypsin/EDTA 0.05% 25300062 Invitrogen, Paisley UK 
Trypsin/EDTA 0.25% 25200072 Invitrogen, Paisley UK 
Tween-20 P1379 Sigma-Aldrich, Dorset UK 
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Water bath clean treatment S5525-40Z Sigma-Aldrich, Dorset UK 
Whatman chromatography paper FB59515 Fisher Scientific, Loughborough UK. 
Wortmanin inhibitor W1628 Sigma-Aldrich, Dorset UK 
ZSTK474 inhibitor 1597-100 Cambridge Bioscience, UK 
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3.1 Assessing the transepithelial resistance of Calu-3 cells  
 
This thesis investigates the role of IL-13 and PI3K in lung epithelial 
barrier modulation.  To establish a model that was physiologically relevant to 
that of the lung, the cell line had to be characterised and optimised to 
achieve an air-liquid interface (ALI) culture system that could be easily 
manipulated.  Calu-3 cells were grown on transwell filters that comprised of a 
12 mm membrane with 0.4 μm pores.  300 μl of cells were placed in the 
apical chamber and 1 ml of complete media was placed in the basolateral 
chamber, cells were grown under immersion culture for 2 days then the 
media was removed from the apical chamber to establish ALI (see Figure 
2.1). 
 
It was important to optimise both the seeding density as well as the 
culture time period.  Calu-3 cells were first plated onto the transwell filters at 
2.5x105 cells/ml and their transepithelial resistance (TER) was monitored 
daily up to 23 days. TER increased dramatically after day 12 and peaked at 
day 16 (Figure 3.1). This seeding concentration was unsuitable for further 
studies due to the length of incubation time before cells reach confluency 
and then the immediate decrease after the maximal TER, giving no time 
period where cells maintained a stable TER in order to carry out various 
stimulations.  Subsequently cells were seeded at the higher concentration of 
5x105 cells/ml and this proved far more effective with a maximal TER being 
reached at day 7 which remained constant up to day 14 as shown in Figure 
3.1.  All later experiments were seeded at 5x105 cells/ml and stimulated with 
various cytokines and inhibitors at confluency.   
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Figure 3.1 Optmising the seeding density of Calu-3 cells grown at ALI.   
Cells were seeded at 2.5x105 cells/ml (A) and 5x105 cells/ml (B) and the 
transepithelial resistance was measured with STX2 electrodes every day.  
The background was measured using a transwell without cells and was 
subtracted from the raw resistance which was then multiplied by the area of 
the transwell to get the units Ωcm2. Data are expressed as mean values ± 
SEM from n=5 independent experiments.   
 
 
 
 
 
A 
B 
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3.2 Surface morphology of Calu-3 cells grown via ALI culture 
 
After monitoring the TER of Calu-3 cells, it was necessary to study the 
surface properties of the cells grown via air-liquid interface.  Under 
immersion culture, which is often termed liquid covered culture (LCC), cells 
have a different phenotype to those exposed to the air.  Cells grown via LCC 
have been shown to produce less mucus and are less differentiated than 
those grown via ALI [275].  Scanning electron microscopy was used to study 
the surface of the cells after 7 days in ALI culture, the point at which the TER 
reached its peak and the cell layer was presumed to be ‘intact’ with fully 
formed tight junction proteins (Figure 3.1). 
Calu-3 cells were clearly shown to express cilia after 7 days in culture 
(Figure 3.2); a feature only present in a differentiated pseudostratified 
epithelium.  Around 90% of all cells in each sample displayed cilia, with each 
cell showing a different degree of differentiation with the shape and length of 
cilia also varying between cells.  The cell boundary between cells can also 
be observed, clearly shown in figure 3.2B as indicated by red arrows.  Figure 
3.2D is a highly magnified image of a cell in which the cilia present appear to 
be clumping together in a star-like appearance, with the tips of four or five 
cilia touching, this is thought to be an effect of the fixing method and was 
only observed on some cells. SEM imaging gives a good indication that the 
culture method used is providing a physiologically relevant airway model to 
study further. 
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Figure 3.2 The surface profile of Calu-3 cells using scanning electron 
microscopy (SEM).   
Calu-3 cells grown via air-liquid interface culture for 7 days were washed with 
serum free media and placed in the fixative solution, 2.5% glutaraldehyde, 0.5g 
potassium ferrocyanide in media for 2h at 37°C.  Cells were then washed and 
postfixed with 1% osmium tetroxide and 1% potassium ferrocyanide for 1 hour at 
room temperature.  After washing with water, cells were stained with 2% uranyl 
acetate for 1 hour in the dark, followed by slow dehydration with acetone and 
HDMS washes.  Cells were coated with an ultra thin layer of gold and viewed on 
a JEOL SEM6480LV scanning electron microscope.  Image A was the lowest 
magnification (1000x) taken of the surface area showing > 10 individual cells.  
Image B was taken at a higher magnification and the junctions can be clearly 
seen between ciliated cells, depicted by red arrows.  Image C (3500x) shows the 
cilia forming a star like appearance and the area encircled in red is shown at the 
higher magnification of 15000x in image D.  Images are representative of three 
independent experiments.    
 
A 
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3.3 Expression of tight junction proteins via immunocytochemistry 
 
Tight junction proteins which are present at the most apical part of the 
junctional complex between cells are essential in maintaining epithelial 
barrier function and controlling what can pass through via paracellular 
permeation.  The intestinal epithelial cell lines Caco-2 and T84 have been 
extensively researched in relation to tight junction modulation, and they have 
been shown to express many tight junction proteins from the claudin family 
along with occludin and the tight junction associated proteins zonula 
occludens 1-3 [199, 236, 276, 277].  In order to begin studying the signalling 
pathways involved in lung epithelial modulation, it was necessary to check 
the basal expression of key junctional proteins present in Calu-3 cells.  Of 
the various methods available to monitor protein expression immunoblotting 
would not be the obvious first choice, however due to the vast size of some 
TJ proteins, it is the most suitable method. Such proteins include ZO-1, 
which has a molecular weight of 225 kDa and often appears as numerous 
sized unclear bands on an SDS-PAGE gel, a feature explained by its many 
phosphorylated forms [278].  Immunofluorescence was used and proved 
useful as although the expression could not be quantified as it would with 
immunoblotting the distribution of the proteins were also observed. 
  As shown in Figure 3.3 Calu-3 cells were found to express the 
junctional proteins occludin, ZO-1, claudin 1, claudin 2, claudin 8, E-cadherin 
and beta-catenin.  Occludin was found at the edges of cells forming a 
continuous ring around each individual cell, a similar situation was seen for 
ZO-1, E-cadherin and beta-catenin.  Claudin 2 basal expression was found 
to be very low compared to the other proteins and appears scattered 
throughout the cell.  Claudin 1 was expressed but the distribution was shown 
to be a mixture between localisation at the cell junctional complex and 
random scattering throughout the cytoplasm.  Claudin 8 was expressed at a 
very low level in basal cells and appeared to be cytoplasmic.  
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Figure 3.3 Basal expression of junctional proteins via 
immunofluorescence.   
Calu-3 cells were grown via ALI culture for 7 days, then washed with PBS and fixed 
using 4% PFA (except for E-cadherin which was fixed with ethanol).  Cells were 
permeabilised and stained for various junctional proteins overnight at 4°C.  They 
were then washed and labelled with a secondary antibody conjugated to either a 
488 or 546 dye. After a series of washing steps, filters were cut out, mounted onto 
to glass slides and left to dry overnight at 4°C.  Cells were visualised using an 
LSM510META confocal microscope.  Occludin, ZO-1, E-cadherin, Claudin 1 and 
beta-catenin were shown to be expressed as a continuous band surrounding each 
cell at the tight junction.  The expression of claudins 2 and 8 were lower than the 
other junctional proteins and were shown to be localised sporadically throughout the 
cytoplasm rather than concentrated at the cell junction.  Images are representative 
of three independent experiments. 
occludin ZO-1 E-cadherin 
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3.4 Discussion  
 
3.4.1 Characterisation of Calu-3 cells  
 
Calu-3 cells are a carcinomic cell line derived from a pleural effusion.  
They are a well characterized bronchial cell line which has serous cell 
properties [279] and can be referred to as a submucosal cell line. When 
confluent, Calu-3s become polarised and express the same membrane 
associated protein and mRNA profiles as that of a normal human lung 
epithelium, with the expression of many key drug transporter proteins such 
as the multidrug resistance-associated transporter protein 1 [280]. There are 
many advantages of using this cell line over primary cells, the most important 
with respect to research ease being their immortality and cost effectiveness.  
Primary cells often give irreproducible results due to donor variability, 
whereas Calu-3 cells are known to be reproducible and unlike many SV-40 
transformed cell lines they maintain their phenotype after many repeat 
passages [273].   
 
3.4.2 Transepithelial resistance as a measure of confluency 
 
Calu-3 cells form an ‘intact’ cell monolayer which reaches a TER of 
around 1000 Ωcm2 after 7 days in culture.  TER values are often used as an 
indirect measure of presence of tight junctions [274] and so it was assumed 
that tight junction proteins were expressed in the Calu-3 cell line.  The 
alveolar epithelial cell line A549 and the bronchial epithelial cell line, 16-HBE 
were also grown on transwell filters and both failed to reach a TER of >300 
Ωcm2 (data not shown). A leaky transwell filter was also observed which 
occurs when media from the basolateral chamber travels through the 
membrane and is a tell-tale sign of cells that have yet to, or are unable to 
form tight junctions between adjacent cells resulting in little resistance to 
liquid passing through.  This finding was consistent with other research in 
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which A549 cells are labelled as a leaky cell line in terms of TER, however 
they are still studied in relation to tight junction modulation [256, 281-284] but 
are known to be unreliable for drug transport studies [285].   
 
3.4.3 Calu-3 cell surface morphology by SEM 
 
 After determining the presence of a high TER and thus concluding 
that tight junction proteins were present, the surface properties of Calu-3 
cells were studied by SEM.  Calu-3 cells are clearly shown to be 
differentiated after ALI culture for 7 days, with cilia present on 90% of the 
overall cell surface and a clear definition between cell boundaries.  The 
difference between Calu-3 cells grown under ALI compared to that of liquid 
covered cells was examined by Zhu et al and it was shown that ALI cells 
form a thicker pseudostratified cell layer in which cells display long cilia 
whereas those grown in immersion culture did not, with the cell layer being 
so thin that the pores of the transwell could be seen on the image [286].  The 
permeability of peptides through the epithelial layer was also shown to be 
different depending on the culture method used, the apical uptake of the 
peptide glycyl-sarcosine was much higher in ALI cultured cells than those in 
LCC [287].  The transwell filter can be composed of polyethylene 
terephthalate (PET) or polycarbonate, however studies have shown that 
there is no difference between using either [286], the factor which influences 
the inconsistencies in the data is the method of culture.  This may explain 
why there are such contrasting conclusions in research undergone using this 
cell line with some researchers using LCC and others ALI culture.   
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3.4.3 Expression of tight junction proteins in Calu-3 cells shown by 
immunofluorescence  
 
Calu-3 cells are known to have a wide range of junctional protein 
expression which is one of the reasons why they are a good cell model to 
use when studying the integrity of the airway epithelium.  Of the many 
junctional proteins commonly expressed by epithelial cells, some were 
examined by immunofluorecence studies.  Occludin, ZO-1, claudins 1, 2, 8 
and beta-catenin were all found to be expressed at some level in basal Calu-
3 cells.  The expression of these proteins in Calu-3 cells is already known 
however it was useful to get an idea of their localisation within the cell before 
beginning various stimulations to study their modulation.   
 
3.4.4 Limitations and future experiments 
 
 Although Calu-3 cells have been shown to be a good model to study 
the tight junction, they are still a carcinomic cell line and undoubtedly have 
many altered signalling pathways. In terms of tight junction expression and 
degree of ciliogenesis, it would be interesting to compare Calu-3 cells to that 
of a primary bronchial epithelial cell culture.  
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3.5 Conclusions  
 
 In this initial part of the study it was determined that Calu-3 cells are a 
suitable model to further study the modulation of tight junction proteins as 
they basally express all the key junctional proteins studied and reach high 
TER values when cultured on filters at ALI.  They were proven to be 
polarised after 7 days of culture by SEM where cilia were observed 
throughout the cell monolayer. 
 
In summary, this chapter shows that:  
 Calu-3 cells form a high TER of up to 1000 Ω cm2  after 7 days in ALI 
culture. 
 SEM images prove that the cells are differentiated and display cilia on 
their surface. 
 ZO-1, occludin, claudin 1, 2, 8 and beta-catenin are all present in 
Calu-3 cells shown by immunofluorescence. 
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Chapter 4 : Role of IL-13 in epithelial barrier 
modulation 
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4.1 Effect of cytokines IL-13, IL-4, IL-1β and IFN-γ on transepithelial 
resistance in Calu-3 cells 
 
IL-13 is known to be up-regulated in the lung of asthmatic patients.  It 
has been shown to play a role in many features of allergic asthma such as 
epithelial-to-mesenchymal transitions [288] and goblet cell metaplasia [34].  
The role of IL-13 in lung barrier modulation has been extensively researched 
in the intestine where it is known to play a key role in the inflammatory bowel 
disease ulcerative colitis [227, 245].  However much less in known about TJ 
regulation in the lung, here the effect of IL-13 on transepithelial resistance 
was researched.  IL-13 was added to the basolateral chamber of the culture 
system on day 7 when the cells had reached a maximum TER and were non 
‘leaky’.  IL-13 was administered at 10 ng/ml and the TER was monitored 
every 24 hours over 3 days.  IL-13 caused a ~40% decrease in 
transepithelial resistance after 24 hours which was sustained for 72 hours. 
(Figure 4.1).  In addition to IL-13, the effect of IL-4, IL-1β and IFNγ were 
investigated after 24 hour stimulation.  The TH2 cytokine IL-4 also 
demonstrated a decrease in TER of 35% compared to control.  The 
proinflammatory cytokine IL-1β which is part of the IL-1 cytokine family did 
not have any significant effect on TER compared with the control.  
Interestingly the TH1 cytokine interferon-γ (IFN-γ) resulted in a 40% increase 
in TER over control cells.  Unfortunately, only the role of IL-13 was 
investigated due to time constraints. 
 
4.2 Role of IL-13 in tight junction distribution by immunocytochemistry 
 
 In order to investigate the underlying mechanism responsible for the 
decrease in TER caused by IL-13 the distribution of key junctional proteins 
were examined by immunocytochemistry.  Cells were grown via ALI and 
when confluent were stimulated with IL-13 at 10 ng/ml for 24 hours, they 
were then fixed and stained as described in section 2.4.   
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 The junctional proteins claudin 1, claudin 2, ZO-1, E-cadherin, 
occludin and β-catenin were investigated.  IL-13 caused an obvious change 
in claudin 2 expression and distribution and a slight change in claudin 1 
expression.  Claudin 2 was found to be expressed more highly after IL-13 
stimulation and its distribution became more membrane associated. 
 
 
 
 
 
 
 
 
 
 
 Figure 4.1 Effect of cytokine stimulation on transepithelial resistance 
in Calu-3 cells.   
For each experiment 5x105  cells/ml were seeded onto transwell filters and 
their transepithelial resistance was monitored every 24 hours.  On Day#7 
when the maximum TER was reached, IL-13 (10 ng/ml) was added to the 
basolateral chamber and TER was measured after 24, 48 and 72 hours (A). 
Confluent Calu-3 cells grown via ALI were starved in serum free media 
overnight and stimulated with IL-13 (10 ng/ml), IL-4 (5 ng/ml), IL-1β (10 
ng/ml) and IFN-γ (10 ng/ml) for 24 hours. The TER was then compared to 
that of the same well 24 h prior to obtain the TER % of control after 24 h 
treatment (B). Data expressed as mean values ± SEM from n=9 (IL-13) and 
n=3 (IL-4, IL-1β and IFN-γ) independent experiments and statistical 
significance is represented as (***) for p<0.001 and (**) for p<0.01. 
A 
B 
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Claudin 1 was shown to have a slight increase in expression following IL-13 
treatment whereas distribution at the cell junction remained the same as in 
the untreated control.  The distribution or relative expression of occludin, E-
cadherin and ZO-1 did not change with IL-13 treatment (Figure 4.2).  The 
graph in Figure 4.3 is representative of the claudin 2 images semi-quantified 
by calculating the intensity per pixel using LSM image examiner.  
 
 
 
 
 
Figure 4.3 Semi-quantification of the effect of IL-13 on claudin 2 
expression in Calu-3 cells via immunocytochemistry.   
Images taken from immunocytochemistry (as shown in Figure 4.2) were 
quantified by intensity per pixel using LSM image examiner software.  The 
data plotted is expressed as mean ± SEM from n=3 independent 
experiments.       
 
4.3 Effect of IL-13 on tight junction expression by immunoblotting 
 
 To further investigate the changes in protein expression seen in 
immunofluorescence data, immunoblotting was used.  Claudin 1, claudin 2, 
occludin, E-cadherin and ZO-1 were blotted following the method described 
in 2.7.  The results mimicked the immunocytochemistry data in that the only 
proteins that changed in expression after IL-13 stimulation were claudin 1 
and claudin 2 (Figure 4.4).  Claudin 1 was only increased slightly with the 
largest increase being 1.5 fold over basal after 48 hours stimulation, the 
increase being gradual up to this point and then dropping slightly after 72  
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Figure 4.4 The effect of IL-13 on junctional protein expression by 
immunoblotting.  
For each experiment, cells were plated onto 3 cm2 dishes in complete MEM. When 
confluent, cells were incubated with IL-13 (10 ng/ml) for up to 72 h.  Samples were 
resolved on SDS-PAGE gel, transferred to nitrocellulose membranes and 
immunoblotted, using antibodies against claudin 1 at 20 kDa, claudin 2 at 23 kDa, 
E-cadherin at 120 kDa, occludin at 65 kDa and ZO-1 at 225 kDa. Each immunoblot 
is representative of 3 independent experiments (except for ZO-1 which is only one 
experiment).  All groups were compared to vehicle control (0 h) for statistical 
significance, which is expressed as (**) for p<0.01 and (*) for p<0.05. 
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hours.  IL-13 treatment induced the upregulation of claudin 2 after 24 hours 
with a 25-fold increase over basal which decreased to 15 fold after 48 hours 
and after 72h was almost returned to basal levels.  E-cadherin, occludin and 
ZO-1 protein levels did not alter with IL-13 stimulation up to 72 hours.   
 
4.4 Effect of IL-13 on paracellular permeability  
 
To further investigate the role of IL-13 in lung barrier modulation, the 
effect of IL-13 on macromolecule paracellular permeability was explored.  To 
standardise the experiment fluorescein isothiocyanate (FITC) dextran (4kDa) 
was diluted to between 0.1-1000 μg/ml to construct a standard curve of 
known FITC concentrations in the absence of cells.  It was important to 
ensure the amount of FITC detected in the basolateral chamber of untreated 
Calu-3 cells was not at the top end of the intensity limit; giving no window to 
monitor changes.  FITC-dextran at 500 μg/ml in HBSS buffer is a standard 
concentration to use in this assay; 200 μl was added to the apical chamber of 
fully confluent untreated cells for 15, 30 and 45 minutes. The optimal 
incubation time was found to be 30 minutes (Figure 4.5), which has also 
been used by other studies investigating paracellular permeability [289].  
Calu-3 cells were grown for 7 days until confluent, they were treated with IL-
13 at 10 ng/ml for 24 hours.  The apical chamber was washed with HBSS 
and 500 μg/ml FITC-dextran in HBSS was added to the chamber for 30 
minutes. The amount of FITC-dextran in the basolateral chamber was 
measured using a fluorescent plate reader at excitation and emission 
wavelengths of 485 and 530 nm respectively.  There was no change 
observed in the paracellular permeability of FITC dextran between the IL-13 
treated cells to that of control untreated cells (Figure 4.6). 
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Figure 4.5 Optimisation of the FITC-dextran paracellular permeability 
assay.  
To ensure that changes in FITC-dextran flux were detected a standard curve was 
constructed using samples of known FITC-dextran concentration in the absence of 
cells (A).  Untreated Calu-3 cells were monitored by TER and when confluent the 
apical chamber was washed with HBSS and 200 μl of FITC-dextran at 500 μg/ml 
was added for 15, 30 and 60 minutes.  Triplicate samples (100 μl) were extracted 
from the basolateral chamber and placed into a black 96-well plate.  The 
fluorescence intensity was measured at excitation 485 nm and emission 530 nm on 
a Fluorstar optima plate reader.  The optimal incubation time with 500 μg/ml FITC-
dextran was 30 minutes which gave a mid range intensity (~5000) on the standard 
curve, giving a window for change throughout subsequent experiments (B).  Data 
shown are from two independent experiments.  
 
 
A 
B 
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Figure 4.6 Effect of IL-13 on paracellular permeability.   
Confluent Calu-3 cells were stimulated with IL-13 (10 ng/ml) for 24 hours, 
after which they were washed twice with HBSS to remove all traces of 
phenol red.  HBSS (600 μl) was placed in the basolateral chamber and 200 
μl of 500 μg/ml FITC-dextran was placed in the apical chamber.  Cells were 
incubated at 37°C for 30 minutes and triplicate samples (each 100 μl) were 
taken from the basolateral chamber and placed into a black 96-well plate. 
The fluorescence intensity was measured at excitation 485 nm and emission 
530 nm on a Fluorstar optima plate reader.  Data are expressed as mean 
values ± SEM from n=3 independent experiments.  
 
4.5 Effect of IL-13 on epithelial surface properties by scanning electron 
microscopy (SEM)  
 Calu-3 cells were stimulated with IL-13 for 24 hours and their surface 
properties were studied using SEM (Figure 4.7).  Vehicle treated cells 
(Figure 4.7 A, B and C) displayed the same ciliated appearance as shown in 
the last chapter in Figure 3.2, the cilia were present on 90% of all cells in the 
monolayer and displayed the same star-like form.  After 24 hour IL-13-
treatment (Figure 4.7 D, E and F), 70% of the cell surface area was covered 
in tangled stringy structures which are believed to be secreted mucus.  
These structures are seen most clearly in image F which is a highly 
magnified area of image E.  Images B and E clearly show the cell boundaries 
labelled with red arrows   
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Figure 4.7 (see next page for legend)  
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Figure 4.7 Effect of IL-13 on the surface properties of Calu-3 cells by 
SEM imaging.   
Calu-3 cells were grown via air-liquid interface culture for 7 days, they were 
then stimulated for 24 hours with IL-13 (10 ng/ml).  Cells were washed with 
serum free MEM and placed in the fixative solution, , 2.5% glutaraldehyde, 
0.5g potassium ferrocyanide in media for 2 hours at 37°C.  Cells were then 
washed and postfixed with 1% osmium tetroxide and 1% potassium 
ferrocyanide for 1 hour at room temperature.  Cells were washed with water 
and were then stained with 2% uranyl acetate for 1 hour in the dark. They 
were then slowly dehydrated with acetone and HDMS washes, then coated 
with an ultrathin layer of gold and viewed on a JEOL SEM6480LV scanning 
electron microscope.  Vehicle control treated cells (A-C) do not display the 
stringy cell surface feature that is displayed on the IL-13 treated cells (D-F).   
Images A and D are at low magnification and give an overall idea of the cell 
surface with many cells visible.   B and E are taken at a higher magnification 
and show the junctional space between cells, illustrated with red arrows. 
Images C and F are the highest magnification taken and clearly show the 
difference in cell surface features between control and IL-13 treated cells.  
Images are representative of n=3 independent experiments. 
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4.6 Effect of IL-13 on MUC5AC expression   
 To investigate whether the ‘stringy’ cell surface features observed by 
SEM were mucus as believed, the expression of one of the main mucins 
present in the lung, MUC5AC protein was investigated using 
immunofluorescence.  Calu-3 cells were grown to confluence at ALI and 
treated with IL-13 for 24 hours; cells were then stained for the MUC5AC 
protein and examined on a confocal microscope.  IL-13 treatment resulted in 
an increase in MUC5AC expression after 24 hours (Figure 4.8 A).  The 
mRNA expression of MUC5AC was explored after long-term IL-13 
stimulation up to 21 days which is the longest time in which cells can be 
studied at ALI by quantitative PCR (Figure 4.8 B).  IL-13 treatment 
demonstrated a noticeable upregulation of MUC5AC after 48 hours which 
continued to increase up to 7 days when the increase was shown to be 
statistically significant compared to control cells.   After 14 days IL-13 
stimulation the level of MUC5AC dipped (due to one low data point) and then 
increased back up to significantly higher levels at days 14 and 21.  The data 
indicates that IL-13 upregulates mRNA after 48 hours however upregulation 
of the IL-13 protein level occurs after just 24 hours.  
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Figure 4.8 Effect of IL-13 stimulation on MUC5AC protein and mRNA 
expression.   
Cells were treated with IL-13 at 10ng/ml for 24 hours (A) and up to 21 days (B), 
IL-13 and culture media were changed every other day.  Cells were washed, 
fixed and stained with antibodies against the mucin MUC5AC.  Transwell filters 
were cut out and mounted onto glass sides and viewed with a LSM510META 
confocal laser scanning microscope. In B, cells were lysed and RNA was 
extracted using an RNeasy mini kit.  qRT-PCR reactions were run on a StepOne 
Plus PCR machine and MUC5AC mRNA expression was compared to β-actin 
as an equal loading gene and then normalised to the control group.  A, images 
are representative of three independent experiments. B, data are shown as 
mean ± SEM for three independent experiments, in which all groups were 
compared to control for statistical significance which is expressed as (*) for 
p<0.05.  
Control IL-13 
24 hours treatment  
A 
B 
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4.7 The signalling pathways that are activated by IL-13 
In order to establish how IL-13 plays a role in epithelial barrier 
modulation, the signalling pathways activated by IL-13 were investigated. 
Figure 4.9 shows that IL-13 phosphorylates Akt which is a common measure 
of PI3K activity; this phosphorylation reaches a maximum at 15 minutes, but 
it not significantly different from the untreated control.  Calu-3 cells are 
known to have very high basal level of phosphorylated Akt [290] which may 
explain why there is no significant stimulation.  Repeating the same 
experiment in the alveolar epithelial cell line A549 showed a significant 
increase in Akt phosphorylation at 10 minutes.  
   
 
 
 
 
 
 
Figure 4.9 IL-13 timecourse study on Akt phosphorylation in Calu-3 
cells and A549 cells. 
For each experiment Calu-3 cells and A549 cells were seeded onto 12-well plates 
until confluency.  The cells were then placed in serum free media at 37°C at 5% 
CO2 overnight.  Cells were treated with IL-13 at 10 ng for up to 90 minutes and then 
cells were washed with ice-cold PBS and lysed to extract all available protein.  
Protein concentration was measured using a Bradford assay and samples were 
boiled with 5X sample buffer and resolved on an SDS-PAGE gel with 25 μg protein 
in each sample. Samples were transferred onto nitrocellulose membrane and 
immunoblotted using antibodies against phosphoSer473 – Akt (pAkt) and Akt1 with 
both protein bands detected at 60 kDa.  Data shown are from three independent 
experiments. Optical density values are expressed as mean fold increase compared 
with control ± SEM. 
Calu-3 cells A549 cells 
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4.8 Discussion  
4.8.1 The effect of cytokines IL-13, IL-4 and IFN-γ on TJ modulation of 
Calu-3 cells grown at ALI  
 
IL-13 has been shown to be highly upregulated in allergic asthma; 
here its role in TJ regulation was examined.  IL-13 stimulation resulted in a 
significant decrease in TER of 40% after 24 hours treatment, this decrease 
was mimicked using the TH2 cytokine IL-4 which resulted in a 35% decrease.  
The cytokine IL-1β did not have any effect on the TER compared to control, 
however the TH1 cytokine IFN-γ brought about the opposite result to IL-13 
and IL-4 and increased the TER 40% over basal levels.  This difference 
between TH1 and TH2 cytokines is interesting and the effect shown by IFN-γ 
has not been shown in studies investigating TJ regulation in IBD whereby 
IFN-γ has a negative effect on the epithelial barrier by disrupting the tight 
junction through internalisation of the TJ proteins occludin, claudin 1, claudin 
4 and JAM-1 [291].  
The decrease shown by IL-13 stimulation in the TER assay was not 
accompanied by an increase in paracellular permeability by FITC-dextran as 
would be expected if a paracellular space had opened up.  There are three 
scenarios which can occur that connect TER and FITC-dextran permeability, 
shown in Figure 4.10 below. The data in the first part of this chapter indicate 
scenario 2 where the result is the formation of an ion channel. 
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Figure 4.10 Possible outcomes in TER vs FITC dextran.   
There are 3 possible scenarios that can occur when looking at TER and FITC 
dextran permeability.  A normal intact epithelial layer will possess a high TER 
and a low FITC dextran flux. If there is a decrease in TER it is often 
accompanied by an increase in FITC dextran flux as shown in scenario 1, but it 
is also possible to see a decrease in TER coupled with no change in FITC-
dextran flux which indicates a small gap opening between cells and could also 
indicate an ion channel forming which would decrease the TER but be too small 
to let FITC-dextran pass through.   
 
4.8.2 The role of IL-13 in regulating TJ expression 
 
The expression of the TJ protein claudin 2 was upregulated 25-fold 
compared to control by IL-13 after 24 hours, it was shown to move from a 
very low level of expression in the cytoplasm to more ordered junctional 
location in rings around each cell.  Claudin 2 has been shown to be 
upregulated in the intestine [292] and has been reported to form a cation 
selective ion channel in MDCK cells with a pore diameter of 6.5 ± 0.3 Å 
[293].  Transfection of human claudin 2 into MDCK C7 cells resulted in a 
cation channel forming which was responsible for the paracellular water flux 
through the tight junction [294].  
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Claudin 2 and claudin 15 have recently been reported to control 
paracellular Na+ ion flow in the intestine.  Claudin 2 -/- and claudin 15 -/- 
double knockout mice were shown to have a reduced concentration of Na+ in 
the lumen as well as a disruption in the absorption of amino acids and 
glucose resulting in death by day 25 from malnutrition [295]. Tamura et al 
argue that claudin 15 but not claudin 2 is responsible for this Na+ ion flow 
regulation in the intestine [296]. 
IL-13 may regulate claudin 2 by post-translational modification, Van 
Itallie et al have recently published data which shows that phosphorylation of 
claudin 2 at Serine 208 is responsible for its retention at the plasma 
membrane [297].  However, to rule out this theory future experiments 
investigating the effect of IL-13 on mRNA expression could be undertaken to 
show whether IL-13 is acting in a transcriptional or post-transcriptional 
manner.  
4.8.3 The effect of IL-13 on the surface morphology and mucus 
secretion of Calu-3 cells 
 
Calu-3 cells treated with IL-13 for 24 hours displayed long stringy 
structures on their surface determined by SEM images at various 
magnifications.  These structures were labelled as mucus.  IL-13 has been 
shown to play a role in the feature of asthma where an overproduction of 
mucus blocks the airways, termed goblet cell metaplasia (GCM) and mucus 
hypersecretion.  Treatment with IL-13 resulted in an increase in MUC5AC 
protein on the cell surface after 24 hours shown by immunofluorescence data 
which correlates with Nakano et al who showed that IL-13 treatment 
increases the number of goblet cells in mouse tracheal after only 24hours 
[298].  In primary epithelial cells IL-13 was shown to increase the number of 
goblet cells, MUC5AC mRNA and protein expression after 14 days [299, 
300], which is consistent with the results shown here in the quantitative PCR 
experiment, which demonstrated an increase in MUC5AC mRNA at 7,14 and 
21 days IL-13 treatment. The expression of the calcium activated chloride 
channel hCLCA1 has also been shown to be up-regulated by IL-13 after 
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14days and was shown to co-localise with MUC5AC in goblet cells 
suggesting a role for hCLCA in IL-13-incuced mucus hypersecretion [300].  
Anti-IL-13Rα1 reduces the IL-13 MUC5AC and goblet cell protein and mRNA 
upregulation in NHBECs in accordance with previous publications stating 
that IL-13 is mediating its affects via the IL-13Rα1 complex. Tanabe et al 
also studied the role of IL-13Rα2 in GCM and found that recombinant IL-
13Rα2 but not anti-IL-13Rα2 decreased goblet cell numbers, PAS positive 
cells, MUC5AC protein and mRNA expression when combined with IL-13, 
implying that soluble the IL-13Rα2 plays a role in the regulation of GCM. 
 
4.8.4 Limitations and future experiments 
To further explore the effect of IL-13 on the proposed ion channel 
formation shown in Figure 4.10, scenario 2, an ion flux assay could be carried 
out. Ion binding dyes such as fluor-2 and ANG-2 which bind to Ca2+ and Na+ 
ions respectively can be added to the apical chamber in the concentrations 10-
100 μM. The ion-bound dye can then be detected by sampling the basolateral 
media and testing the fluorescence [301]. An unfortunate limitation of the work 
in this chapter was the inability to further investigate the effect of IFN-γ on 
barrier modulation after the result observed in the TER assay.  Stimulation 
with the TH1 cytokine IFNγ resulted in the opposite effect on TER to that of 
IL-13, with an increase in resistance above control. This result is conflicting 
with studies that have shown that IFNγ disrupts the epithelial barrier in 
intestinal bowel disease and decreases the TER [302]. This indicates that the 
regulation of tight junctions in the lung may not be the same as those in the 
intestine. 
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4.9 Conclusions 
 
 In this chapter the role of IL-13 in the modulation of tight junction 
proteins was explored.  IL-13 was shown to decrease TER by ~30% after 24 
hours treatment, however, this was not coupled with an increase in the 
paracellular permeability of the macromolecule FITC-dextran which indicates 
that an ion channel has formed in response to IL-13 stimulation.  Claudin 2 
protein upregulation by IL-13 shown by both immunoblotting and 
immunofluorescence after 24 hours emphasises the validity of the theory of 
ion channel formation as it is known to be a pore forming tight junction 
protein which is involved in forming a paracellular water channel [294]. 
 
In summary, in this chapter the following was determined: 
 IL-13 causes a decrease in TER of up to ~30% after 24 hours 
treatment. 
 IL-13 has no effect on the paracellular permeability of FITC-dextran. 
 The TJ proteins claudin 1 and 2 were upregulated by IL-13 shown by 
immunoblotting. 
 The distribution of claudin 2 altered from cytoplasmic to junctional 
after 24 hour IL-13 treatment.  
 Junctional proteins occludin, ZO-1, E-cadherin and β-catenin were not 
altered by IL-13 treatment. 
 IL-13 causes an upregulation of mucus on the cell surface of Calu-3 
cells after 24 hour treatment.  
 
With the results in this chapter indicating a role for IL-13 in the modulation of 
the tight junction, the next step was to look at the signalling pathways behind 
these IL-13-induced responses.   
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Chapter 5 : Role of PI3K in epithelial barrier 
modulation 
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One of the most common signalling pathways activated by IL-13 is the 
PI3K pathway.  In the context of this thesis, it was necessary to investigate 
the possible role of this pathway in the regulation of the TJ complex in the 
lung and particularly the IL-13-induced effects on TJ proteins mentioned in 
chapter 4.   
 
The PI3K pathway has been extensively researched in a variety of 
cancers [65, 74, 303-305] as well as in inflammatory diseases [73, 76, 88, 
89, 106, 277, 306].  Class IA PI3Ks are involved in human cancers as they 
drive Akt activation by producing PtdIns(3,4,5)P3 which promotes tumor cell 
survival and proliferation [61].  PI3K has been reportedly involved in 
inflammatory bowel disease (IBD), where it was found to control adherens 
junction formation as well as activating the p38 MAPK cascade [277].  Over 
the last decade the dysregulation of the PI3K pathway has been shown to be 
involved in the pathogenesis of respiratory diseases such as severe asthma, 
yet its exact role and the key isoforms involved are yet to be discovered.  
 
IL-13 has been shown to phosphorylate Akt, the key protein kinase 
downstream of PI3K, at Serine 473 [307] and this phosphorylation is often 
used as a measure of PI3K activity.  PI3K can be silenced using synthetically 
generated siRNA specific to individual isoforms or inhibited by the addition of 
small molecule inhibitors which usually competitively block to the ATP 
binding pocket.  Previous members of the group have used siRNA systems 
to observe PI3K due to the lack of commercially available isoform selective 
inhibitors [73], however recently many highly selective class I PI3K isoform 
inhibitors have been produced (see Figure 1.4).  This chapter will assess the 
role of class I PI3K inhibition in the modulation of junctional proteins in the 
lung using small molecule inhibitors.    
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5.1 Effect of PI3K inhibition on the IL-13-induced decrease in 
transepithelial resistance 
 
IL-13 was shown to cause a 30-40% decrease in TER, in order to 
discover the signalling pathways behind this response, cells were pretreated 
with the Class I PI3K inhibitor ZSTK474 for 30 minutes and then 
subsequently subjected to IL-13 stimulation for up to 72 hours.  Class I PI3K 
inhibition with the highest concentration of ZSTK474 (10 μM) resulted in the 
prevention of the IL-13-induced decrease in TER (shown in Figure 5.1 A).  
Treatment with ZSTK474 and IL-13 resulted in a 60% increase in TER over 
IL-13-stimulated cells (Figure 5.1 B). Cells were treated with lower 
concentrations of ZSTK474 (1 and 0.1 μM) for 24 hours; neither 1 μM nor 
0.1μM ZSTK474 showed a significant effect on the IL-13-induced decrease 
in TER.  Pre-treatment with ZSTK474 at the lowest concentration 0.1 μM 
followed by IL-13 was statistically different from the control groups as was 
the case with the IL-13 stimulated cells.  Cells were also treated with the 
pan-PI3K inhibitor LY294002 for 24 hours which prevented the IL-13 induced 
decrease in TER (Figure 5.1 B).     
In an attempt to uncover the PI3K isoform responsible for the effect 
shown, selective small molecule PI3K isoform inhibitors were used.  The 
PI3K selective isoform inhibitor IC87114 targets the p110δ isoform of PI3K 
and cells treated with this inhibitor alone showed a slightly higher TER than 
that of untreated cells, however this increase was not statistically significant 
(Figure 5.2).  There was also no significant difference between the IL-13 
treated cells and those pre-treated with the p110δ inhibitor followed by IL-13.  
The same was observed for the p110β inhibitor TGX-221. Addition of TGX-
221 alone resulted in TER that was identical to that of control cells and the 
decrease in TER observed when cells were pretreated with TGX-221 before 
IL-13 stimulation mimicked the IL-13 alone result.  Treatment with the p110α 
inhibitor PIK75 resulted in a large decrease in TER indicating that the p110α 
isoform is required to maintain a high basal TER.  The dual p110β and p110δ 
inhibitor TGX-121 had no effect on TER and produced the same results with 
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or without inhibitor addition.  These data do not correlate with the results 
seen using the pan-class I inhibitor ZSTK474, which indicates that either all 
isoforms play individual but vital roles in maintaining the TER or that the 
ZSTK474 inhibitor is having off target effects. 
In order to investigate whether each class I PI3K isoform had an 
essential role in modulating the epithelial barrier, all the selective isoform 
inhibitors were added at the same time and the TER was monitored.  Cells 
treated with IC87114, TGX-221 and PIK75 together resulted in a 20% 
decrease in TER (Figure 5.3) which did not change upon IL-13 stimulation.  
To eliminate the possible involvement of the class II PI3Ks along with the key 
serine/threonine kinase mammalian target of rapamycin (mTOR), cells were 
treated with PI-103 which had been shown to inhibit PI3K C2β, p110α and 
mTOR at high concentration [308]. Pre-treatment with PI-103 (300 nM) alone 
had no effect on TER and the same was shown for the combined PI-103 and 
IL-13 treatment (Figure 5.3 B)  
 The PI3K inhibitors LY294002 and wortmannin have been reported to 
inhibit mTOR by irreversibly inhibiting its serine specific autokinase activity; 
[85] ZSTK474 has been shown not inhibit mTOR in this way [99]. To 
investigate whether mTOR inhibition was the reason behind the IL-13-
induced TER recovery seen by ZSTK474, Calu-3 cells were treated with the 
potent mTOR inhibitor, Rapamycin.  In this experiment, Rapmycin was 
administered in two concentrations, the highest of which (20 nM) resulted in 
a decrease in TER in both inhibitor and inhibitor + IL-13 treatments. The 
lower concentration of Rapamycin (2 nM) was shown to have little to no 
effect on the TER (Figure 5.3 C), indicating that mTOR is not responsible for 
causing the IL-13-induced decrease in TER.  
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Figure 5.1 Effect of Class I PI3K inhibition on transepithelial resistance.  
For each experiment 5x10
5 
cells/ml were seeded onto transwell filters and their 
transepithelial resistance was monitored every 24 hours.  When cells reached 
confluency on day#7 they were treated with ZSTK474 (10 μM) followed by addition of 
IL-13 (10 ng/ml) for up to 72 hours.  The TER was measured after 24, 48 and 72 hours, 
this raw value was subtracted from the background reading (obtained from a transwell 
insert without cells) and multiplied by the transwell area to obtain TER Ωcm2 (A). 
Confluent cells at day#7 were treated with ZSTK474 (10, 1 and 0.1 μM) or LY294002 
(20 μM) and IL-13 (10 ng/ml) for 24 hours.  The TER was measured before treatment 
and after 24 hours and the raw value was converted to a percentage of the TER prior to 
treatment (B). Data expressed as mean values ± SEM from n=5 (C, IL-13 and ZSTK474 
10μM) and n=3 (ZSTK474 1μM, ZSTK474 0.1μM and LY294002 20 μM) independent 
experiments.  All inhibitor + IL-13 treated groups were compared to IL-13 stimulation 
alone and statistical significance is expressed as (###) for p<0.001.  All groups were 
compared to control and statistical significance is expressed as (*) for p<0.05, (**) for 
p<0.01 and (***) for p<0.001. 
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Figure 5.2 Effect of isoform selective PI3K inhibitors on transepithelial resistance.   
For each experiment 5x105 cells/ml were seeded onto transwell filters and their transepithelial resistance was monitored every 24 hours.  On 
day#7 when the maximum TER was reached IC87114 (p110δ inhibitor, 10 μM) TGX-221 (p110β inhibitor, 100 nM), PIK75 (p110α inhibitor, 100 
nM) and TGX-121 (p110β and p110δ dual inhibitor, 10 nM) were added to the basolateral chamber for 30mins followed by IL-13 (10 ng/ml) and 
the TER was measured after 24, 48 and 72 hours (A,C, E and G). The TER was then compared to that of the same well 24 h prior to obtain the 
TER as a percentage of the control after 24 h treatment (B, D, F and H). Data expressed as mean values ± SEM n=6 (A,B), n=3 (C,D),  n=3 
(E,F), n=6 (G,H) independent experiments.  All groups were compared to each other and statistical significance is expressed as (*) for p<0.05, 
(**) for p<0.01 and (***) for p<0.001. ns; not significant.   
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Figure 5.3 Effect of combined PI3K individual class I isoform addition, 
PI-103 and Rapamycin on transepithelial resistance. 
 For each experiment 5x105  cells/ml were seeded onto transwell filters and 
their transepithelial resistance was monitored every 24 hours.  On Day#7 
when the maximum TER was reached IC87114 (p110δ inhibitor, 10 μM) 
TGX-221 (p110β inhibitor, 100 nM), PIK75 (p110α inhibitor, 100 nM) (A), PI-
103 (300 nM) (B) and Rapamycin (20 nM and 2 nM) (C) were added to the 
basolateral chamber for 30 min followed by IL-13 at 10 ng/ml and the TER 
was measured after 24 hours.  Data expressed as mean values ± SEM from 
three independent experiments (A and B) and two independent experiments 
(C).  All groups were compared to the control group for statistical significance 
which is expressed as (*) for p<0.05 and (**) for p<0.01.  
A B 
C 
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5.2 Investigating the efficacy of PI3K inhibitors  
 
Phosphorylation at serine 473 of Akt was used as a marker of PI3K 
activity to investigate the efficacy of the various PI3K inhibitors.  An IL-13 
time course of Akt phosphorylation was carried out, where cells were pre-
treated with the pan Class I PI3K inhibitor ZSTK474 or the specific class I 
isoform inhibitors IC87114, TGX-221 and PIK75 which target the delta, beta 
and alpha isoforms of PI3K respectively.  The Class I PI3K inhibitor 
ZSTK474 completely abolished the Akt phosphorylation at all time points 
between 5 and 90 minutes (Figure 5.4 A) The PI3Kα inhibitor PIK75 reduced 
the Akt phosphorylation at both 15 and 30 minutes; both the PI3Kβ and δ 
inhibitors TGX-221 and IC87114 only slightly decreased the Akt 
phosphorylation (Figure 5.4 B).    
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Figure 5.4 Effect of ZSTK474 pre-treatment on IL-13-induced Akt 
phosphorylation in Calu-3 cells.   
Cells were plated onto 12-well plates in serum containing MEM. When 
confluent, cells were cultured in serum free MEM at 37°C at 5% CO2 
overnight.  After which they were incubated for 30 minutes with ZSTK474 (10 
μM) (graph A) or IC87114 (10 μM), TGX-221 (100 nM) and PIK75 (100 nM) 
(graph B) and then stimulated with IL-13 (10 ng/ml) for up to 90 minutes in 
graph A or 15 and 30  minutes in graph B.  Samples were resolved by SDS-
PAGE, transferred to nitrocellulose membranes and immunoblotted, using 
antibodies against phosphoSer473-Akt (pAkt) and Akt1 with both protein 
bands measured at 60 kDa. Data are presented as n=3 (A) and n=2 (B) 
independent experiments. All groups were compared to vehicle control for 
statistical significance, which is expressed as (**) for p<0.01 and (*) for 
p<0.05 
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5.3 Effect of class I PI3K inhibition on paracellular permeability 
 
 In chapter 4, IL-13 was shown to decrease TER but have no effect on 
the paracellular permeability of FITC-dextran, which was concluded to be 
through small cationic pore formation.  To test the effect of PI3K inhibition on 
FITC-dextran flux cells were treated with PI3K inhibitors prior to IL-13 
stimulation for 24 hours (see section 2.3 for more details). None of the PI3K 
inhibitiors tested (ZSTK474, IC87114, TGX221 and PIK75) had any 
significant effect on the permeability of FITC-dextran compared to that of 
untreated control cells. (Figure 5.5) 
 
 
 
 
 
 
Figure 5.5 Effect of class I PI3K inhibition on paracellular permeability.  
Calu-3 cells were stimulated with ZSTK474 (pan-class-I-PI3K inhibitor,10 
μM), IC87114 (p110δ inhibitor, 10 μM), TGX-221 (p110β inhibitor, 100 nM) 
and PIK75 (p110α inhibitor, 100 nM) for 30mins followed by IL-13 at 10 
ng/ml. They were washed twice with HBSS to remove all traces of phenol red 
and 600 μl HBSS was placed in the basolateral chamber and 200 μl of 500 
μg/ml FITC-dextran was placed in the apical chamber.  Cells were incubated 
at 37°C at 5% CO2 for 30 minutes after which 100 μl was pipetted from the 
basolateral chamber of each sample in triplicate onto a black 96-well plate. 
The fluorescence intensity was measured at excitation 485 nm and emission 
530 nm on a Fluorstar optima plate reader. Data are presented as n=6 (A) 
and n=3 (B) independent experiments. 
A B 
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5.4 Effect of PI3K inhibition on junctional protein expression and 
distribution by immunocytochemistry 
 Confluent cells grown via ALI were pretreated with PI3K inhibitors for 
30 minutes then stimulated with IL-13 for 24 hours and claudin 2 was probed 
for using immunocytochemistry (see section 2.4 for details).  Treatment with 
ZSTK474, PIK75 and LY294002 decreased the basal expression of claudin 2 
which was not restored following stimulation with IL-13; LY294002 did not 
completely abolish the IL-13-inducation of claudin 2 to the same extent of 
ZSTK474 and PIK75 (Figure 5.6).  The p110β and p110δ inhibitors (IC87114 
and TGX221) had no effect on basal or IL-13-stimulated claudin 2 
upregulation.   
 
5.5 Effect of PI3K inhibition on claudin 2 mRNA expression by qRT-PCR 
 
 To evaluate the mRNA expression of the TJ protein claudin 2 after IL-
13 and PI3K inhibition, quantitative PCR was carried out.  Confluent cells at 
ALI were treated with IL-13 and various PI3K inhibitors for 24 hours, they 
were lysed and RNA was extracted using an RNeasy mini kit (see section 
2.6).  Although stimulation with IL-13 seemed to show an increase in mRNA 
expression, there was no significant difference due to one experiment 
demonstrating a much higher IL-13 stimulated effect than the previous two 
experiments, so the result remains inconclusive and further experiments are 
needed to clarify this affect. Treatment with the PI3K inhibitors (ZSTK474, 
IC87114 and PIK75) did not show any significant difference in mRNA 
expression compared with that of the untreated control (Figure 5.7).  
Treatment with ZSTK474 appears to reduce the expression of claudin 2 
compared with that of the IL-13 stimulated cells, but as previously 
mentioned, further experiments are needed in order to form accurate 
conclusions on the effect of both IL-13 and PI3K on claudin 2 mRNA 
expression.  
 
Chapter 5 – Results III 
110 
 
Control IL-13 ZSTK474 + IL-13 
LY294002 LY294002 + IL-13 
ZSTK474 IC87114 IC87114 + IL-13 
TGX-221 + IL-13 TGX-221 PIK75 PIK75 + IL-13 
 
Figure 5.6 Effect of Class I PI3K inhibition on claudin 2 distribution.  
Calu-3 cells were stimulated with ZSTK474 (pan-class-I-PI3K inhibitor,10 μM), IC87114 (p110δ inhibitor, 10 μM), TGX-221 (p110β 
inhibitor, 100 nM), PIK75 (p110α inhibitor, 100 nM) and LY294002 (20 μM) for 30mins followed by IL-13 (10 ng/ml) for 24 hours.  After 
which they were fixed and probed for the tight junction protein claudin 2 (see section 2.4 for details).  The filters were then mounted onto 
glass slides and viewed using a LSM510META confocal laser scanning microscope.  Each image is representative of three similar 
images taken during three independent experiments (n=3), for magnification see scale bars displayed on each image.  
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Figure 5.7 Effect of PI3K inhibition on claudin 2 mRNA expression by 
qRT-PCR.   
Confluent Calu-3 cells grown via ALI were treated with ZSTK474 (pan-class-
I-PI3K inhibitor, 10 μM), IC87114 (p110δ inhibitor, 10 μM) and PIK75 (p110α 
inhibitor, 100 nM) for 30mins followed by 10 ng/ml IL-13 for 24 hours. Cells 
were lysed and RNA was extracted, reversed transcribed to cDNA and 
reactin were performed on a StepOnePlus Real-time PCR system.  All 
samples were compared to the equal loading gene β-actin and normalised to 
the untreated control sample.  Data expressed as mean values ± SEM from 
n=3 independent experiments. 
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5.6  Apical vs basolateral chamber stimulation on the role of PI3K in IL-
13-induced decrease in TER 
 
 As most asthma drugs are administered by inhalation and transported 
from the apical side of the epithelium to the basolateral side into the 
underlying smooth muscle cell layer, inhibitors were placed into the 
basolateral chamber.  Figure 5.8 shows preliminary data showing that adding 
the various PI3K inhibitors to the top side of the cells (apical) brought about 
the same response as if they were added to the basolateral (basement 
membrane) side.  Interestingly, treatment with PIK75 to the apical chamber 
resulted in a ~60% decrease in TER which is around a 20% greater 
decrease than when administered to the basolateral side in Figure 5.2.   IL-
13 was administered to the basolateral side of the chamber as 
physiologically in the lung IL-13 will come from T-cells present in the 
submucosa.  
 
 
 
 
 
 
Figure 5.8 Effect of apical vs basolateral chamber administration of 
PI3K inhibitors on TER in Calu-3 cells.  
Calu-3 cells were grown via ALI and when confluent they were placed in serum-free 
media overnight.  PI3K inhibitors ZSTK474 (10 μM), IC87114 (10 μM), TGX-221 
(100 nM) and PIK75 (100 nM) were placed in 200 μl of serum free-media and 
placed in the apical chamber (on top of cells) for 30 minutes prior to IL-13 addition 
to the basolateral chamber for  24 hours. The TER was monitored before and after 
as in previous TER experiments. Data shown is preliminary data expressed as the 
mean of triplicate values from n=1 experiment. 
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5.7 Effect of IL-13 and PI3K inhibition on IL-13 receptor surface 
expression by flow cytometry 
 
 Research has shown that increased expression of IL-13Rα2 at the cell 
surface can impact signalling by inhibiting IL-13 responses [60].  Higher 
expression of this second IL-13 receptor, IL-13Rα2 is presumed to compete 
against the first receptor IL-13Rα1 for IL-13 and therefore results in less IL-
13 available for the IL-13Rα leading to a dampened response. It was 
necessary to study the expression of IL-13Rα2 on basal and stimulated Calu-
3 cells, as a possible explanation of the results observed to date using the 
PI3K inhibitors may be due to upregulation of the IL-13Rα2 expression. 
   To investigate the surface expression of IL-13Rα2 fluorescence-activated 
cell sorting (FACS), a specific type of flow cytometry was used (Figure 5.9). 
Calu-3 cells proved difficult to analyse by FACS due to their heterogeneous 
nature being a submucosal cell line.  IL-13Rα2 was expressed on 20% of 
control Calu-3 cells, after IL-13 stimulation with both 1 and 10 ng/ml this 
surface expression increased to 34% and 33% respectively.  Pretreatment 
with the PI3K inhibitor ZSTK474 and the isoform selective inhibitors IC87114, 
TGX-221 and PIK75 before IL-13 stimulation returned IL-13Rα2 surface 
expression to control levels.  These data indicate that PI3K signalling is 
involved in regulation of the expression of IL-13Rα2 on the cell surface of 
Calu-3 cells, but further experiments need to be carried out to prove this. 
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Figure 5.9 Effect of IL-13 and PI3K inhibition on IL-13Rα2 surface 
expression.   
Cells were grown at ALI and once confluent at day#7 were stimulated with 
IL-13, with or without pre-treatment with ZSTK474 (10 μM), IC87114 (10 
μM), TGX-221 (100 nM) and PIK75 (100 nM) for 24 hours.  Cells were 
washed with PBS then 0.25% Trypsin/EDTA was added to detach the cells 
from the surface of the filter. Cells were then washed with PBS followed by 
addition of an antibody against IL-13Rα2 in 2% FBS in PBS for 1 hour.  Cells 
were washed with PBS and resuspended with a secondary conjuated 488 
Alexa Fluor labelled antibody for 1 hour at 4°C in the dark. Cells were 
washed with PBS, resuspended in 500 μl of ice-cold PBS and samples were 
analysed on a FACSCanto flow cytometer.  Data are presented as mean 
values from n=2 independent experiments.  
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5.8 Role of pan PI3K and selective isoforms in cell migration  
The ability of cells to migrate and repair wounds is an essential part of 
epithelium constitution. PI3K has been shown to be involved in epithelial 
wound repair in skin fibroblasts and also has a role in IL-6 induced migration 
of BEAS2B lung epithelial cells [309]. 
  A549 and Calu-3 cells were investigated in a wound healing assay.  
A549 cells had an average percentage regrowth of 33.4 ± 7% of the wound 
which was significantly lower than that of Calu-3 cells which was 62.6 ± 5% 
(Figure 5.10).    In both A549 and Calu-3 cell lines IL-13 treatment resulted in 
little to no response after 24 hours with A549 cells staying the same at 33.6 ± 
3% and Calu-3 cells  decreasing to 54.9 ± 6% wound closure.    PI3K was 
found to play an essential role in cell migration during the wound healing 
response, in both cell lines treatment with the pan-PI3K inhibitor ZSTK474 
reduced the percentage of the wound healed to 19.9 ± 4.5% in A549 cells 
and -7.6 ± 4% in Calu-3 cells.  The combined treatment of ZSTK474 + IL-13 
did not change the percentage of wound healed in either cell line.  
The PI3K response in cell migration was further investigated by 
addition of the PI3K isoform inhibitors PIK75, TGX-221 and IC871114 
(Figure 5.11).  In both cell lines the order in which the inhibitors reduced cell 
migration was TGX-221< IC87114 < PIK75.  With p110β inhibition only 
resulting in a small decrease to 49.1 ± 4% in Calu-3 cells and 28.5 ± 6% in 
A549 cells.  IC87114 showed a larger decrease in wounds with 36.9 ± 12% 
closure in Calu-3 cells and 16.5 ± 1.3% in A549 cells.  Treatment with the 
p110α isoform was shown to reduce the wound healing response 
significantly in both cell lines with only 5.1 ± 2.1% regrowth in Calu-3 cells 
and 5.9 ± 2.5 % regrowth in A549 cells.  These data imply the involvement of 
the p110α isoform in the role of PI3K in epithelial migration and wound 
healing. 
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Figure 5.10 Effect of IL-13 and PI3K inhibition on cell migration in Calu-
3 and A549 cells.   
For each experiment, cells were plated onto 12-well plates in complete 
media and when confluent were placed in serum free media overnight at 
37°C at 5% CO2.  Cells were then scratched with a pipette tip to make a 
wound, the wound was washed and photographed.  PI3K was inhibited using 
the class-I inhibitor ZSTK474 (10 μM), which was added to serum free media 
for 30 minutes prior to IL-13 stimulation.  IL-13 (10 ng/ml) was added to cells 
and they were incubated for 24 hours.  Cells were washed and photographed 
and the % of wound healed was calculated using Tscratch software [310].  
Data are presented as mean values ± SEM for three independent 
experiments. All groups were compared to control for statistical significance, 
which is expressed as (**) for p<0.01 and (*) for p<0.5 
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Figure 5.11 Effect of PI3K isoforms on cell migration in wound healing 
assay.  
For each experiment, cells were plated onto 12-well plates in complete 
media and when confluent were placed in serum free media overnight at 
37°C at 5% CO2.  Cells were then scratched with a pipette tip to make a 
wound which was washed and photographed.  PI3K isoforms p110α, p110β 
and p110δ were inhibited using the selective isoforms inhibitors PIK75 (100 
nM), TGX221 (100 nM) and IC87114 (10 μM) respectively, which were 
added to serum free media and incubated for 24 hours.  Cells were washed 
and photographed and the % of wound healed was calculated using Tscratch 
software [310].  Data are presented as mean values ± SEM for three 
independent experiments.  All groups were compared to control for statistical 
significance, which is expressed as (**) for p<0.01. 
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5.9 Investigating the role of PI3K in junctional protein re-formation 
using a calcium switch assay 
 
 The ‘calcium switch’ assay is useful for studying the biogenesis of 
epithelial polarity and junctional protein formation [230, 231].  When calcium 
levels are changed from <5 μM to 1.8 mM, cells change from a non-polarized 
state with little cell-cell contact to a polarized state with the formation of 
junctional protein complexes (tight junctions, adherens junctions and 
desmosomes) that separate the apical and basement membranes. Calcium 
is essential in maintaining and in the assembly of adherens junctional 
proteins. E-cadherin which is part of the cadherin family gets its name from 
being a calcium dependent adhesion molecule, as repeated cadherins are 
known to be the extracellular binding sites for calcium. [229, 231] 
 Confluent cells grown at ALI were starved overnight in serum-free 
media and then placed in a 4 mM solution of EGTA at pH 8 for 30mins to 
disrupt the adherens junctional proteins which in turn breaks open the tight 
junction proteins, a process which can be observed by a dramatic decrease 
in TER.  Cells were placed back in normal calcium containing serum free 
media with the addition of IL-13 (10 ng/ml) or various PI3K inhibitors 
(ZSTK474, LY294002, IC87114, TGX-221 and PIK75).  IL-13 hindered the 
ability of cells to re-form their junctional protein complexes after 24 hours, 
control cells reached a 25% higher TER than the IL-13 treated cells (Figure 
5.12).  Pan class I-PI3K inhibition with ZSTK474 resulted in cells reaching a 
higher TER than that of control cells, however this was only true for the 
highest concentration of ZSTK474 (10 μM), the lower concentrations (1 and 
0.1 μM) displayed the same TER as control cells.  From the selective isoform 
inhibitors tested, only PIK75 had a significant effect on the re-formation of the 
tight junctions with a decrease of 45% compared to control.  The p110δ 
inhibitor IC87114 and the pan-inhibitor LY294002 slightly increased the end 
point TER over control but not significantly, whereas TGX-221 had no effect 
at all. 
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Figure 5.12 Effect of IL-13 and PI3K inhibition on tight junction re-
formation.   
For each experiment Calu-3 cells were grown via ALI and once confluent 
were placed in serum-free media for 24 hours and monitored by TER 
measurements.  Cells were then placed in 4 mM EGTA for 30 minutes 
followed by serum-free media with the addition of IL-13 (10 ng/ml) or PI3K 
inhibitors ZSTK474 (10 μM), IC87114 (10 μM), TGX-221 (100 nM), PIK75 
(100 nM) and LY294002 (20 μM) for 24 hours.  Data are presented as mean 
values ± SEM for three independent experiments.   All groups were 
compared to the control group using a 2-way ANOVA and statistical 
significance is expressed as (***) for p<0.001. 
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5.10 Investigating the effect of IL-13 and PI3K inhibition on LDH release 
as a marker of cell necrosis 
  
           To assess whether the various inhibitors used were having a negative 
effect on cell viability by inducing cell necrosis, an LDH assay was carried 
out.  Confluent cells were exposed to IL-13 and PI3K inhibitors for 24 hours 
as in all previous experiments.  The media from each well was sampled and 
examined for LDH release using a LDH assay kit which utilized a 
spectroscopic colour change observed with higher amounts of protein 
present analysed by absorbance. (see section 2.11 for more details).  The 
LDH released from each sample was compared with that of the total LDH in 
the cell sample by lysing the cell to release all the protein present. 
         The un-stimulated control cells released 17 ± 3% LDH over the total 
LDH available in the sample (Figure 5.13).  None of the treatments studied 
resulted in a statistically significant increase in LDH release after 24 hours. 
Treatment with IL-13 (10 ng/ml) resulted in 18.5 ± 2% LDH release whereas 
ZSTK474 (10 μM) and IC87114 (10 μM) treatment for 24 hours showed an 
LDH release of 17 ± 3% and 15 ± 5% respectively.  The p110α isoform which 
was inhibited using PIK75 (100 nM) showed slightly higher levels of cell 
necrosis compared to control cells with 24 ± 4% of LDH released.  p110β 
inhibition using TGX-221 (100nM) also displayed slightly higher levels of 
LDH (25 ± 8%) and results were seen to be more variable.  The pan PI3K 
inhibitor LY294002 (20 μM) which is often referred to as a ‘dirty’ PI3K 
inhibitor released the highest amount of LDH 37 ± 8% which demonstrated 
that the cells were not content in the presence of this concentration for 24 
hours. 
            These data are essential when using any type of small molecule 
inhibitor as it is important to know if the results obtained are a consequence 
of blocking certain signalling pathways (as is hoped) or merely the cell being 
‘poisoned’ by the inhibitor itself.  This negative result indicates that the 
inhibitors used are not having adverse effects on the cells necrotic pathways 
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and results obtained thus far are true of the complex signalling pathways 
being manipulated.   
  
 
 
 
 
 
 
 
 
Figure 5.13 Effect of PI3K inhibition on Lactate dehydrogenase release. 
Cells grown to confluence at ALI were treated with IL-13 (10 ng/ml), 
ZSTK474 (10 μM), IC87114 (10 μM), TGX-221 (100 nM), PIK75 (100 nM) 
and LY294002 (20 μM) for 24 hours.  Samples from the media were tested 
for LDH presence by measuring the reduction of NADP to NADPH which 
results in a shift to a deep red colour and can be monitored spectroscopically 
at a wavelength of 490 nm. These values were converted to a percentage of 
released LDH over the total LDH in each sample which was obtained through 
lysing the transwell to release all protein present. Data are plotted as mean 
values ± SEM for three independent experiments.  
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5.11 Effect of PI3K inhibition on the IL-13-induced increase in MUC5AC 
expression by immunocytochemistry  
IL-13 was shown to increase the expression of the mucin protein 
MUC5AC (Figure 4.9) after 24 hours treatment.  The role of PI3K in this 
upregulation was investigated; ZSTK474 was added to the basolateral 
chamber 30 minutes prior to IL-13 to ensure its entry into the cell.  MUC5AC 
protein expression was shown to be reduced following PI3K inhibition (Figure 
5.14 A).  The reduction is seen more clearly in the images in Figure 5.14 B, 
where the images are represented as a z stack.  A z-stack is where the 
whole layer of the cell monolayer is observed e.g. 10 x 4 μm slices are 
imaged then placed together on top of each other, so you look at the cell 
monolayer side on instead of from the top.  In the control and the IL-13 
stimulated groups MUC5AC expression is mainly located on the surface, 
whereas in the ZSTK474 and ZSTK474 + IL-13 treated cells show less 
MUC5AC surface staining and more intracellular staining in the same plane 
with the nuclear stain.  IL-13 appears to increase the MUC5AC expression 
according to the images in 5.14 A and B, however there is no significant 
difference when the images are quantified to give fluorescence intensity per 
pixel (Figure 5.14, C).  PI3K inhibition with ZSTK474 alone and in 
combination with IL-13 significantly reduces MUC5AC levels 32% and 24% 
respectively compared to control.    
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Figure 5.14 Effect of IL-13 and PI3K inhibition on MUC5AC expression 
in Calu-3 cells.  Confluent cells grown at ALI were stimulated with IL-13 with 
or without pre-treatment with ZSTK474 for 24 hours, after which they were 
fixed in 4% PFA and probed with a mouse monoclonal antibody against 
MUC5AC, followed by an Alexa Fluor 488 conjugated secondary antibody 
Filters were cut out, mounted onto glass slides and viewed using a 
LSM510META confocal laser scanning microscope. The images in A show 
MUC5AC staining taken at the focal point immediately after the 
disappearance of the DAPI blue stain (i.e the top section or surface of the 
cells)  after IL-13 stimulation(10 ng/ml) and/or ZSTK474 treatment (10 μM).  
The Z-stack images in B are side on profiles from the images shown in A (i = 
control, ii = IL-13, iii = ZSTK474 iv = ZSTK474 + IL-13).  Images in A and B 
are representative of three similar images taken during three independent 
experiments.  C shows the semi quantified graph of the average intensity per 
pixel expressed as mean ±SEM from n=3 experiments.  
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5.12 Discussion  
5.12.1 The role of PI3K in IL-13-induced TER decrease 
 
 PI3K pan-class I inhibition reverses the IL-13-induced decrease in 
TER after 24 hours, a finding that is consistent with Ceponis et al. who 
reported the involvement of PI3K in the IL-4/IL-13 induced decrease in TER 
in intestinal epithelial cells [248].  The isoform of PI3K that was responsible 
for its role in the regulation of the TJ however had not been studied.  This 
data shows that the inhibition of p110δ using IC87114 produced a slightly 
higher TER than vehicle treated cells, although this increase was not 
statistically significant in this study, p110δ has been recently been reviewed 
in relation to having potential as an effective drug target in allergic asthma 
[311].  The only selective inhibitor that caused a statistically significant 
difference in TER was PIK75 which resulted in a decrease in TER of 30% 
below control cells when administered alone. When combined with IL-13 
treatment this decreased a further 10% indicating that p110α signalling to the 
TJ may be involved in the maintenance of basal TER. 
 None of the selective isoform inhibitors brought about the same 
response as the pan PI3K inhibitor ZSTK474, so they were studied in 
combination to rule out isoform redundancy.  Combined treatment with TGX-
221, IC87114 and PIK75 reduced basal TER and had no effect on IL-13 
stimulation.   These data suggest that ZSTK474 is having off target effects 
and isn’t as selective as previously claimed [99].  The possible role of mTOR 
and the class II PI3Kβ, which are reported as being off target effects of the 
first generation PI3K inhibitors wortmannin and LY294002 [85] were studied.  
Treatment with PI-103 which is equipotent against both PI3K C2β, p110α 
and also targets mTOR [308] resulted in no change in TER compared to 
controls.  The potent mTOR inhibitor rapamycin displayed a 35% decrease in 
TER when administered alone and in combination with IL-13 at the highest 
concentration of 20 nM, but this was not seen for the lower concentration 2 
nM and neither concentration mimicked the effects observed with ZSTK474 
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in the prevention of the IL-13-induced decrease.  These results indicate that 
mTOR is not involved in the prevention of TER observed by ZSTK474.  
 Inhibitor location between basolateral and apical chambers did not 
change the effect of PI3K inhibition, with apical inhibitor incubation also 
preventing the IL-13-induced decrease in TER which was previously shown 
by the basolateral incubation.  This finding was useful as if a PI3K inhibitor 
was to become a new drug for treatment in severe asthma then it would be 
administered to the apical side (top side) of the epithelial cells.  
 
5.12.2 Investigating the efficacy of pan PI3K and isoform selective 
inhibition in Calu-3 cells 
 
In order to ensure that ZSTK474, IC87114, TGX-221 and PIK75 were 
inhibiting the PI3K pathway effectively, cells were pre-treated with the 
inhibitor for 30 minutes to allow penetration into the cell and then treated with 
IL-13 for up to 90 minutes.  Phosphorylation of Akt at Serine 473 was 
measured as a marker of PI3K activity.  ZSTK474 was shown to successfully 
inhibit Akt phosphorylation proving it adequately inhibited PI3K as claimed 
[99].   The only isoform selective inhibitor that caused a decrease in Akt 
phosphorylation was PIK75 which inhibits the p110α isoform, IC87114 and 
TGX-221 which inhibit p110δ and β respectively did not significantly reduce 
Akt phosphorylation in the given time scale.  This finding initially proved 
concerning, however it was consistent with related research that has shown 
that IC87114 has little effect on Akt phosphorylation in HUVEC endothelial 
cells which was concluded to be due to the low levels of p110δ present [289]. 
Another explanation for this finding is the idea of isoform redundancy i.e Akt 
is phosphorylated by all isoforms of PI3K and if one is blocked then another 
will simply take over in its place.  Further studies into the expression of 
individual isoforms and their effect on IL-13 stimulated Akt phosphorylation in 
Calu-3 cells is needed in order to come to an accurate conclusion.   
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5.12.3  The role of PI3K on the expression and distribution of TJ 
proteins and IL-13Rα2 
 
 The effect of PI3K inhibition on the IL-13 induced increase in claudin 2 
was studied using immunofluorescence and mRNA levels of the TJ protein 
were investigated using qRT-PCR.  Pan-PI3K inhibition with ZSTK474 
prevented the IL-13-induced upregulation of the tight junction protein claudin 
2 shown by immunofluorescence. Claudin 2 has been previously shown to 
be upregulated by  the non-proteolytic house dust mite allergen in A549 cells 
and the PI3K pathway was found to be involved through inhibition with 
wortmannin [256]. In addition to the role of PI3K the EGFR pathway has also 
been linked to an upregulation of claudin 2 [281].  This is the first study 
investigating the role of the selective PI3K isoform inhibitors in TJ 
modulation.  
  Pre-treatment with the selective p110α inhibitor PIK75 mimicked this 
result observed by ZSTK474 and LY294002 in that, claudin 2 was barely 
visible in either the inhibitor alone or inhibitor + IL-13 treatments, indicating a 
basal effect on claudin 2 expression as well as blocking its upregulation after 
IL-13 stimulation.   
 In addition to studying the protein expression of the TJ protein claudin 
2, its mRNA expression was also monitored by qRT-PCR.  IL-13 was shown 
to increase claudin 2 mRNA compared to control cells, however this was not 
significant due to one anomaly experiment. Pretreatment with ZSTK474 and 
PIK75 reduced the expression of claudin compared with IL-13 stimulation, 
however as results were not significant, the experiment needs to be repeated 
in order to come to an accurate conclusion.   
The expression of the IL-13 receptor alpha 2 after PI3K inhibition was 
studied due to research which reported that it can play an inhibitory role on 
IL-13 effects in the cell if expressed highly enough [60].   It was necessary to 
check that the effects being observed from PI3K inhibition on the expression 
and TER studies were not due to the upregulation of the IL-13Rα2 at the cell 
surface thus inhibiting the IL-13 response.  FACS studies showed that IL-
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13Rα2 was basally expressed on the cell surface of Calu-3 cells and that IL-
13 treatment resulted in an increase in IL-13Rα2 surface expression from 
20% to 35% which is consistent with results published by Daines et al [60].  
Pretreatment with ZSTK474 reduced this IL-13-induced expression to 15%, 
which hints that the concern that PI3K was only having an effect through 
increasing the IL-13Rα2 expression and dampening the IL-13 response is 
not true.  However this experiment needs to be repeated in order to 
demonstrate the role of PI3K signalling on the expression of IL-13Rα2 on the 
cell surface of Calu-3 cells.   
 
5.12.4 The role of PI3K on cell migration and reformation of the TJ  
 
            A typical scratch assay was used in order to study the role of PI3K in 
the process of epithelial wound healing, also termed re-epithelisation.  Other 
methods such as the chemical wounding using NaOH [312] are also used 
but the mechanical scratch method is the least harmful to the cell monolayer.  
PI3K inhibition was shown to inhibit the wound healing response in both 
A549 and Calu-3 cell lines, a finding which is not entirely surprising as PI3K 
signalling is known affect cell migration and proliferation. Involvement of 
PI3K in wound repair is supported by Lai et al who have shown that inhibition 
of the negative regulator of PI3K pathway, PTEN  increases the wound 
healing response in BEAS2B cells [313, 314].  An interesting result in this 
experiment was the difference observed in the basal cell healing response 
between Calu-3 and A549 cells, with Calu-3 cells closing the wound almost 
double the distance of that of A549s in the same amount of time.  It has been 
reported that the tight junction protein claudin 2 is expressed 160-fold higher 
in basal A549 cells than in normal tissue and that this decreases cell motility 
and the expression of the matrix metallopeptidase 9 (MMP-9), which is also 
referred to as Gelatinase B [282].  Claudin 2 levels between normal lung 
tissue and Calu-3 cells have been shown to be comparable [286] which may 
explain the vast difference seen between the cell lines basal motility in this 
study.  The PI3K pathway has been shown to reduce the expression of many 
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MMPs which are responsible for the degradation of the extracellular matrix 
(ECM).  Andrographolide, a potential chemotherapeutic agent was shown to 
reduce cell migration and motility by suppressing the PI3K pathway through 
Akt and AP1 by reducing MMP-7 expression [315].  Regulation of the 
epidermis has also been reported to involve the PI3K pathway where it 
strongly enhances keratinocyte migration and proliferation [316].   
         The level of extracellular calcium has been reported to play a role in TJ 
maintenance, permeability and regulation [317].  Calcium was shown to be 
important in assembly of the junctional complex in keratinocytes in 1987 
following the discovery of the cadherin family in 1984 which were named 
after their “calcium dependent adhesion” properties [217].  Depletion of 
extracellular calcium leads to disruption of the adherens junctional proteins 
including E-cadherin and subsequently breaks open the tight junction 
complex.  Here, we used a common technique called a calcium switch assay 
which utilizes this dependence on calcium by lowering levels to deplete all 
junctional proteins and then restores levels to monitor the de-novo synthesis 
of the junctional complex [318]. 
           The calcium switch experiment showed that IL-13 treatment 
decreases the ability of cells to reform an intact junctional complex and 
hence display a high TER.  It is not known whether IL-13 affects the rate of 
junctional formation or the expression of a particular junctional protein which 
hinders the re-formation.  Previous results show that IL-13 upregulates the 
pore forming junctional protein claudin 2 so this may explain the observed 
result, however it cannot be assumed that the regulation of basal tight 
junctions is the same as that of de-novo synthesis of tight junctions required 
for epithelial reconstitution.  PI3K inhibition alone at high concentration 
resulted in an increase in TER above basal levels as witnessed in the regular 
TER experiment. This increase was not observed in the lower concentrations 
of ZSTK474 which displayed the same TER after 24 hours treatment as the 
vehicle controls; a finding which strongly indicates off-target effects of the 
inhibitor. The role of the PI3K-class I isoforms were also studied in the 
reformation of the TJ and it was shown that p110β and p110δ inhibition had 
no effect on TJ reformation after 24 hours compared with controls.  
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Interestingly, inhibition of p110α significantly reduced the TER compared to 
control cells after 24 hours, which suggests a role for p110α signalling in the 
formation of tight junction proteins in Calu-3 cells.  
 
5.12.5 The role of PI3K in IL-13-induced goblet cell metaplasia 
 
IL-13 was shown to increase MUC5AC after 24 hours treatment in 
accordance with Nakano et al  who reported IL-13 increased MUC5AC 
expression in mice trachea at this time [298]. The role of PI3K in IL-13-
induced mucus hypersecretion was investigated and it was shown to reduce 
the expression of MUC5AC present on the surface of the cells, shown clearly 
in z-stack images. This increased expression was not replicated to the same 
extent in the semi-quantification graph, which only portrays a small difference 
between control, IL-13 and ZSTK474 treatments.  An explanation for this 
finding could be that IL-13 and PI3K have a more substantial effect on the 
distribution/secretion of the mucin rather than its expression alone.  In the IL-
13 stimulated cells, MUC5AC is highly localised on top of the cells; PI3K 
inhibition may block the IL-13-induced release of MUC5AC from intracellular 
stores.  Although this result itself is interesting this section of work was not 
followed up due to time constraints.  Recently, IL-13 –induced MUC5AC 
expression has been shown to be mediated by 15-lipooxygenase 1 in 
bronchial epithelial cells [319], which has been shown to rely on the two IL-
13 receptors, soluble IL-13Rα2 and surface IL-13Rα1 [299]. 
 
5.12.6 Limitations and future work 
 The main limitation in this chapter is: the use of small compound 
inhibitors to study the role of PI3K.  Firstly, the starting point for using this 
approach should have been to assess the isoform expression within the 
Calu-3 cell line.  Subsequent concentration and dose response experiments 
should have been carried out to ensure that the both the optimal 
concentration and experimental time was being used.  PI3K silencing with 
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synthetically generated siRNAs that target each isoform of PI3K could have 
also been used, however when using siRNA technology, experiments 
assessing the basal cell activity would be required to ensure the was no 
change in cell proliferation and survival which would alter the signalling 
pathways and lead to misinterpretation of results.  It would be interesting to 
verify the role of PI3Kα by either silencing or overexpressing the p110α gene 
and investigating its role in maintaining the junctional complex by TER, Ca2+ 
switch and tight junction expression studies.  However as p110α is essential 
in many cell cycle processes, there would only be a small window in which 
experiments could be carried out following knockdown. 
Another limitation with many results in this chapter is the lack of 
repeated independent experiments carried which was due to time 
constraints, repeating these data will enable statistical analysis of results and 
more accurate interpretation. 
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5.13 Conclusions 
 
The role of PI3K in TJ regulation was researched in this chapter and it was 
shown to play an important role in maintaining the basal TER of the epithelial 
layer by keeping levels of the TJ protein claudin 2 low. 
 
In summary, in this chapter the following was determined: 
 Pan-PI3K inhibition prevents the decrease in TER shown by IL-13 in 
chapter 3 
 The result seen with the ZSTK474 pan-PI3K inhibitor was not 
observed in any of the selective isoform inhibitor studies or when 
studying them in combination, indicating off –target effects of the 
ZSTK474 inhibitor. 
 PI3KC2β and mTOR were shown not to be responsible for the 
prevention in IL-13-induced TER by ZSTK474 
 ZSTK474 was shown to bring about the same response regardless of 
apical or basolateral addition. 
 Increased claudin 2 protein and mRNA expression by IL-13 was 
reduced by pre-treatment with ZSTK474 and PIK75 
 p110α was shown to be essential for the wound healing response in 
both Calu-3 and A549 cells 
 The re-formation of the TJ was shown to be hindered by IL-13 
treatment and p110α inhibition.  
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Chapter 6 : Role of STAT6, MEK and GSK3β 
in epithelial barrier modulation 
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6.1 Role of STAT6, MAPK and GSK3β in IL-13-dependent or 
independent junctional protein regulation 
 To further investigate the molecular signalling pathways involved in 
the highly dynamic role of tight junction regulation, STAT6, GSK3β and 
MAPK pathways were examined. IL-13 has been shown to exert its affects 
via PI3K/Akt signalling and Akt has many roles within the cell including, cell 
proliferation, migration and regulation of GSK3 activation through Akt 
phosphorylation which results in inactivation [320] [321].  IL-13 has also been 
shown to act via STAT6 by recruiting Jak proteins to the RTK that activates 
STAT proteins, which are subsequently released into the cell and have many 
roles including transcription [109].  The MAPK pathway is another important 
cellular pathway which is involved in many vital cell processes and many 
studies have linked IL-13 activation to MAPK signalling [23, 162, 322]  
 With the results so far indicating a role for PI3K in TJ regulation it was 
necessary to look at the other pathways that are linked to IL-13 activation 
and investigate their possible roles. 
 
6.1.1 IL-13 signalling via STAT6, GSK3 and MAPK 
 
In order to study the possible role of STAT6, MEK and GSK3 in TJ 
regulation it was necessary to first look at if they are activated through short 
term treatment with IL-13.  Calu-3 cells were stimulated with IL-13 (10 ng/ml) 
for up to 90 minutes.  Figure 6.1 shows that STAT6 is phosphorylated 40-fold 
over basal after 90 minutes treatment with IL-13.   Phosphorylation of GSK3β 
and ERK were also investigated and the results were much less obvious 
than the STAT6 activation.  Phospho-GSK levels remain exactly the same as 
GSK levels over the 90 minute period, indicating that IL-13 is having no 
effect on GSK3 activation which may be explained by GSK activity being 
constituently active in Calu-3 cells so the activation is masked.  A similar 
result was seen when MAPK activity was monitored by assessing the 
presence of phosphorylated threonine 202 and tyrosine 204 residues on 
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Figure 6.1 Effect of IL-13 stimulation on MAPK, GSK3β and STAT6 
activation in Calu-3 cells.  
For each experiment, cells were plated onto 12-well plates in serum 
containing MEM. When confluent, cells were placed in serum-free media 
overnight and then stimulated with IL-13 (10 ng/ml) for up to 90 minutes.  
Samples were resolved on SDS-page gel, transferred to nitrocellulose 
membranes and immunoblotted, using antibodies against A) 
phosphoThr202/Tyr204-ERK (pERK) at 44 and 42 kDa, B) phosphoSer9-GSKβ 
(pGSK3β) at 46 kDa and C) phopshoTyr641-STAT6 (pSTAT6) at 110 kDa.  
Membranes were then re-probed using antibodies against ERK1, GSK3β 
and STAT6.  Data are presented as n=3 independent experiments.  All 
groups were compared to vehicle control (0 h) for statistical significance, 
which is expressed as (**) for p<0.01. 
 
C 
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Chapter 6 – Results IV 
135 
 
ERK.  IL-13 was shown to slightly increase the phosphorylation of ERK after 
5 minutes stimulation; this increase was quite variable hence why the 
immunoblot does not match the quantified graph and is not statistically 
significant. 
 
6.2 Effect on STAT6 phosphorylation using the histone deacetylase 
inhibitor SAHA 
 
Suberoylanilide hydroxamic acid (SAHA) has been shown to be a 
potent inhibitor of all isoforms of histone deacetylases (HDAC) with highest 
selectivity for class I and II with an IC50 of <86 nM [115, 121].  It was 
discovered to possess antitumor properties and inhibited growth in prostate, 
breast and endometrial cancer cell lines [323-325].   HDAC 1 has been 
shown to directly acetylate STAT3, a requirement for activation by IL-6.  
Overexpression of HDAC-1 in hepatoblastoma cells resulted in reduced IL-6-
induced STAT3 expression [134]. Treatment with SAHA has been 
demonstrated to inhibit STAT6 activation, which led to dampening of the IL-
13 response in ulcerative colitis [247].  LPS-induced cytokines were shown to 
be reduced in vivo following SAHA treatment signifying its anti-inflammatory 
properties [129].  The role of STAT6 in the regulation of the TJ in bronchial 
epithelial cells has not been investigated. 
 
 To assess the effect of SAHA (5 μM) on IL-13-induced activation of 
STAT6, cells were cultured with SAHA 30 minutes prior to IL-13 treatment 
and pSTAT6 was immunoblotted after 24 and 48 hours treatment (Figure 
6.2).  Membranes were stripped and re-probed for STAT6 and then again for 
the common loading control β-actin to check if SAHA had any effect on 
overall protein expression.  STAT6 phosphorylation increased 1.8-fold over 
control after 24 hours and this dropped to 1.4-fold after 48 hours both of 
which proved statistically significant over vehicle control.  Inhibition with 
SAHA completely abolished the IL-13-induced STAT6 phosphorylation at 
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both 24 and 48 hours treatment.  Additionally, SAHA didn’t alter the overall 
STAT6 protein expression, indicating that the mechanism of inhibition is 
through blocking the phosphorylation site without affecting the protein itself.  
STAT6 phosphorylation was shown to be much higher after short term IL-13 
stimulation (90 minutes) shown in figure 6.1 but as the subsequent 
experiments were studied for longer time periods of 24-48 hours it was 
necessary to see the effect of SAHA on the cells after this duration.  
 
 
 
 
 
 
 
 
 
Figure 6.2 Effect of SAHA on IL-13-induced STAT6 activation.   
For each experiment, cells were plated onto 12-well plates in serum 
containing MEM. When confluent, cells were placed in serum-free media 
overnight and then stimulated with IL-13 (10 ng/ml) and SAHA (5 μM) for up 
to 48 hours.  Samples were resolved by SDS-PAGE, transferred to 
nitrocellulose membranes and immunoblotted, using antibodies against 
phopshoTyr641-STAT6 (pSTAT6) and STAT6 both at 110 kDa and β-actin at 
45 kDa as an equal loading control.   Data are presented as n=3 
independent experiments and all groups were compared to each other for 
statistical significance, which is expressed as (***) for p<0.001 and (**) for 
p<0.01 compared to vehicle control (VC).  The IL-13 treated groups were 
compared to the IL-13 + SAHA treated groups and statistical significance is 
expressed as (##) for p<0.01.   
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6.2.1 Effect of STAT6 of junctional protein regulation and formation 
 
 The role of SAHA on junctional protein regulation and formation was 
studied by TER and calcium switch experiments respectively. The effect of 
SAHA on basal TER was investigated and it was shown that both 
concentrations of SAHA (5 μM and 1 μM) alone increased the TER of cells 
over that of the vehicle control (Figure 6.3 A). The higher concentration of 
SAHA alone (5 μM) increased the TER over double compared to the 
standard baseline control.  Pre-treatment and incubation of SAHA with IL-13 
prevented the IL-13-induced decrease in TER in both concentrations of 
SAHA, however only the higher concentration was statistically significant.  
This data mimicked the results with the pan-PI3K inhibitor ZSTK474 (Figure 
5.1) indicating that both PI3K and STAT6 pathways have an involvement in 
junctional protein regulation which is essential to maintaining an intact 
epithelial layer. 
 In the calcium switch assay the intact epithelial layer was disrupted by 
addition of an EGTA solution (4 mM) for 30 minutes which decreased the 
extracellular calcium concentration leading to breakdown of both adherens 
and tight junction proteins.  The junctional protein disruption was observed 
by monitoring the TER and a dramatic decrease in TER is witnessed where 
values fall to between 200-300 Ωcm2.  When cells reached a TER between 
the range 200-300 Ωcm2, they were washed to remove all traces of EGTA 
and were placed back in serum-free media (normal Ca2+ concentration) with 
the addition of IL-13 and SAHA for 24 hours (Figure 6.3 B).  IL-13 alone 
caused a decrease in TER indicating that it not only has an effect on an 
intact epithelial layer but may also be involved in the re-formation of 
junctional proteins and their recruitment back to the cell membrane.  STAT6 
inhibition alone using SAHA lead to an increase over control cells as seen in 
Figure 6.3 A.  In the combined treatment of SAHA and IL-13 the results 
mimicked the SAHA alone treated cells where SAHA prevented the IL-13-
induced prevention of TER to normal basal levels.  The STAT6 pathway is 
therefore important in both the regulation of the intact epithelial layer as well  
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Figure 6.3 Effect of SAHA on the IL-13-induced decrease in 
transepithelial resistance and tight junction reformation.  
For each experiment 5x10
5 
cells/ml were seeded onto transwell filters and their 
transepithelial resistance was monitored. For A, on Day#7 when the maximum 
TER was reached IL-13 (10 ng/ml) and SAHA (5 μM) were added to the 
basolateral chamber and the TER was measured after 24 hours.  This TER was 
then compared to that of the same well 24 h prior to obtain the TER % over 
control after 24 h treatment. For B, on day#7 cells were placed in serum-free 
media for 24 hours after which they were placed in 4 mM EGTA for 30 minutes 
followed by serum-free media with the addition of IL-13 (10 ng/ml) with or 
without SAHA (5 μM) for 24 hours.  Data are presented as mean values ±SEM 
from three independent experiments.   All groups were compared to the control 
group and statistical significance which is expressed as (**) for p<0.01.  All 
groups were also compared to each other and statistical significance which is 
expressed as (###) for p<0.001.   
A 
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as exhibiting its importance in junctional protein re-formation.  The 
involvement of STAT6 in this highly dynamic area is similar to that of PI3K 
suggesting that they may work together downstream of IL-13 or as 
independent pathways.   
 
6.2.2 Effect of SAHA on tight junction protein expression and 
distribution by immunocytochemical studies 
  
 To investigate the role of STAT6 further in an attempt to uncover the 
molecular mechanisms involved in the regulation of junctional proteins, 
immunocytochemical studies were carried out. Cells were stimulated with 
SAHA for 24 hours, fixed and stained with antibodies against claudin 2 and 
claudin 8 (see section 2.4 for more experimental detail). 
 As Claudin 2 had previously shown to be affected by IL-13 treatment 
(chapter 4) it was observed first.  IL-13 treatment alone resulted in a dramatic 
increase in claudin 2 expression as illustrated before and it was shown that 
SAHA treatment alone also resulted in a decrease of claudin 2 protein 
expression compared with control (Figure 6.4 A).  When SAHA was 
combined with IL-13 treatment the expression of claudin 2 was shown to be 
slightly increased compared with the SAHA alone treated sample but the 
observed level of expression was much lower than that of the IL-13 alone 
treated sample.  This is shown more clearly in Figure 6.4 B where the 
average intensity of fluorescence per pixel is shown for each of the 
treatments.  Treatment with SAHA decreases the IL-13-induced claudin 2 
upregulation from 34 ± 5 arbitrary units to 14.5 ± 1.(Figure 5.6).   
The expression of claudin 8 was also examined by 
immunocytochemistry due to the limited research into its regulation in the 
lung.  In control cells it was found to be expressed at a low level quite 
sparsely and appeared to be cytoplasmic rather than gathered at the 
junctional membrane in ring like structures.  IL-13 was shown to increase the 
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expression of claudin 8 compared to control, with around 50% of cells 
expressing the tight junction protein (Figure 6.5).  SAHA treatment alone (5 
μM) resulted in a prominent increase in claudin 8 within almost every cell in 
the image field expressing claudin 8, this expression was shown to be mainly 
localised to the nucleus along with low level cytoplasmic staining.  This 
increase in nuclear expression slightly decreased after pre-treatment of 
SAHA followed by IL-13 stimulation.  Figure 6.5 B shows more clearly the 
relative expression of claudin 8 as the intensity per pixel is plotted for each 
treatment group, although these data are only semi-quantified they give a 
much clearer overall picture.  IL-13 treatment alone results in a 25% increase 
of claudin 8 intensity and SAHA treatment alone causes an increase in 
claudin 8 expression levels to 90 arbitrary units which is reduced to 53 ± 4 
with the combined SAHA and IL-13 treatment.  This finding illustrates that 
STAT6 inhibition leads to a vast increase of >10 fold in the expression of 
claudin 8 protein after 24 hours treatment.  The role of claudin 8 in the TJ is 
still unknown, however these results suggest that there is an important role 
for STAT6 signalling in normal epithelial barrier maintenance. 
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Figure 6.4 Effect of SAHA on claudin 2 protein expression and mRNA 
expression.   
Calu-3 cells grown via ALI were stimulated with 10 ng/ml IL-13 with or without 
SAHA (5 μM) for 24 hours.  They were fixed in 4% PFA and probed with an 
antibody against claudin 2 (see section 2.4 for details), They were mounted onto 
glass slides and viewed using a LSM510META confocal laser scanning 
microscope.  Each image is representative of three similar images taken during 
three independent experiments (n=3).  B is a semi-quantified representation of 
the mean intensity per pixel from n=3 independent experiments.  All groups 
were compared to each other for statistical significance which is expressed as 
(**) for p<0.01 compared to control and (#) for p<0.05 for IL-13 vs SAHA + IL-13 
groups. 
A 
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Figure 6.5 Effect of SAHA on claudin 8 protein expression and 
distribution.  
 Calu-3 cells grown via ALI were stimulated with 10 ng/ml IL-13 with or 
without SAHA (5 μM) for 24 hours.  They were fixed in 4% PFA and probed 
with an antibody against claudin 8 (see section 2.4 for details), Cells were 
mounted onto glass slides and viewed using a LSM510META confocal laser 
scanning microscope.  Each image is representative of three similar images 
taken during two independent experiments (n=2).  B is a semi-quantified 
graph of the mean intensity per pixel from n=2 independent experiments. 
Data expressed as mean values ± SEM.  
B 
A 
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6.2.3 Effect of SAHA on mRNA expression of claudin 2 and claudin 8 
 
The mRNA expression of the TJ proteins claudin 2 and 8 were studied 
in order to investigate a correlation between protein and mRNA expression.  
Quantitative PCR (qRT-PCR) was used to study the mRNA expression of 
claudins 2 and 8 after 24 hour treatment with SAHA.  Figure 6.6 shows that 
the IL-13-induced increase in claudin 2 mRNA is reduced by STAT6 
inhibition using SAHA from 5-fold to 2-fold higher than controls, which 
mimicked the results observed with the protein expression.  Claudin 8 mRNA 
was briefly looked at after the interesting finding demonstrating the 
upregulation in protein expression following STAT6 inhibition.  SAHA was 
shown to increase claudin 8 mRNA expression 12-fold over basal after 24 
hours treatment.  This increase was slightly abrogated with the combined 
SAHA and IL-13 treatment to 10-fold. IL-13 stimulation was shown to have  
 
 
 
 
 
 
Figure 6.6 Effect of SAHA on claudin 2 and claudin 8 mRNA expression.   
Confluent Calu-3 cells grown via ALI were stimulated with SAHA (5 μM) for 
30 min followed by 10 ng/ml IL-13 for 24 hours. Cells were lysed and RNA 
was extracted, reversed transcribed to cDNA and reactions were performed 
on a StepOnePlus Real-time PCR system.  All samples were compared to 
the equal loading gene β-actin and normalised to the untreated control 
sample.  Data expressed as mean values ± SEM from n=2 and n=1 
independent experiments (A and B) 
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no effect on claudin 8 mRNA expression which contrasts what was observed 
in the protein expression data with IL-13 stimulation resulting in a ~25% 
increase in claudin-8 levels.  This suggests that IL-13 may regulate claudin 8 
by post-transcriptonal or post-translational modification; further experimental 
repeats are required before this idea can be followed up.  
 
6.2.4 Investigating the effect of the PI3K inhibitor ZSTK474 on STAT6 
signalling  
 
 As the results from the PI3K inhibitor ZSTK474 and the STAT6 
inhibitor SAHA were so similar, it was necessary to look at whether the PI3K 
inhibitor was also having an effect on STAT6 activation.  Calu-3 cells were 
treated with SAHA (5 μM) and ZSTK474 (10 μM) for 24 hours with or without 
IL-13 stimulation (10 ng/ml) and membranes were blotted against pSTAT6 
and STAT6.  As shown at the beginning of this chapter IL-13 phosphorylates 
STAT6 at both 24 and 48 hours, which is completely prevented by SAHA 
inhibition.  The combined treatment of ZSTK474 and IL-13 showed a 
reduction in STAT6 phosphorylation compared to the IL-13 alone treatment 
after 24 hours but not 48 hours.  This finding indicates that at 24 hours 
ZSTK474 is having off target effects and inhibiting STAT6 phosphorylation.   
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Figure 6.7 Effect of ZSTK474 and SAHA on IL-13-induced STAT6 
activation.  
For each experiment, cells were plated onto 12-well plates in serum 
containing MEM. When confluent, cells were placed in serum-free media 
overnight and then stimulated with IL-13 (10 ng/ml), ZSTK474 (10 μM) and 
SAHA (5 μM) for up to 48 hours.  Samples were resolved by SDS-PAGE, 
transferred to nitrocellulose membranes and immunoblotted, using 
antibodies against phosphoTyr641-STAT6 (pSTAT6) and STAT6 both at 
110kDa and β-actin at 45kDa as an equal loading control.   Data are 
presented as mean values from n=2 independent experiments.  
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6.3 Investigating a possible role for GSK3β in epithelial barrier 
regulation 
GSK is a complex signalling molecule that has been shown to 
promote inflammation and play a role in cell migration and has been reported 
to be involved in alzheimers, diabetes and cancer [326, 327].  Here the role 
of GSK3β in epithelial barrier regulation was explored. 
 
6.3.1 Effect of GSK3β inhibition on transepithelial resistance and 
calcium switch studies  
 
 GSK3β was inhibited using 1m, an extremely selective inhibitor which 
consists of a macrocyclic bisindolylmaleimide structure (Figure 1.6). Bone et 
al showed that 1m had an IC50 of 1-3μM in human stem cells and reduced 
levels of phospho-beta-catenin in a concentration dependent manner [149, 
328].   
 
 The effect of 1m on the resistance between the apical and the 
basolateral chamber was explored in the standard TER experiment (Figure 
6.8 A).  1m treatment alone (2 μM) decreased the TER 40% compared to the 
control.  When 1m was combined with IL-13 treatment the TER dropped a 
further 9% compared to the 1m alone group.  Tukey’s post hoc test was used 
to check the statistical significance between all treatment groups and it was 
shown that the IL-13 treated group was statistically different to the IL-13 + 
1m group, indicating that inhibiting GSK3β acts in aiding the actions of IL-13 
further.  In the calcium switch assay 1m prevented the re-formation of the 
junctional proteins and resulted in a 37% decrease in TER compared with 
that of control cells (Figure 6.8 B). The IL-13 + 1m group mimicked the 1m 
alone result, proving further that GSK3β has a role in not only the basal 
maintenance of epithelial barrier modulation but also in the reconstitution of 
the junctional proteins after disruption or injury.     
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Figure 6.8 Effect of GSK3β inhibition on transepithelial resistance and 
junctional protein re-formation.  
 For each experiment 5x105 cells/ml were seeded onto transwell filters and 
their transepithelial resistance was monitored. On Day#7 when the maximum 
TER was reached IL-13 (10 ng/ml) and 1m (2 μM) were added to the 
basolateral chamber and TER was measured after 24 hours.  The TER was 
then compared to that of the same well 24 h prior to obtain the TER % over 
control after 24 h treatment (A). For B, on day#7 cells were placed in serum-
free media for 24 hours after which they were placed in 4 mM EGTA for 30 
minutes followed by normal calcium containing serum-free media with the 
addition of IL-13 (10 ng/ml) with or without 1m (2 μM) for 24 hours.  Data are 
presented as mean values ±SEM from three independent experiments.   All 
groups were compared to the control group and statistical significance which 
is expressed as (*) for p<0.05, (**) for p<0.01 and (***) for p<0.001.  All 
groups were also compared to each other and statistical significance which is 
expressed as (##) for p<0.01.   
B 
A 
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6.4 MAPK signalling in epithelial barrier modulation 
 
  Whilst carrying out the previous TER experiments, an interesting 
finding was observed while monitoring the TER of cells in serum free media 
overnight; a 50% increase over control was seen (Figure 6.9 A). In an 
attempt to discover the explanation for this result the content of the serum 
was explored and in particular the growth factors present.  Amongst many 
growth factors present in serum EGF is one and it is known to activate the 
MAPK pathway as well as the PI3K pathway through activation of EGFR 
[329, 330]. 
 To test out the hypothesis that MAPK was being activated by the 
presence of growth factors such as EGF in the serum containing medium, 
the selective inhibitor PD0325901 was used to inhibit the activation of the 
MAPK protein MEK and the role of MEK in the maintenance of junctional 
proteins and their reformation were investigated.   The TER study showed 
that inhibition of MEK using PD0325901 (1 μM) alone increased the 
transepithelial resistance of the cell monolayer 50% over untreated control 
cells after 24 hours.  This increase in TER exactly matched that of the 
increase in TER after incubation in serum-free media overnight, which 
indicated that the hypothesis predicted may be credible with an increase in 
TER being a result of a reduction in MEK signalling through serum starvation 
of the cells.  The combined treatment of IL-13 with PD0325901 had no effect 
on the result with PD0325901 alone suggesting that MEK is not involved in 
the IL-13-induced effects in TER. 
 A similar result was observed in the calcium switch assay which 
investigates the re-formation of the junctional proteins after disruption 
through the reduction of extracellular calcium concentration.  MEK inhibition 
by PD0325901 (1 μM) was shown to increase TER 34% over control after 24 
hours.  The combined treatment of PD0325901 with IL-13 gave the same 
result as the PD0325901 alone as is the case in the classic TER experiment. 
These results also indicate that IL-13 does not exert its effects on TJ re-
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Figure 6.9 Effect of serum and MEK inhibition on TER and junctional 
protein re-formation. 
 Cells were grown via ALI and monitored by TER measurements; they were placed 
in serum or serum-free media for 24 hours (A). Cells were stimulated with IL-13 (10 
ng/ml) with or without PD325901 (1 μM) for 24 hours and the TER was then 
compared to that of the same well 24 h prior to obtain the TER % over control after 
24 h treatment (B). For calcium switch studies (C), cells were grown via ALI to 
confluency, they were starved overnight with serum-free media and their TER was 
measured.  Serum-free media containing 4mM EGTA at pH8 was added to both the 
apical and basolateral chambers for 30 minutes in which time junctional proteins 
were diminished shown by a reduction in TER of <300 Ωcm2.  The EGTA solution 
was removed, cells were washed once with serum-free media and fresh serum-free 
media containing IL-13 (10 ng/ml) or PD0325901 (1 μM) was placed into the 
basolateral chamber for 24 hours.  Data are presented as mean values ±SEM from 
n=3 independent experiments, a paired T-test (A) and a 1-way ANOVA (B and C) 
were used to determine statistical significance which is expressed as (*) for p<0.05, 
(**) for p<0.01 and (***) for p<0.001. 
B A 
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6.5 Effect of SAHA, 1m and PD0325901 on paracellular permeability 
using FITC-dextran. 
 
 To further investigate the role of STAT6, GSK3β and MEK in epithelial 
barrier modulation, the paracellular permeability was studied after 24 hour 
treatment with the inhibitors SAHA, 1m and PD0325901 respectively (Figure 
6.10). Inhibiting STAT6 alone with SAHA (5 μM) or in combination with IL-13 
did not have any effect on the paracellular permeability compared to the 
basal response.  Inhibiting GSK3β with 1m (2 μM) resulted in a dramatic 
increase in the amount of FITC detected in the basolateral chamber. This 
increase in paracellular permeability proved to be statistically significant 
when compared to the untreated control with a Dunnett’s post hoc test.  Cells 
treated with 1m and IL-13 showed a reduction in FITC-dextran permeability 
compared to that of the 1m alone stimulated cells, but they still showed a 
significant increase over basal cells.   MEK inhibition using PD0325901 (1 
μM) alone did not have a great effect on FITC-dextran flux with the result the 
same as that for the IL-13 group and only slightly higher than the control 
group.  Treating cells with the combination of IL-13 and PD0325901 resulted 
in a significant increase in FITC-dextran flux, which was a surprising result 
due to the fact that PD0325901 alone increased TER.     
 
6.6 Effect of SAHA, 1m and PD0325901 on LDH release  
 
 To check that the cells were not undergoing cell necrosis caused by 
treatment of SAHA, 1m and PD0325901 the cells were treated for 24 hours 
with these inhibitors, after which samples of the media were collected and 
tested for LDH release compared to the total lysed LDH in the cell.  The 
amount of LDH released was represented as a percentage of the total LDH.  
None of the inhibitors tested had high levels of LDH release which indicates 
that cells are happy in the inhibitors for the allocated time shown (Figure 
6.11). 
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Figure 6.10 Effect of STAT6, MEK and GSK3β inhibition on FITC-
dextran flux. 
Calu-3 cells were stimulated with SAHA (5 μM), PD3205901 (1 μM) and 1m 
(2 μM) with or without IL-13 (10 ng/ml) for 24 hours (inhibitors were added 30 
minutes prior to IL-13). They were washed twice with HBSS to remove all 
traces of phenol red and 600 μl HBSS was placed in the basolateral chamber 
and 200 μl of 500 μg/ml FITC-dextran was placed in the apical chamber.  
Cells were incubated at 37°C at 5% CO2 for 30 minutes and 100 μl was 
pipetted from the basolateral chamber of each sample in triplicate onto a 
black 96-well plate. The fluorescence intensity was measured at excitation 
485 nm and emission 530 nm on a Fluorstar optima plate reader.  Data are 
presented from n=3 independent experiments and values are expressed as 
mean ± SEM.  All groups were compared to control and statistical 
significance is expressed as (*) for p<0.05, (**) for p<0.01 and (***) for 
p<0.001.  
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Figure 6.11 Effect of SAHA, PD3205901 and 1m on LDH release. 
 Cells were treated with IL-13 (10 ng/ml), PD3205901 (1 μM), 1m (2 μM) and 
SAHA (5 μM) for 24 hours.  Samples from the media were tested for LDH 
presence by measuring the reduction of NADP to NADPH which results in a 
shift to a deep red colour and can be monitored spectroscopically at a 
wavelength of 490 nm. These values were converted to a percentage of 
released LDH over the total LDH in each sample which was obtained through 
lysing the transwell to release all protein present. Data are plotted as mean 
values ± SEM for three independent experiments.  
 
6.7 Effect of STAT6, GSK3β, MEK and ZSTK474 inhibition on junctional 
protein mRNA expression via qRT-PCR 
 
 Quantitative real-time PCR was used to investigate the effect of 
SAHA, 1m, PD0325901 and ZSTK474 (pan class I PI3K inhibitor) on the 
mRNA expression of various junctional proteins (Figure 6.12).   The 
junctional proteins examined were, claudin 2, claudin 4, claudin 5, claudin 7, 
claudin 8, claudin 10, occludin, E-cadherin and ZO-1. (For primer sequences 
see 8.4)  Data shown are preliminary from triplicate values from one 
independent experiment; they give an idea of the expression of a wide range 
of TJ genes present in Calu-3 cells and with repeated data can act as a
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Figure 6.12 Effect of ZSTK474, SAHA, 1m and PD0325901 on junctional 
mRNA expression.   
Confluent Calu-3 cells grown via ALI were stimulated with ZSTK474 (10 μM), 
SAHA (5 μM), PD0325901 (1 μM) or 1m (1 μM) for 30 min followed by 10 
ng/ml IL-13 for 24 hours. Cells were lysed and RNA was extracted, reversed 
transcribed to cDNA and reactions were performed on a StepOnePlus Real-
time PCR system (see section 2.6 for details).  All samples were compared 
to the equal loading gene β-actin and normalised to the untreated control 
sample.  Data expressed as mean values from preliminary n=1 experiment. 
 
useful screen to uncover proteins which are vastly altered following inhibition 
of various pathways. The expression of claudin 2 mRNA was upregulated by 
IL-13 as previously shown and PI3K inhibition with ZSTK474 and STAT6 
inhibition with SAHA reduced this upregulation. 1m treatment had no effect 
on claudin 2 mRNA expression and PD0325901 seemed to slightly increase 
the IL-13-induced upregulation when used in combination with IL-13.  
Treatment with SAHA, 1m (either with or without IL-13) and PD0325901 
(alone) decreased the level of Claudin 4 mRNA compared to controls 
between 30-40% and ZSKT474 slightly increased its expression.  All 
treatments (excluding PD+IL-13) decreased the mRNA expression of the TJ 
protein claudin 5 (70-85%) compared to the control after 24 hour treatment.  
Claudin 7 mRNA remained unchanged after all treatments, whereas claudin 
8 expression was shown to drastically increase 12-fold over controls in the 
SAHA treated samples, but remained unchanged in all other treatments.  
PI3K inhibition was shown to increase the mRNA expression of claudin 10 
and noticeably all IL-13 treatment groups display a decrease in expression.  
Occludin and ZO-1 mRNA expression were changed solely by ZSTK474, 
which upregulated levels 4.5 fold and 2.5 fold respectively compared to 
controls.  All treatments excluding 1m resulted in an slight increase in E-
cadherin expression with SAHA increasing levels most highly with a 1.5-1.7 
fold increase.       
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 The mRNA expression of IL-13 and IL-4 receptors was also studied 
after PI3K, STAT6, GSK3β and MEK inhibition (Figure 6.13).  The main 
differences to take from these results is the 50% decrease in IL-4Rα mRNA 
expression by STAT6 inhibition and the 50% increase by PI3K inhibition, an 
interesting result as these pathways have been portrayed as having high 
synergy throughout this project and in research.  IL-13 treatment resulted in 
the 4.5-fold increase of IL-13Rα2 expression which was shown to be reduced 
by both ZSTK474 and SAHA, data which correlates nicely with the claudin 2 
expression results which could possibly suggest a role for IL-13Rα2 in 
regulation of claudin 2 levels.  The expression of IL-13Rα1 remained fairly 
constant with only PI3K inhibition using ZSTK474 showing a slight increase. 
This experiment proved very interesting in screening junctional proteins 
following a variety of pathway inhibitors.   
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Figure 6.13 Effect of PI3K, STAT6, GSK3β and MEK inhibiton on IL-13 
and IL-4 receptor mRNA expression.  
Confluent Calu-3 cells grown via ALI were stimulated with ZSTK474 (10 μM), 
SAHA (5 μM), PD0325901 (1 μM) or 1m (2 μM) for 30 min followed by 10 
ng/ml IL-13 for 24 hours. Cells were lysed and RNA was extracted, reversed 
transcribed to cDNA and reactions were performed on a StepOnePlus Real-
time PCR system (see section 2.6 for details).  All samples were compared 
to the equal loading gene β-actin and normalised to the untreated control 
sample.  Data expressed as mean values from preliminary n=1 experiment. 
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6.8 Discussion  
6.8.1 The role of STAT6 in TJ regulation and reformation  
 
 The class I and II HDAC inhibitor SAHA was used to inhibit STAT6 
activation as previously reported in colonic HT29 and T84 cells [247].  To test 
its activity in Calu-3 cells, it was administered in combination with IL-13 
treatment for up to 48 hours and was shown to completed abolish STAT6 
phosphorylation after both 24 and 48 hours.  SAHA was subsequently tested 
in the standard TER experiment carried out in this project where cells 
cultured at ALI are monitored by TER to confluency and then stimulated with 
IL-13 with or without the combination of inhibitors.  STAT6 inhibition with 
SAHA resulted in a dramatic increase in TER over control cells when 
administered alone and the IL-13-induced decrease in TER was prevented 
when cells were pre-treated with SAHA.    This data is in accordance with 
Madden et al who discovered that the IL-13-induced increase in mucosal 
permeability and chloride secretion was dependent on STAT6 signalling 
using knockout mice [246].   
 The role of STAT6 in the distribution and expression of the TJ protein 
claudin 2 was explored, with levels shown to be increased by IL-13 in 
intestinal cells [245, 292], alveolar cells [281]  and now bronchial epithelial 
cells in this project.  STAT6 inhibition through treatment with SAHA (5 μM) 
resulted in a 57% decrease in the IL-13 induced increase in claudin 2 shown 
by immunofluorescence data.  This result was supported by data gained from 
the quantitative PCR experiment, where SAHA reduced the mRNA 
expression of IL-13-induced claudin by 3-fold.  Together the beginning of this 
chapter provides strong evidence for the role of STAT6 in the IL-13-induced 
upregulation of claudin-2 which leads to a disruption in epithelial barrier 
properties. 
 These data obtained with the HDAC inhibitor SAHA were almost 
identical to that obtained using the pan class I PI3K inhibitor ZSTK474 in 
chapter 5.  To investigate whether the pathways were acting independently 
to produce the same result or they were both being blocked by the same 
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inhibitor, ZSTK474 was administered to Calu-3 cells and STAT6 activation 
was studied.  It was decided to investigate ZSK474 on STAT6 activation 
rather than SAHA on pAkt activation as a marker of PI3K due to STAT6 
activation providing a far clearer signalling result than Akt.  Cells treated with 
ZSTK474 for 24 hours completely inhibited IL-13-induced STAT6 activation 
providing evidence that this inhibitor is not a selective class I PI3K inhibitor 
as reported [99].  However this result was only witnessed after 24 hours, 
after 48 hours, IL-13-induced STAT6 phosphorylation returned to 
comparative levels to that of the IL-13 treatment alone.  In retrospect, if this 
experiment was carried out earlier in the project a greater understanding on 
this PI3K and STAT6 relationship and their involvement in the IL-13 induced 
effects on claudin 2 expression would have been carried out.  However, at 
this point it can only be concluded that both pathways play a role in TJ 
regulation and in particular both reduce the basal and IL-13-induced 
expression of the cationic pore forming TJ claudin 2.  Whether this result of 
ZSTK474 and SAHA treatment is via the same target (or an off-target effect) 
is not known.  
 SAHA has recently been shown to acetylate α-tubulin in a dose 
dependent and concentration dependent manner; in addition the heatshock 
protein 90 (HSP90) was inhibited, which was demonstrated by a decrease in 
CDK4 expression [331].  The role of α-tubulin in tight junction regulation is 
yet to be explored. 
 
6.8.2 Role of STAT6 in claudin 8 regulation  
  
 Preliminary results obtained studying claudin 8 expression proved 
particularly interesting with STAT6 inhibition with SAHA resulting in a 12-fold 
increase in claudin 8 mRNA over controls after 24 hours.  This finding was 
supported by immunofluorescence data which also showed a significant 
upregulation of claudin 8 protein after 24 hours after treatment with SAHA.  
These data suggest that basal STAT6 signalling is required to keep levels of 
claudin 8 low.  There is very little research presented on the role of claudin 8 
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at the TJ, with most papers focused on its role in the kidney.  Claudin 8 has 
been reported to interact with claudin 4 to form an anion selective pathway in 
the kidney [332], a finding which was supported by Amasheh et al who 
reported that Na+ absorption was coupled with claudin 8 upregulation which 
seals the TJ to prevent back leakage [333].  Interestingly, claudin 8 has been 
shown to displace claudin 2 at the TJ and increase the TER of the cell 
monolayer. However, it was reported to have this effect in MDCK I but not 
MDCK II cells [334]. This result led researchers to conclude that levels of 
endogenous and exogenous claudin proteins interfere with each other so the 
cell line used can impact the results significantly.  In their study MDCK I cells 
were not affected by claudin 8 overexpression as they did not express 
endogenous claudin 2; MDCK II cells who do endogenously express claudin 
2 responded, with claudin 8 transfection promoting TER by reducing claudin 
2 expression at the TJ.  The way in which claudin 2 and claudin 8 interact is 
unknown, with possible reasons being claudin 8 may destabilise claudin 2 at 
the junction or block its insertion into the TJ.  Our data obtained from the 
preliminary qRT-PCR experiment revealed that claudin 4 which has been 
reported to associate with claudin 8 in the kidney [332] was slightly down-
regulated by SAHA, however, further experimental repeats are required to 
properly investigate this.  Claudin 1 has recently been shown to be 
upregulated by HDAC inhibition with sodium butyrate via an increased 
association between SP1 and the claudin 1 promoter [335]; this mode of 
action could also be true for the effects of SAHA on claudin 8. 
 
6.8.3 Role of GSK3β and MAPK in TJ regulation 
 
 The role of GSK3β in TJ regulation has mainly focused on the 
synergistic activation of AMPK and inhibition of which has been reported to 
lead to TJ deposition in kidney and intestinal cell lines [232, 233, 336].  
GSK3β inhibition was shown to induce the upregulation of ZO-1 and occludin 
independently of extracellular calcium [234].    Severson et al also reported 
an upregulation of occludin and ZO-1 protein following GSK3β inhibition 
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[235].  These results do not correlate with our findings in that, the preliminary 
data obtained from the quantitative PCR studies showed that GSK3β 
inhibition with 1m did not alter any of the TJ proteins studied including 
occludin and ZO-1.  However this data is only a very basic idea and needs to 
be repeated in order to form any solid conclusions.  
 In Calu-3 cells GSK3β was not activated by IL-13 treatment, which 
could be explained by the cell line already expressing constituently inactive 
(phosphorylated) GSK3β.  GSK3β inhibition alone resulted in a decrease in 
TER, which was unaffected when combined with IL-13, this was coupled with 
an increase in FITC dextran flux, indicating the GSK3β is essential for 
maintaining an intact TJ complex.  This result is the opposite of another 
paper which found that inhibition of GSK3β has a beneficial effect on TER.  
Degradation of GSK3 by Akt following serum and glucocorticoid protein 
kinase (Sgk) activation resulted in E-cadherin organization and TJ sealing 
shown by an increase in TER through inactivation of beta-catenin [337].    
Calcium switch studies showed that GSK3β also has a negative effect of the 
re-formation of the TJ, with decreased TER compared with control cells after 
24 hours stimulation.  This discrepancy between published results could be 
explained by the selectivity of the inhibitors used by other investigators, who 
used far less selective GSK3β inhibitors so their results observed may be 
explained through GSK3α inhibition. 
IL-13 stimulation did not activate the MAPK pathway in Calu-3 cells 
shown by no significance in ERK phosphorylation compared with control.  A 
recent study by Petecchia et al who investigated the effect of IL-4, IFN and 
TNFα on MAPK signalling also saw a small increase in ERK phosphorylation 
in Calu-3 cells [338].  Hence this may be a signalling defect in this cell line as 
other cell lines such as A549 cells, IL-13 has been shown to phosphorylate 
ERK 1/2 [339]. The role of the MAPK was investigated by inhibiting MEK 1/2 
with the small molecule inhibitor PD0325901; a non-competitive inhibitor that 
has been shown to be a potent inhibitor of tumour growth in human 
melanoma cells [340].  Inhibition of the MAPK pathway was shown to 
increase the TER of Calu-3 cells 2-fold over control and this increase in TER 
was also observed in TJ reformation during the calcium switch assay.  
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Results observed after MEK inhibition were independent of IL-13 treatment in 
both basal and reformation TJ experiments.  The combined treatment of 
PD0325901 and IL-13 produced a bizarre result with an increase in FITC-
dextran flux observed along with increases in the mRNA of claudin 2, claudin 
4 and IL-13Rα2 after 24 hours.  These data indicate that inhibition of MAPK 
is having an additive effect on IL-13 responses, which may be through more 
of the IL-13 response being forced down the PI3K pathway instead of being 
split amongst the two.  The beneficial effect seen in our TER study is 
supported in research in which the MAPK pathway has been shown to be 
involved in the protection of epithelial integrity from hydrogen peroxide 
through EGF activation via prevention of tyrosine phosphorylation on ZO-1 
and occludin [236] 
There are papers that do not agree with MAPK having a positive effect 
on TJ integrity and it has been shown that Der p 2 increases the cell surface 
expression of claudin 2 in A549 cells via ERK 1/2 and GSK3β 
phosphorylation which leads to a decrease in TER [256, 281]. A similar result 
was observed in human corneal epithelial cells where inhibition of MEK 
resulted in changes in ZO-1 and disruption of the TJ [270].  Cytokines IL-4, 
TNFα and IFNγ were shown to decrease the expression of ZO-1 and 
occludin via a MAPK dependent pathway [338].  These inconsistencies may 
be explained by different cell types having diverse expression of endogenous 
tight junctions, which has been shown to play a role in TJ regulation [334].      
 
6.8.4 Limitations and future work  
 
 This chapter provides a variety of interesting findings, however many 
experiments need to be repeated in order to statistically analyse and form 
conclusions.  The work conducted with the HDAC inhibitor SAHA has shown 
inhibition of STAT6 phosphorylation; this had a beneficial effect on TER as 
well as, a reduction in the expression of the pore-forming tight junction 
protein claudin 2.  It is still unclear whether blocking phosphorylation of 
STAT6 is how SAHA elicits its effects on TER and TJ expression as HDAC6 
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inhibition has been shown to have other targets such as, α-tubulin which it 
directly acetylates [331].  In order to verify the exact role of STAT6 within 
these assays, gene silencing or overexpression studies would be required.   
Another limitation of the data using SAHA treatment is the use of 24 and 48 
hour time points to look at IL-13-induced STAT6 phosphorylation, as after 
this time, there is no way of telling if IL-13 is the sole mediator, or whether 
there could be a secondary mediator involved.  It is therefore necessary to 
study the effect of SAHA on IL-13-induced STAT6 phosphorylation in a much 
shorter time-scale of around 0-90 minutes.   
  To study the relationship between claudin 2 and claudin 8, protein 
dynamics involving fluorescent techniques such as fluorescence recovery 
after photobleaching  (FRAP) and fluorescence loss in photobleaching  
(FLIP) can be utilised [341]. Claudin 2 and 8 can be green fluorescent protein 
(GFP) fusion tagged and their mobility within the membrane can be 
monitored to investigate the theory that claudin 8 may displace claudin 2 at 
the junction following SAHA treatment.   
It would prove interesting to further study the signalling mechanism in 
which MEK inhibition enhances basal TER.  This can be achieved through 
immunoblotting and immunofluorescence experiments to investigate tight 
junction expression and distribution.  These studies could also be performed 
to assess the mechanisms behind the decrease in barrier resistance and 
increase in paracellular FITC-dextran flux after GSK3β inhibition with 1m. 
The effect of the PI3K inhibitor ZSTK474 on claudin 8 expression should also 
be examined. 
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6.9 Conclusions 
 
 This chapter investigated the roles of STAT6, GSK3β and MEK in TJ 
regulation in Calu-3 cells.   
 
In summary, in this chapter the following was determined: 
 The STAT6 pathway is upregulated by IL-13 and STAT6 
phosphorylation is inhibited by treatment with the histone deacetylase 
inhibitor SAHA. 
 Treatment with SAHA increases basal TER 2-fold over control and 
enhances the ability of cells to reform their TJ complex in the calcium 
switch assay. 
 Treatment with SAHA decreases the IL-13-induced increase in claudin 
2 protein and mRNA expression 
 SAHA treatment dramatically increases the expression of claudin 8 
protein and mRNA after 24 hours   
 ZSTK474 was shown to have off target effects by inhibiting STAT6 
phosphorylation after 24 hours but not 48 hours 
 MEK inhibition was shown to have a positive effect on the epithelial 
barrier by increasing TER.  
 GSK3β inhibition had a negative effect on the epithelial barrier 
properties of Calu-3 cells by decreasing TER and increasing 
paracellular flux of FITC dextran. 
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7.1 PI3K in the modulation of the epithelial barrier 
The aim of this project was to determine the role of PI3K in lung 
barrier integrity after IL-13 stimulation.  IL-13 had been reported to be 
involved in features of asthma such as B-cell switching, mast cell 
degranulation and epithelial transitions such as EMT and GCM.  In order to 
assess the role of PI3K, small molecule inhibitors were administered to the 
cells prior to stimulation with IL-13.  The measurement of TER was used as a 
marker of epithelial barrier integrity as an intact epithelial layer will possess 
high basal resistance – whereby no ion exchange between basolateral and 
apical chambers can take place. Treatment with IL-13 alone resulted in a 
decrease in the measured resistance (inverse of ion flux), which implied a 
breakdown of the epithelial barrier.  This breakdown has been researched in 
IBD and tight junctions that make up the apical junctional complex between 
adjacent epithelial cells, was shown to be responsible for regulating the 
‘tightness’ of epithelial cells and therefore the barrier properties.  Pre-
treatment with the pan class I inhibitor ZSTK474 was shown to prevent the 
IL-13 induced decrease in TER. Upon further investigation of the expression 
and distribution of common junctional proteins known to be present in Calu-3 
cells, it was shown that IL-13 treatment resulted in an increase in expression 
of the tight junction protein claudin 2.  Levels of claudin 1 were also slightly 
increased following IL-13 treatment however levels of ZO-l, occludin, beta 
catenin and E-cadherin remained unaltered, a finding that is inconsistent with 
Ahdieh et al who showed that expression of ZO-1 and occludin, were 
downregulated by IL-13 [252].  Upregulation of claudin 2 following IL-13 
treatment was shown to be PI3K dependent with ZSTK474 treatment 
reducing claudin 2 protein and mRNA expression significantly; ZSTK474 also 
reduced the basal level of claudin 2.  These data indicate that, PI3K 
signalling is involved in the regulation of the TJ protein claudin 2, which is 
shown to be upregulated by IL-13.      
The next part of this project focused on investigating the isoform of 
PI3K that was responsible for the prevention of IL-13-induced TER decrease 
and the reduction of claudin 2 protein.  The effects of the PI3K selective 
inhibitors IC87114, TGX221 and PIK75, which inhibit p110δ, p110β and 
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p110α respectively, were studied.  The IL-13-induced increase in claudin 2 
protein levels was prevented by p110α inhibition with PIK75; although PIK75 
treatment also reduced basal claudin 2 expression.  None of the selective 
inhibitors alone or in a combined treatment mimicked the prevention of the 
IL-13 induced decrease in TER shown by the pan-inhibitor ZSK474.  This 
finding was puzzling but may could be explained by the suggestion that 
whilst PI3K isoforms have their own specific role within a cell, if one is 
removed then another will compensate for its signalling (analogised for 
instance by a colleague covering another colleagues shift in work).  This 
concept is referred to as isoform redundancy and is supported by other 
researchers who propose that immortalized cells can use multiple PI3K 
isoforms for the same function [342, 343].     
 
7.2 STAT6 in IL-13 induced modulation of the TJ 
Aside from PI3K signalling IL-13 has also been shown to activate the 
STAT6 pathway, which itself has been shown to be involved in the regulation 
of mucin expression [344] along with the attenuation of airway inflammation 
in mice [345].    In this project STAT6 phosphorylation was inhibited with the 
histone deacetylase inhibitor SAHA and pre-treatment resulted in the 
prevention of the IL-13-induced decrease in TER along with reduction of the 
tight junction protein claudin 2.  These results indicated a role for STAT6 in 
the modulation of the airway by IL-13.  Surprisingly, these data with SAHA 
mirrored the results seen (with regards to TER and claudin 2 regulation) with 
the PI3K inhibitor ZSTK474.  It was considered whether both results were 
from inhibition of the same protein, so STAT6 phosphorylation was 
monitored after ZSTK474 stimulation and was shown to be reduced at 24 
hours but not 48 hours, indicating an off-target effect of the apparent 
‘selective’ pan-class I PI3K inhibitor.  This effect of ZSTK474 on STAT6 
activation may explain why none of the selective isoform inhibitors prevented 
the IL-13-induced TER decrease, even when administered in combination in 
an attempt to mimic pan-PI3K inhibition.  This idea that all the results 
obtained with ZSTK474 were through blocking STAT6 phosphorylation rather 
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than through PI3K inhibition, would be a credible conclusion if it wasn’t for 
the results obtained by the p110α selective inhibitor PIK75, which showed 
that p110α played a role in the claudin 2 upregulation.  However, the 
selectivity of this inhibitor may not be quite what was reported either [98] and 
its effect on STAT6 phosphorylation was not tested.  Another possible 
explanation could be that both STAT6 and PI3K pathways are equally 
important in the maintenance of the TJ and whether they act in synergy or 
independently of each other is yet to be confirmed.  Research into the 
mechanisms behind the IL-13 effects in intestinal epithelial cells, do not shed 
much light on the role of PI3K vs the role of STAT6 in TJ regulation in the 
lung.  Ceponis et al reported a link between IL-13-induced TER and PI3K 
and stated that there is no role for the STAT6 pathway [248].  This finding 
opposes what is predicted in this project with the main emphasis of the IL-13 
effect on the epithelial barrier being put down to STAT6.  An involvement for 
the STAT6 pathway in IL-13-induced effects has been reported in mice 
where inhibition reduces airway inflammation [345] as well as reducing 
glucose absorption and chloride secretion in the intestine [246].  In a paper 
published recently (January 2013), ulcerative colitis was attenuated in 
STAT6 knockout mice by a reduction in the tight junction protein claudin 2, 
proving that epithelial barrier modulation is reliant on STAT6 signalling [346].  
The results on the effect of STAT6 signalling on the TJ in Calu-3s cells are, 
equivalent to those published in this recent paper on ulcerative colitis proving 
that, the mechanism behind the modulation is similar in both inflammatory 
diseases. 
 It has be taken into account that the majority of the data presented in 
this thesis focuses on the regulation of one tight junction protein, claudin 2, 
as there are 23 other claudins shown to be present in the TJ, with each one 
possessing its own unique role, along with an individual pattern of regulation.  
Whilst there are a number of other proteins to consider, every piece of 
knowledge on the mechanisms behind the highly dynamic process of tight 
junction regulation, is important in the search for new treatment for diseases, 
such as asthma and ulcerative colitis.  An additional point to mention, which 
was covered in more detail in 6.8.4, is that SAHA is a HDAC inhibitor so it is 
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not selective for STAT6 and therefore, could be eliciting its effects through 
regulation of an alternative signalling mediator. 
 Another key finding in this project was the significant upregulation of 
the tight junction protein claudin 8 following treatment with SAHA.  The role 
of claudin 8 at the TJ is relatively unknown, it has been reported to interact 
with claudin 4 to form an anion selective pathway in the kidney [332]; a 
finding which was supported by Amasheh et al who reported that, Na+ 
absorption in the kidney was coupled with claudin 8 upregulation, which, 
seals the TJ to prevent back leakage [333]. Interestingly, claudin 8 has been 
shown to displace claudin 2 at the TJ and increase the TER of the cell 
monolayer.  This finding could explain the effect seen by SAHA treatment in 
Calu-3 cells, whereby, IL-13 causes an upregulation of claudin 2, leading to a 
decrease in TER both of which are prevented by SAHA treatment. A 
suggestion of how this effect is brought about may be through the increase in 
claudin 8 displacing claudin 2 at the TJ, as in IBD. It has also been shown 
that along with displacing claudin 2, claudin 8 also reduces the gene 
expression of claudin 2 and impedes its insertion back into the TJ, however 
the reason for this is unknown [334].  This result led its researchers to 
conclude that, levels of endogenous and exogenous claudin proteins 
interfere with each other, so the cell line used can impact the results 
significantly.  The complexity of claudins regulation is increased further by, 
their ability to interact with the same or different claudins in homomeric, 
homotopic, heteromeric and heterotopic interactions. 
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Figure 7.1 Overview of signalling pathways involved in TJ regulation in Calu-3 cells.   
This thesis has studied the signalling pathways involved in tight junction regulation in Calu-3 cells.  IL-13 stimulation decreases epithelial barrier resistance, 
has no effect on the paracellular permeability to FITC-dextran flux and dramatically increases claudin 2 protein expression.  PI3K class I inhibition with 
ZSTK474 prevents the IL-13-induced TER decrease and reduces both basal and IL-13-induced claudin 2 expression.  Only the PI3K α isoform affects the 
barrier properties, decreasing basal TER, claudin 2 expression and slightly increasing FITC-dextran flux. The HDAC inhibitor SAHA which inhibits STAT6 
phosphorylation increases basal TER, decreases claudin 2 and increases claudin 8 protein expression.  Research shows that claudin 2 forms a cationic pore 
[292] and claudin 8 forms an anionic pore in kidney cells [333]. Recently HDAC inhibition has been shown to target the cytoskeletal protein α-tubulin via direct 
acetylation [331]; here it is speculated that this leads to reorganisation of the actin cytoskeleton and hence the TJ complex.   GSK3β inhibition with 1m 
reduces TER and increases FITC-dextran flux, suggesting a role for GSK3β signalling in basal junctional complex maintenance.   The MAPK pathway also 
affects barrier properties as MEK inhibition with PD0325901 increases basal TER but has no affect on FITC-flux. * IL-13 was not shown to activate MAPK in 
Calu-3 cells but it has been shown in other lung cell lines such as A549s [339].  
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7.3 Future Work 
 The next step in this research would be to further investigate the 
expression of claudin 8 in Calu-3 cells and study its interaction with claudin 
2.  If treatment with SAHA is eliciting its effects via the upregulation of 
claudin 8, as is the case for HDAC inhibition increasing claudin 1 [335], then 
a likely mechanism of action would be that this upregulation of claudin 8 is 
displacing the claudin 2 at the TJ.  It would be interesting to overexpress 
claudin 8 and investigate the IL-13-induced decrease in TER and increase in 
claudin 2, which is likely to be diminished if this theory is correct.  To enable 
accurate conclusions regarding PI3K isoform and STAT6 involvement in 
basal and IL-13-induced TJ regulation, overexpression or gene silencing 
studies should undertaken.   One exciting area of research which is yet to be 
explored is that on the role of HDAC/HAT balance in TJ regulation, including 
a possible involvement of actin reorganisation.  Actin reorganisation is 
regulated by RhoA signalling, this pathway could also be studied in 
connection with HDAC regulation.  Finally the work in this thesis has 
focussed on the effect of IL-13, initial results showed that the TH1 cytokine 
IFN-γ increases the TER 40% over basal levels and this finding warrants 
further investigation.  
 
7.4 Final conclusions 
In conclusion, this thesis has researched the effect of the cytokine IL-
13 and the PI3K, STAT6, MAPK and GSK3β pathways on the modulation of 
epithelial barrier integrity in Calu-3 cells.  It can be concluded that one way in 
which IL-13 disrupts the epithelial barrier is by increasing the tight junction 
protein claudin 2; resulting in a decrease in TER. Both ZSTK474 and SAHA 
treatment has proven beneficial for the epithelial barrier; measured by an 
increase in TER above control and a decrease in the basal level and IL-13-
induced increased levels of claudin 2.  Targeting the MAPK pathway using 
the MEK 1/2 inhibitor PD0325901 also demonstrated an increase in TER 
above control; however the mechanism behind this is unknown.  GSK3β 
inhibition disrupted the epithelial barrier, reducing TER and increasing the 
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paracellular flux of the macromolecule FITC-dextran.  Data which suggests 
that GSK3β signalling is vital for TJ maintenance, nonetheless the way in 
which this affect is produced is still unknown. These data give an important 
insight into the highly dynamic regulation of the TJ complex, in which further 
knowledge will ultimately aid in the discovery of new drug targets for asthma.    
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8.1 Immunnoblot buffers 
 
Lysis Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Nonidet P40, 
10% Glycerol (both v/v), 5 mM EDTA, 1 mM sodium 
vanadate, 1 mM sodium molybdate, 10 mM sodium 
fluoride, 40 μg/ml PMSF, 0.7 μg/ml Pepstatin A, 10 μg/ml 
Aprotinin, 10 μg/ml Leupeptin, 10 μg/ml and  Soyabean 
trypsin inhibitor. 
5X sample buffer 10% SDS, 50% Glycerol, 200 mM Tris-HCl pH 6.8, 
bromophenol blue to taste and 5% 2-mercaptoethanol  
(50μl/ml) to be added before use.   
SDS-PAGE Running 
Buffer 
25 mM Tris base, 192 mM glycine, 0.1% (w/v) SDS and 
MQ water  
Semi-dry transfer 
buffer 
39 mM glycine, 48 mM Tris base, 0.0375% SDS, 20% (v/v) 
methanol and MQ water  
PBS 5x phosphate buffered saline tables were dissolved in 1L 
of MQ water 
PBST 1L of PBS was supplemented with 5 ml of Tween-20  
5X stripping buffer 10 g SDS, 31.25ml 1M Tris HCl at pH 7.4 and made up to 
100ml with MQ water. After diluting to 1X stripping buffer 
2-mercaptoethanol was added (770μl to 100ml). 
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8.2 Antibody table 
 
      
   
Western blotting Immunofluorescence 
Target of primary antibody Species 
Molecular 
weight  Blocking buffer 
Primary 
antibody  
Fixing 
method 
Primary 
antibody  
    kDa   concentration   concentration 
phospho Akt (Ser473) rabbit 60 5% BSA in PBST 1 in 1000 N/A N/A 
phospho ERK (Thr202, Tyr204) rabbit 42, 44 5% BSA in PBST 1 in 1000 N/A N/A 
phospho GSK (Ser21/9) rabbit 46, 51 5% BSA in PBST 1 in 1000 N/A N/A 
phospho STAT6 (Tyr641) rabbit 110 5% BSA in PBST 1 in 1000 N/A N/A 
Akt 1 rabbit 60 5% BSA in PBST 1 in 1000 N/A N/A 
ERK1/2 rabbit 42, 44 5% BSA in PBST 1 in 1000 N/A N/A 
GSK rabbit 110 5% BSA in PBST 1 in 1000 N/A N/A 
STAT6 rabbit 90 5% BSA in PBST 1 in 1000 N/A N/A 
beta-actin rabbit 45 5% milk in PBST 1 in 1000 N/A N/A 
occludin mouse 120 5% milk in PBST 1 in 1000 1 1 in 200 
claudin 2 mouse 25 5% milk in PBST 1 in 1000 1 1 in 200 
claudin 1 rabbit 20 5% milk in PBST 1 in 1000 1 1 in 100 
ZO-1 mouse 225 5% milk in PBST 1 in 1000 1 1 in 100 
E-cadherin mouse 135 5% milk in PBST 1 in 1000 2 1 in 100 
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8.3 PCR reaction mixtures 
 
 
 
 
 
 
 
 
 
 
8.4 Primer sequences 
Gene Forward (5'-3') Reverse (5'-3') 
Occludin GGAACACATTTATGATGAGC GGCGTGGATTTATAGGAAGA 
E-cadherin ACCAGGACTTTGACTTGAGC CGAGCAGAGAATCATAAGGC 
Claudin 1 CCACCTGCAAACTCTCCGCC CCAGGAGGATGCCAACCACC 
Claudin 2  ATCGCTCCAACTACTACGATGC  CAGGCTGTAGGAATTGAACTCAC 
Claudin 5 CTCTGCTGGTTCGCCAACAT CACAGACGGGTCGTAAAACTC 
Claudin 7  AGCTGCAAAATGTACGACTCG GGAGACCACCATTAGGGCTC 
Claudin 8  CAACCCATGCCTTAGAAATCGC CCATTCCAACACCACCAAGAAA 
Claudin 10 GCATGTAGAGGACTTATGATCGC AGAGCGCAAATATGGAACCAAA 
ZO-1 GTTGTATTGAAGATAAATGG CAGAAGGCTCTGACCGCTGG 
MUC5AC TGACCCACCAGTGTGAGAAG GGATGATCAGGCTCCTATCG 
IL-13RA2  GGGCATTGAAGCGAAGATACA GCCCAGGAACTTTGAACTTCTG 
IL-13RA1  TCGTCGTTCAATAGAAGTACCCC CCACTTGCAGACAAATCCTCTC 
IL-4RA1  CGTGGTCAGTGCGGATAACTA TGGTGTGAACTGTCAGGTTTC 
 
cDNA synthesis (per rxn) 
  10x RT Buffer 2 μl 
  25x dNTP Mix 0.8 μl 
  10x RT Random primers 2 μl 
  Multiscribe reverse transcriptase 1 μl 
  Rnasin 0.2 μl 
  RNA/MQ water 14 μl 
  
    Each reaction is made up 1 μg RNA diluted to 14  μl with MQ water   
    cDNA synthesis programme 
   25°C for 10 min 
   37°C for 120 min 
   85°C for 10 min 
   4°C hold 
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